

CURRICULUM VITAE

DATE UPDATED: January 2024

NAME: CHRISTOPHER R. McCURDY, Ph.D., F.A.A.P.S.

DATE, PLACE OF BIRTH: March 29, 1971; Pittsburgh, Pennsylvania

ADDRESS: Associate Dean for Faculty Development
Professor of Medicinal Chemistry
Frank A. Duckworth Eminent Scholar Chair in Drug Research and Development
Director, UF Translational Drug Development Core
2017-2018 President, AAPS
Department of Medicinal Chemistry
College of Pharmacy
University of Florida
1225 Center Drive, HPNP 4322
PO Box 100484
Gainesville, FL 32610
Phone: (352) 294-8691
email: cmccurdy@cop.ufl.edu

EDUCATION

<u>Institution</u>	<u>Degree</u>	<u>Year</u>
The University of Georgia College of Pharmacy Department of Pharmaceutical and Biomedical Sciences Athens, Georgia 30605	Ph.D. Medicinal Chemistry	1998
Dissertation Advisor: Dr. J. Warren Beach; Dissertation Title: "Cholinergic Channel Modulators: Analogs of Lobeline."		
Ohio Northern University Raabe College of Pharmacy Ada, Ohio 45810	B.S. Pharmacy	1994

POSTDOCTORAL FELLOWSHIP

<u>Institution</u>	<u>Position</u>	<u>Dates</u>
University of Minnesota College of Pharmacy Department of Medicinal Chemistry Minneapolis, MN 55455	NIDA/NIH Research Training Award	1998 – 2001
Advisor: Distinguished Professor Philip S. Portoghese		

LICENSURE

United States Department of Justice, Drug Enforcement Administration Research License, 2003
– 2017; 2022 – present

Registered Pharmacist: State of Minnesota, License #116692-7. 1998 – 2002

Registered Pharmacist: State of Georgia, License #18003. 1994 – 2010

ACADEMIC APPOINTMENTS

05/23 – Present	Associate Dean for Faculty Development, College of Pharmacy, University of Florida, Gainesville, FL
04/23 – Present	Graduate Faculty Appointment, Department of Pharmacology and Therapeutics, College of Medicine, University of Florida, Gainesville, FL
01/23 – Present	Graduate Faculty Appointment, Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL
01/22 – Present	Frank A. Duckworth Eminent Scholar Chair in Drug Research and Development, College of Pharmacy, University of Florida, Gainesville, FL
07/20 – Present	Professor (courtesy appointment), Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL
01/17 – Present	Professor, Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL
07/16 – 12/16	Interim Chair, Department of BioMolecular Sciences, School of Pharmacy, University of Mississippi, University, MS
01/14 – 12/16	Professor of Medicinal Chemistry, Department of BioMolecular Sciences, School of Pharmacy, University of Mississippi, University, MS
01/14 – 12/16	Professor of Pharmacology, Department of BioMolecular, School of Pharmacy, University of Mississippi, University, MS
07/13 – 01/14	Professor of Medicinal Chemistry, Department of Medicinal Chemistry, School of Pharmacy, University of Mississippi, University, MS
07/13 – 01/14	Professor of Pharmacology, Department of Pharmacology, School of Pharmacy, University of Mississippi, University, MS
07/08 – 06/11	Dean's Advisory Committee Distinguished Teaching Scholar, School of Pharmacy, University of Mississippi, University, MS (Three-year appointment, second continuous cycle - only 2 cycles allowed)
07/07 – 06/13	Associate Professor of Medicinal Chemistry, Department of Medicinal Chemistry, School of Pharmacy, University of Mississippi, University, MS
07/07 – 06/13	Associate Professor of Pharmacology, Department of Pharmacology, School of Pharmacy, University of Mississippi, University, MS
07/05 – 06/08	Dean's Advisory Committee Distinguished Teaching Scholar, School of Pharmacy, University of Mississippi, University, MS (Three-year appointment)
09/04 – 06/07	Assistant Professor of Pharmacology, Department of Pharmacology, School of Pharmacy, University of Mississippi, University, MS
07/01 – 06/07	Assistant Professor of Medicinal Chemistry, Department of Medicinal Chemistry, School of Pharmacy, University of Mississippi, University, MS
08/94 – 05/98	Graduate Teaching Assistant, Department of Medicinal Chemistry, College of Pharmacy, University of Georgia, Athens, GA

SCIENTIFIC APPOINTMENTS/EXPERIENCE

08/23 – Present	Board Member, State of Florida Consortium for Medical Marijuana Clinical Outcomes Research; University of Florida President appointed representative
-----------------	--

04/23 – Present	Member, Scientific Advisory Board, Nuka Enterprises, LLC, Delaware
05/22 – 02/23	Advisory Board Member, Kratom Vendors Association, Napa, CA
12/21 – Present	Director of Medical Innovation, Novium Wellness, St. Augustine, FL
11/21 – Present	Member, Scientific Advisory Board, Forbes & Manhattan, Inc., Toronto, ON, Canada
10/21 – Present	Founding Advisor, PainVox, LLC., Oxford, MS
09/20 – Present	Editorial Advisory Board, ACS Pharmacology & Translational Science, American Chemical Association Publications
11/19 – Present	Past President, American Association of Pharmaceutical Scientists (AAPS), Arlington, VA
01/19 – Present	Editorial Advisory Board, AAPS Open, Springer Open (https://aapsopen.springeropen.com/about/editorial-board)
06/17 – Present	Consultant, United States Food and Drug Administration (US FDA), Drug Safety and Risk Management (DSaRM) Advisory Committee
01/17 – Present	Director, University of Florida Translational Drug Development Core, University of Florida, Gainesville, FL
11/18 – 11/19	Immediate Past-President, American Association of Pharmaceutical Scientists (AAPS), Arlington, VA
11/17 – 11/18	President, American Association of Pharmaceutical Scientists (AAPS), Arlington, VA
11/16 – 11/17	President-Elect, American Association of Pharmaceutical Scientists (AAPS), Arlington, VA
07/16 – 12/16	Director, NIH-COBRE Center of Research Excellence in Natural Products Neuroscience (CORE-NPN), University of Mississippi
04/16 – 07/16	Research Development Faculty Fellow, Office of Research and Sponsored Programs, University of Mississippi, University MS
09/15 – Present	Board of Grants, American Foundation for Pharmaceutical Education, Alexandria, VA
09/15 – Present	Review Editor, Editorial Board of Frontiers in Neuropharmacology, a specialty of Frontiers in Neurology, Neuroscience, Pharmacology and Psychiatry, www.frontiersin.org
02/15 – Present	Member, United States Pharmacopeial Convention, AAPS voting member
03/14 – Present	Research Team Member, Research Center on Substance Abuse and Depression, Roseman University of Health Sciences, Henderson, NV
11/13 – 11/16	Executive Council (Board of Directors) Member-At-Large, American Association of Pharmaceutical Scientists, Alexandria, VA
07/13 – 12/16	Research Professor, Research Institute for Pharmaceutical Sciences, University of Mississippi, University, MS
06/12 – 10/12	Editor-In-Chief, Ad Hoc, AAPS PharmSciTech, AAPS Publications
03/12 – Present	Editorial Board of Referees, Arkivoc Journal, ARKAT USA, Inc.
01/12 – 08/15	Editorial Advisory Board Member, Letters in Drug Design and Discovery, Bentham Publishing
01/12 – 08/17	Editorial Board, Scientifica - Pharmaceuticals, online open access
02/11 – 07/11	Associate Editor, Ad Hoc, AAPS PharmSciTech, AAPS Publications
01/11 – Present	Editorial Advisory Board Member of the Journal of Medicinal Chemistry, American Chemical Society Publications
01/11 – 12/19	Senior Editor, Medicinal Chemistry Research, Springer

01/11 – Present	Editorial Board Member of the World Journal of Pharmacology, Baishideng Publishing Group Co., Limited
09/10 – 06/16	Co-Director, NIH-COBRE Center of Research Excellence in Natural Products Neuroscience (CORE-NPN), University of Mississippi
07/08 – Present	Editorial Board Member of Future Medicinal Chemistry, Future Science Group
04/08 – 08/15	Editorial Board Member of Current Bioactive Compounds, Bentham Publishing
02/08 – 11/11	Editorial Board Member of The Open Enzyme Inhibition Journal, Bentham Publishing (Journal Discontinued 11/2011)
07/07 – 06/13	Research Associate Professor, Research Institute for Pharmaceutical Sciences, University of Mississippi, University, MS.
01/07 – 06/17	Editorial Board Member of Open Medicinal Chemistry, Bentham Publishing
01/07 – Present	Editorial Board Member of Perspectives in Medicinal Chemistry, Libertas Academica
04/06 – 09/09	Editorial Advisory Board Member of Current Topics in Medicinal Chemistry, Bentham Publishing
02/06 – Present	Editorial Board Member of Pharmacologyonline
07/05 – Present	Senior Editorial Board of Molecular Conceptor Medicinal Chemistry Curriculum, Synergix Ltd.
01/02 – 12/11	New Trends Editor, Medicinal Chemistry Research, Springer Boston.
07/01 – 06/07	Research Assistant Professor, Research Institute for Pharmaceutical Sciences, University of Mississippi, University, MS.
07/98 – 07/01	Post-Doctoral Fellow. Research Training Award Fellow, National Institute on Drug Abuse, University of Minnesota, College of Pharmacy, Department of Medicinal Chemistry, Minneapolis, MN. Advisor: Distinguished Professor Philip S. Portoghese.
08/96 – 06/98	Coordinator of Bruker NMR Facility, University of Georgia, College of Pharmacy, Athens, GA.
06/93 – 08/93	Undergraduate Research Fellow, Department of Medicinal Chemistry, College of Pharmacy, University of Georgia, Athens, GA. Advisor: Professor C. DeWitt Blanton.
09/93 – 12/93	Research Assistant, Department of Pharmaceutical and Biomedical Sciences, Raabe College of Pharmacy, Ohio Northern University, Ada, OH. Advisor: Assistant Professor David Kinder.
09/91 – 05/92	Research Assistant, Department of Pharmaceutical and Biomedical Sciences, Raabe College of Pharmacy, Ohio Northern University, Ada, OH. Advisor: Assistant Professor Stephen J. Cutler.

PROFESSIONAL PHARMACY APPOINTMENTS/EXPERIENCE

09/98 – 07/01	Pharmacist, Part-time, SuperValu Pharmacy, Minneapolis, MN
07/94 – 07/98	Pharmacist, Part-time, Publix Super Markets, Inc., Atlanta, GA
05/94 – 07/94	Graduate Pharmacy Intern, Phar-Mor, Inc., Youngstown, OH
03/87 – 05/94	Pharmacy Technician, Phar-Mor, Inc., Youngstown, OH

STUDENT AND TECHNICIAN SUPERVISION, PRECEPTING, AND ADVISING

Dissertation/Thesis Committee Director

Doctor of Philosophy

University of Florida, College of Pharmacy, Department of Medicinal Chemistry, Gainesville, Florida

- Kareem Galal, 1/17 – 5/20 (Ph.D. defense March 19, 2020)
Synthesis and Biological Evaluation of Optimized Analogues of Benzyl Piperidine Based Neuropeptide FF Receptor Ligands.
- John Fortner, 1/17 – 12/20 (Changed to Master of Science program)
- Morgan Crowley, 1/17 – 7/22 (Ph.D. defense July 5, 2022)
Synthesis and Pharmacological Evaluation of Compounds Inspired by Indole Alkaloids Isolated From *Mitragyna speciosa* For Opioid Use Disorder
- Heba Agha, 5/17 – 5/21 (Ph.D. defense March 18, 2021)
Targeting Chronic Pain Through the Design of Sigma-1 Receptor Antagonists with Insights on Structure Activity and Structure Metabolism Relationships
- Sarah Mallory Burns, 8/18 – 8/23 (Ph.D. defense July 6, 2023)
Design and Synthesis of Novel Sigma-1 Receptor Ligands for the Treatment of Chronic Pain
- Shelby Green, 7/21 – present (admitted to candidacy, November 22, 2022)
- Seif A. Abouheif, 8/23 – present
- Christian Barnard, 8/23 – present

University of Florida, College of Pharmacy, Department of Pharmaceutics, Gainesville, Florida

- Tamara I. King, 3/18 – 3/20 (Ph.D. defense February 26, 2020)
Bioanalytical method development, validation, and application to preclinical pharmacokinetic studies of Neuropeptide FF targeting compounds and kratom alkaloids
- Erin Berthold, 3/19 – 6/22 (Ph.D. defense June 27, 2022)
Pharmacokinetics and Interaction Potential of Mitragynine and Cannabidiol
- Michelle Kuntz, 8/20 – present (admitted to candidacy, December 12, 2022)
- Alexandria Senetra, 8/20 – present

University of Florida, College of Medicine, Department of Pharmacology and Therapeutics, Gainesville, Florida (BioMedical Sciences DMD/PhD program)

- Kyle V. Kasparian, 8/23 – present

University of Mississippi, Department of Medicinal Chemistry, University, Mississippi

- Ashok E. Philip, 10/01 – 8/06 (Ph.D. defense August 22, 2006)
Design, Synthesis, Molecular Modeling, and Biological Evaluation of Novel NOP (Nociceptin/Orphanin FQ Peptide) Receptor Ligands
- Nidhi Singh, 12/02 – 5/07 (Ph.D. defense May 4, 2007)

- Part A. Protein Modeling in Rational Drug Design: Case Study with Deoxyxylulose Phosphate Reductoisomerase (DXR) Enzyme.
Part B. A Combined Ligand- and Target-Based Drug Design Strategy for G-Protein Coupled Receptors: Application to Salvinorin A, a Selective κ -Opioid Receptor Agonist
- Neha Vyas Philip, 12/02 – 04/07 (Ph.D. defense April 20, 2007)
Design, Synthesis, and Biological Evaluation of Neuropeptide FF Receptor Ligands
 - Jessica Erin Adkins, 5/04 – 10/08 (Ph.D. defense October 8, 2008)
Analytical Methodology for the Quantitation of Mitragynine and the Fingerprinting of Crude Extracts of *Mitragyna speciosa*
 - Sanju Narayanan, 12/04 – 2/09 (Ph.D. defense February 27, 2009)
Design, Synthesis, and Biological Evaluation of Novel Sigma-2 Selective Ligands
 - Tammy Nolan, 12/04 – 1/10 (Ph.D. defense January 22, 2010)
Molecular Recognition Studies for the Kappa Opioid and Sigma Receptors using Virtual Screening, Pharmacophore Modeling and Semi-Synthesis
 - Velvet Blair Journigan, 9/05 – 4/10 (Ph.D. defense April 28, 2010)
Part I. Design, Synthesis and Biological Evaluation of Ligands for Neuropeptide FF1 and FF2 Receptors. Part II. Design, Synthesis, and Biological Evaluation of Ligands for the κ Opioid Receptor
 - Marco Arribas, 12/04 – 11/10 (Ph.D. defense November 3, 2010)
Synthesis of Analogues Based on the Opioid Alkaloid Mitragynine
 - Edward “Sonny” B. Furr, 10/06 – 5/10 (Left program)
 - Rohit Bhat, 10/06 – 11/11 (Ph.D. defense November 8, 2011)
Design, Synthesis, Biological Evaluation and Metabolic Stabilities Studies of Sigma Receptor Ligands
 - David Watson, 12/07 – 11/13 (Ph.D. defense November 19, 2013)
Quasi-Comprehensive Scaffold Perception, Pharmacophore Development, and Structure-Affinity Relationships of Sigma Site Ligands
 - Jessica Mankus, 12/07 – 11/12 (Ph.D. defense July 23, 2012)
 - Walid Alsharif, 03/10 – 12/15 (Ph.D. defense December 2, 2015)
Design, Synthesis, and Biological Evaluation of Sigma Receptors (σ Rs) Ligands as Potential Pharmacotherapy for Cancer and Drug Addiction
 - Kelsey Gabrielle Luecke McPherson, 8/13 – 4/18 (Ph.D. defense April 24, 2018)
Synthesis and Evaluation of Dual-Acting Ligands for Mu Opioid and Neuropeptide FF Receptors
 - Lisa Leona Wilson, 1/14 – 4/17 (Transferred to UF/Jay McLaughlin director)
 - Kareem Galal, 1/15 – 12/16 (Transfer to UF)
 - John Fortner, 8/15 – 12/16 (Transfer to UF)
 - Heba Agha, 8/15 – 5/17 (Transfer to UF)
 - Vedanjali Gogineni, 7/16 – 11/17 (Ph.D. defense November 11, 2017)
Phytochemical investigation of Psychoactive Medicinal Plants for the Treatment of Neurological Disorders
 - Morgan Crowley, 8/16 – 12/16 (Transfer to UF)

Beni-Suef University, Beni Suef, EGYPT

- Ahmed Hassan Abdelazeem, 8/08 – 10/10 (Ph.D. defense in Egypt January 12, 2011)

Master of Science

University of Florida, Department of Medicinal Chemistry, Gainesville, Florida

-John D. Fortner, 12/20 – 5/21 (M.S. defense March 30, 2021)

University of Mississippi, Department of Medicinal Chemistry, University, Mississippi

-Shivangi Awasthi, 8/11 – 11/13 (M.S. defense November 21, 2013)

Senior Honors Thesis

University of Florida, College of Liberal Arts, Department of Chemistry, Gainesville, Florida

-Dawson W. Jackson, 5/21 – 4/23 (Thesis accepted “summa cum laude” April 18, 2023)

University of Mississippi, Sally McDonnell Barksdale Honors College, University, Mississippi

- Joshua Swan Taylor, 12/06 – 4/07 (Thesis defense April 16, 2007)
- Ashley Jasmine Stubblefield, 7/06 – 4/07 (Thesis defense April 26, 2007)
- Andrea Malone Green, 12/06 – 4/08 (Thesis defense April 9, 2008)
- Sarah E. Clark, 12/07 – 04/09 (Thesis defense April 15, 2009)
- Yang Song, 09/09 – 08/10 (left to attend pharmacy school at the University of MN)
- Jonathan Shih, 01/10 – 05/13 (Thesis defense May 3, 2013)
- Jessie J. Xie, 06/10 – 04/13 (Thesis defense April 30, 2013)
- Chad Burch, 09/12 – 05/16 (decided to drop Honors College)
- John Yi, 03/13 – 05/16 (Thesis defense April 29, 2016)
- May Ly, 05/13 – 04/15 (Thesis defense April 16, 2015)
- Jason Teng, 12/13 – 04/15 (Thesis defense April 30, 2015)
- Jennifer Miller, 03/14 – 05/16 (Thesis defense March 28, 2016)
- Jacqueline Morris, 06/14 – 02/17 (Thesis defense February 24, 2017)
- Jamie Stone, 7/15 – 04/17 (Thesis defense April 26, 2017)

Advisory Committee Member

Doctor of Philosophy

University of Florida, College of Liberal Arts, Department of Chemistry, Gainesville, Florida

- Breanna Tomiczek, 2/18 – 11/22 (Alex Grenning – Advisor; Ph.D. defense November 2, 2022)
- Anirudra Paul, 3/18 – 5/20 (Daniel Seidel – Advisor; Ph.D. defense April 15, 2020)
- Zhongling Liang, 2/20 – present (Boone Prentice – Advisor)
- Nessa Pesaran Afsharian, 9/22 – present (Matthew Eddy – Advisor)
- Anthony Rodriguez Pesci, 6/23 – present (Aron Aponick – Advisor)
- Michael Christopher, 7/23 – present (Tim Garrett and Boone Prentice – Co-advisors)

University of Florida, College of Liberal Arts, Institute of Food and Agricultural Sciences (IFAS), Department of Environmental Horticulture, Gainesville, Florida

- Mengzi Zhang, 9/20 – present (Brian Pearson – Advisor)
- Larissa Laforest, 9/21 – present (Satya Swathi Nadakuduti – Advisor)

University of Florida, College of Pharmacy, Department of Medicinal Chemistry, Gainesville, Florida

- Jeremy S. Coleman, 5/17 – 3/20 (Jane Aldrich – Advisor)
- Saikat Kumar Poddar, 3/23 – present (Guangrong Zheng – Advisor)

University of Florida, College of Pharmacy, Department of Pharmaceutics, Gainesville, Florida

- Tamara I. King, 7/17 – 3/20 (Ph.D. defense February 26, 2020 – Bonnie Avery/Thomas Schmittgen/Christopher McCurdy – Advisors)
- Erin Berthold, 3/19 – 6/22 (Ph.D. defense June 27, 2022 – Bonnie Avery/Christopher McCurdy/Abhisheak Sharma – Advisors)
- Michelle Kuntz, 8/20 – present (Christopher McCurdy/Abhisheak Sharma – Advisors)
- Alexandria Senetra, 8/20 – present (Christopher McCurdy/Abhisheak Sharma – Advisors)
- Yi-Hua Chiang, 3/22 – present (Abhisheak Sharma – Advisor)

University of Florida, College of Pharmacy, Department of Pharmacodynamics, Gainesville, Florida

- Lisa Leona Wilson, 4/17 – 3/22 (Jay McLaughlin – Advisor)

University of Florida, College of Public Health and Health Professions, Department of Epidemiology, Gainesville, Florida

- Carolyn Hoefflich, 9/21 – present (Catherine Striley – Advisor)
- Anna Wang, 10/21 – present (Linda Cottler – Advisor)
- Vijaya Seegulam, 10/23 – present (Linda Cottler – Advisor)

University of Mississippi, Department of BioMolecular Sciences, University, Mississippi (department formed in 2014 by combination of Medicinal Chemistry, Pharmacology and Pharmacognosy)

Division of Medicinal Chemistry

- Pankaj Pandey, 11/14 – 11/15 (Defense November 30, 2015)
- Amer Tarawneh, 11/14 – 11/15 (Defense November 16, 2015)
- Vedanjali Gogineni, 4/15 – 7/16 (Transferred to my supervision from Dr. S. Cutler)

Division of Pharmacology

- Rhianna Morgan, 7/15 – 3/17 (Defense March 6, 2017)
- Taisen Hao, 5/16 – 12/16 (Dropped off committee due to move)

University of Mississippi, Department of Medicinal Chemistry, University, Mississippi

- Aaron Beeler, 09/01 – 05/02
- Yogesh Sabnis, 06/02 – 12/02
- Maralea Gourley, 11/03 – 01/04
- Lindsay Odom, 04/04 – 06/06
- S. Anand , 10/04 – 05/08
- Li Zi, 12/04 – 01/06
- Cassia S. Mizuno, 09/05 – 05/06
- Nakul Telang, 10/05 – 12/07
- Young Kim, 10/06 – 11/08
- Seoung-Ryoung Choi, 3/06 – 12/06
- Akshay Patney, 10/06 – 8/07
- Prasenjit Mukherjee, 9/07 – 6/08
- David Weldon, 09/07 – 8/08
- Tuwanda Simmons, 07/08 – 09/09
- Sarah Chajkowski Scarry, 07/10 – 04/12
- Afeef Husni, 11/11 – 07/12
- Xiaoning Wang, 11/11 – 07/12
- Munia Sowaileh, 4/16 – 04/18

University of Mississippi, Department of Pharmacognosy, University, Mississippi

- Jeremy Stewart, 07/02 – 02/05

University of Mississippi, Department of Pharmaceutics, University, Mississippi

- Praveen K. Mididoddi, 5/05 – 04/06
- Harsha Vinnakota, 9/09 – 11/10
- Pradeep Kumar Vuppala, 09/09 – 04/12
- Seshulatha Jamalapuram, 09/09 – 11/12
- Sai Prasad Boddu, 09/09 – 11/10

University of Mississippi, Department of Chemistry and Biochemistry, University, Mississippi

- Brian W. Hopkins, 01/03 – 04/06
- Emily Rowland, 12/04 – 05/05
- Lingzhi Sun, 4/08 – 5/10
- Rajesh Kota, 11/08 – 1/12
- Christopher Fox, 3/16 – 12/16

University of Mississippi, Department of Psychology, University, Mississippi

- Jason E. Warnick, 8/03 – 05/07
- Matthew Feltenstein, 12/03 – 8/04

Master of Science

University of Mississippi, Department of Medicinal Chemistry, University, Mississippi

- Tiffany D. Clark, 4/08 – 6/08
- Zarana Chauhan, 4/13 – 7/13

University of Mississippi, Department of Pharmacology, University, Mississippi

- Nidhi Kaushal, 11/07 – 3/08
- James Fishback, 11/07 – 8/08

University of Mississippi Sally McDonnell Barksdale Honor's College Senior Thesis

- Morgan Davis, 10/14 – 12/14
- Lindsay Wencel, 12/14 – 4/15
- John Fitzpatrick, 12/14 – 4/15
- John Franklin, 12/14 – 4/15
- Kelsey Pettus, 2/16 – 5/16
- Ashley Noblin, 1/16 – 4/16

Research Supervisor

University of Florida, College of Pharmacy, Gainesville, Florida

Fulbright Scholar

- Dr. Mohammed A. Helal, University of Science and Technology, Zewail City, Egypt, 5/18 – 8/18
- Dr. Ahmed Awad Zaki Bayumi, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt, 9/22 – 8/23
- Dr. Amer Tarawneh, Tafila Technical University, Tafila, Jordan, 1/23 – 10/23

Research Assistant Professor

- Dr. Juan Francisco Leon Oyola, 5/19 – 8/20
- Dr. Abhishek Sharma, 3/19 – 11/22

Assistant Scientist

- Dr. Juan Francisco Leon Oyola, 6/17 – 5/19
- Dr. Marco Mottinelli, 4/20 – 4/22
- Dr. Samuel Obeng, 12/21 – 6/22
- Dr. Sampa Gupta, 6/22 – present
- Dr. Siva Rama Raju Kanumuri, 1/22 – present
- Dr. Sushobhan Mukhopadhyay, 7/22 – present
- Dr. Maria Aparecida Seabra, 11/23 – present

Chemist III

- Mr. Birk Sutton Shaikoski, 8/21 – 8/23
- Mr. Yanni Panayioti Moraites, 9/21 – 8/22
- Mr. Nicholas Guadagnoli, 7/23 – present

Biological Scientist I

- Dr. Maria Aparecida Seabra, 5/22 – 11/23

Postdoctoral Fellow

- Dr. Marco Mottinelli, 1/17 – 3/20
- Dr. Sebastiano Intagliata, 1/17 – 7/19
- Dr. Shyam Harishchandra Kamble, 3/19 – 7/21
- Dr. Siva Rama Raju Kanumuri, 6/19 – 12/21
- Dr. Sampa Gupta, 2/20 – 6/22
- Dr. Sushobhan Mukhopadhyay, 2021 – 6/22
- Dr. Katarzyna (Kasia) Szczepanska, 9/22 – 11/22
- Dr. Ahmed Awad Zaki Bayumi, 8/23 – present

Ph.D. Candidate

- Kareem Galal, 1/17 – 5/20
- John Fortner, 1/17 – 3/21 (switched to MS)
- Morgan Crowley, 1/17 – 7/22
- Heba Agha, 5/17 – 3/21
- Sarah Mallory Burns, 8/18 – 7/23
- Tamara King, 3/19 – 5/20
- Erin Berthold, 3/19 – 7/22
- Michelle Kuntz, 8/20 – present
- Alexandria Senetra, 8/20 – present
- Shelby Green, 7/21 – present
- Yi-Hua Chiang, 3/22 – present

Visiting Graduate students (Ph.D. Candidates)

- Nelson Chear Jeng Yeou, 1/18 – 7/18 (Universiti Sains Malaysia, Penang, Malaysia)
- Nelson Chear Jeng Yeou, 11/21 – 7/22 (Universiti Sains Malaysia, Penang, Malaysia)
- Chiew Sengnon, 4/23 – present (Prince of Songkla University, Thailand)

Visiting Graduate students (M.S. Candidates)

- Gerrit (Guido) Remko Huisman, 12/21 – Present (Maastricht University, The Netherlands)

Undergraduate students

- Jonah Harrington, 5/17 – 5/20 (UF, COP)
- Andrew Viegas, 5/18 – 5/20 (UF, COP)
- Paula Paseiro-Nunez, 5/18 – 9/18 (FSU, SURF student)
- Hannah Malin Neumann, 5/19 (Goethe University, Frankfurt, Germany)
- Katharina Meyer, 5/19 – 10/19 (Germany)
- Grant M. Zwolinski, 1/19 – 5/22 (UF, COP)
- Nicholas Guadagnoli, 8/21 – 7/23 (UF, Chemistry)
- Daniel Kohl, 5/22 – 7/22 (Creighton University, SOP)
- Lauren R. Rozic, 5/22 – 7/23 (UF, Chemistry graduate 5/22)

University of Mississippi, School of Pharmacy, University, Mississippi.

Research Scientist

- Dr. Christophe Mesangeau, 9/07 – 7/12
- Dr. Juan Francisco Leon, 7/16 – 5/17

Postdoctoral Fellow

- Dr. Surya Vangapandu, 9/02 – 11/04
- Dr. Marcelo J. Nieto, 10/02 – 9/06
- Dr. Gweneal Cheve, 2/04 – 5/06
- Dr. Christophe Mesangeau, 10/04 – 08/07
- Dr. Jianmei Cui, 11/06 – 2/09
- Dr. Basile Peres, 9/07 – 1/09
- Dr. Anthony Comeau, 6/13 – 10/13
- Dr. Coco Nankwa Kapanda, 2/14 – 12/15
- Dr. Marco Mottinelli, 2/15 – 1/17
- Dr. Sebastiano Intagliata, 5/16 – 1/17

Research & Development Biologist

- Ms. Lisa Leona Wilson, 1/13 – 12/16

Ph.D. Candidate

- Ashok E. Philip, 10/01 – 8/06
- Nidhi Singh, 12/02 – 5/07
- Neha Vyas, 12/02 – 4/07
- Mark Jaggers, 12/02 – 6/03 (left program)
- Jessica E. Adkins, 5/04 – 10/08
- Marco Arribas, 12/04 – 11/10
- Tammy L. Nolan, 12/04 – 1/10
- Sanju Narayanan, 12/04 – 2/09
- Velvet B. Journigan, 10/05 – 4/10
- Edward B. Furr, 10/06 – 07/13 (left program)
- Rohit Bhat, 10/06 – 11/11

- David E. Watson, 12/07 – 11/13
- Jessica V. Mankus, 12/07 – 11/12
- Walid Alsharif, 3/10 – 12/15
- Kelsey G. Luecke McPherson, 08/13 – 04/18
- Lisa L. Wilson, 1/14 – 4/17 (switched to Dr. Jay McLaughlin at UF)
- Kareem Galal, 1/15 – 12/16 (Transferred to University of Florida with me)
- John Fortner, 8/15 – 12/16 (Transferred to University of Florida with me)
- Heba Agha, 8/15 – 5/17 (Transferred to University of Florida with me)
- Morgan Crowley, 8/16 – 12/16 (Transferred to University of Florida with me)

M.S. Candidate

- Shivangi Awasthi, 8/11 – 11/13

Visiting Graduate students (Ph.D. Candidates)

- Nicola Fazio, 7/07 – 4/08 (University of Bologna, Bologna, Italy)
- Ahmed Hassan Abdelazeem, 8/08 – 10/10 (Beni-Sueif University, Egypt)
- Natalia Valadares de Moraes, 8/08 – 12/08 (University of São Paulo, Brazil)
- Emanuele Amata, 1/09 – 5/09 (University of Catania, Italy)
- Sebastiano Intagliata, 7/15 – 9/15 (University of Catania, Italy)

Undergraduate students

- Bryan Miller, 6/03
- Azadeh Mirbagheri, (Belgium) 7/03
- Alexia Jadot, (Belgium) 7/03
- Stephen S. Scully, 5/04 – 7/05
- Julie Reuther, 9/04 – 12/04
- Jameika Stuckey, 4/05 – 5/06
- Adel Elsohly, 5/05 – 8/07
- Grant Smith, 5/05 – 5/06
- Leigh Ann Tadlock, 9/05 – 5/06
- Jennnifer Nobles, 9/05 – 5/06
- Rachel Camburn, 1/06 – 5/06
- Ashley Stubblefield, 7/06 – 5/07
- Neil White, (Princeton University) 6/06 – 8/06, 7/07 – 8/07
- Jean Francois Denef, (Belgium) 7/06 – 8/06
- Joffory Mulongo, (Belgium) 7/06 – 8/06
- Bilal Souilem, (Belgium) 7/06 – 8/06
- Natalia Valadares de Moraes, (Brazil) 8/06 – 11/06
- Andrew Whitaker, 9/06 – 5/07
- Andrea Malone Green, 12/06 – 5/08
- Ronald Kim, 7/07 – 9/07
- Nihed Draoui, (Belgium) 7/07 – 08/07
- Olayinka Fasanya, (Belgium) 7/07 – 08/07
- Sabrina Montante, (Belgium) 7/07 – 08/07
- Sarah E. Clark, 12/07 – 5/09

- Jessica Hall, 6/08 – 7/08
- Florian Langer, (Belgium) 7/08
- Yang Song, 7/09 – 8/10
- Jonathan Shih, 2/11 – 5/13
- Jessie J. Xie, 6/10 – 5/13
- Florian Thinard, (Belgium) 7/12
- Chad Burch, 9/12 – 5/16
- John Yi, 3/13 – 8/16
- May Ly, 3/13 – 4/15
- Neal Tisher, 6/13 – 7/13
- Jason Teng, 1/14 – 4/15
- Jennifer Miller, 3/14 – 4/16
- Jacqueline Morris, 6/14 – 5/17
- Ethan Collier, 6/14 – 7/14
- Mary “Caroline” Morris, 6/14 – 7/14
- Morgan Crowley, 6/15 – 7/15
- Jamie Stone, 6/15 – 5/17
- Garrett Rogers, 6/16 – 9/16
- Jonah Harrington, 8/16 – 12/16

High School students

- Neil White, 6/04 – 7/04 (Oxford High School, Oxford, MS)
- Andrew Mullen, 6/10 – 7/11 (Oxford High School, Oxford, MS)
- Taide Ding, 7/10 – 8/13 (Oxford High School, Oxford, MS)

University of Minnesota, Department of Medicinal Chemistry, Minneapolis, MN.
M.S. Candidate

- Amol Kulkarni, 9/99 – 7/01

University of Georgia, Department of Medicinal Chemistry, Athens, GA.
Summer Undergraduate Intern

- Reagan Miller, 6/97 – 8/97

University of Florida PharmD Student Advisor

08/21 – Present Annie Alexis, Madiha Ali, Tanner Beachy, Alyssa Mickler, Juan Ramos-Perez

University of Florida Preceptor for Advanced Pharmacy Practice Experience (APPE)

08/18 – 08/18 Mallory Pullman, University of Mississippi School of Pharmacy

University of Mississippi School of Pharmacy Professional Development Advising Team

08/14 – 12/16 Philip Kelly, Rachel Lee, May Ly, Jim Still, Jessica Thornsburg, Lily Van, Payton Brown, Lauryn Easterling, MacKenzie Lewis

08/13 – 12/16 Emily Buckley, Jordan Michaels, Colleen Riley, Jessica Ruiz, Andrew Smelser, Stephanie Sollis, Blake Williams

Pharmacy Undergraduate Student Faculty Mentor

Fall 2006 formal mentoring program ended by School of Pharmacy

08/05 – 08/06 Stephanie Davis, Samuel King, Wesley Pierce, Janelle Austrom, Lauren Courtney, Jay Gulley, Bailey Melton, Sally Putt, Andrea Rowling, Bart Smith, Makena Swanson, Jennifer Chadwick, Erin Clark, Lara Garrard, Holly Massey, Haley Peel, May Shackelford, Laura Summerford

08/04 – 05/05 Sally Putt, Andrea Rolwing, Laura Carpenter, Holly Massey, May Shackelford, Lara Youngblood, Stephen Scully.

08/03 – 05/05 Sheila Gilliland, Jennifer Hutchinson, Kimberly Mann Dorrah, Patrick Obriant, Ryan Sewell, Melissa Williams Greene, Matt Windham, Haley Peel.

08/02 – 05/04 Ann Magee, Amanda Massengill, Carolyn McClure, Megan McGinnis, Marin Myers, Brandi Wise.

08/02 – 05/03 Suvapun Bunniran, Jennifer Cameron, Troy Hudson, Debralee Jefcoat, Tywanda Jefferson, Haley Phelps, Stephen Poole.

SCIENTIFIC/PROFESSIONAL ASSOCIATIONS

Scientific Associations

American Chemical Society, Member, 1994 – present
Medicinal Chemistry Division Member, 1994 – present
Ole Miss Local Section Member, 2001 – present
Secretary 2004 – 2005
Journal of Medicinal Chemistry, Editorial Advisory Board Member, 2011 – present
3rd Portuguese Lectureship Selection Committee, 2011 – 2012 (JMC EAB representative)
5th Portuguese Lectureship Selection Committee, 2013 – 2014 (JMC EAB representative)
6th Portuguese Lectureship Selection Committee, 2015 (JMC EAB representative)
ACS Pharmacology & Translational Science, Editorial Advisory Board Member, 2020 – present
American Association for the Advancement of Science, Member, 2001 – 2007
American Association of Pharmaceutical Scientists, Member, 1996 – present
National Biotechnology Conference Planning Committee, 2003 – 2004
Vice-Chair, Drug Design and Discovery (DDD) Section, 2005 – 2006
Chair-Elect, Drug Design and Discovery (DDD) Section, 2006 – 2007
Chair Drug, Design and Discovery (DDD) Section, 2007 – 2009
Past-Chair, Drug Design and Discovery (DDD) Section, 2009 – 2010
Chair-Elect, AAPS Publications Committee, 2010 – 2011
Chair, AAPS Publications Committee, 2011 – 2012
Past-Chair, AAPS Publications Committee, 2012 – 2013
Co-Chair, 2012 AAPS Annual Meeting Planning Committee, 2011 – 2012
Chair, 2013 AAPS Annual Meeting Planning Committee, 2012 – 2013
Past-Chair, 2014 AAPS Annual Meeting Planning Committee, 2013 – 2014
Member-At-Large, Executive Council, AAPS, 2013 – 2016
Fellow, 2014
Voting Delegate to the United States Pharmacopeial Convention, 2015 – present
President-Elect, Executive Council, AAPS, 2016 – 2017
President, Board of Directors, AAPS, 2017 – 2018
Immediate Past President, Board of Directors, AAPS, 2018-2019
Past President, Board of Directors, AAPS, 2019 – 2020
International Narcotics Research, Member, 2002 – present
Organizing Committee Member, 2012 meeting, Kansas City, MO
Sigma Xi, The Scientific Research Society, Member, 1997 – present
Ole Miss Local Section
President-Elect, 2006 – 2008
President, 2008 – 2010
Society for Neuroscience, Member, 2003 – 2009
American Society of Pharmacognosy, Member, 2007 – 2014
United States Pharmacopeial Convention, Member, 2015 – present
International Pharmaceutical Federation (FIP), 2015 – 2020
Co-Chair, Drug Design and Discovery Special Interest Group, 2015 – 2019
International Cannabinoid Research Society, Member, 2016 – 2017
United States Association for the Study of Pain (USASP), Member, 2020 – 2021

Professional Pharmacy Associations

National

American Association of Colleges of Pharmacy, Member 1998 – present
-Academic Leadership Fellow, 2005 – 2006
-Council of Faculties Nominations Committee, 2012
American Pharmaceutical Association, Member. 1994 – 1995
Phi Delta Chi Pharmaceutical Fraternity, Member, 1989 – present
-National Executive Committee Member, 1992 – 1993
-Mid-West Regional Correspondent, 1992 – 1993

State

Mississippi Pharmacists Association, 2007 – 2016
Minnesota Pharmacists Association, 1998 – 2000
Georgia Pharmacy Association, 1994 – 1998
Ohio Pharmacists Association, 1991 – 1994

Local

Phi Delta Chi Pharmaceutical Fraternity, Alpha Upsilon Chapter, Ohio Northern University, Ada, OH
-Chapter President, 1991 – 1992
-Chapter Correspondent, 1990 – 1991

AWARDS AND HONORS

Inaugural Ronald F. Borne Endowed Distinguished Lecturer, University of Mississippi, School of Pharmacy, 2023
Distinguished Alumnus of the Year, University of Georgia, College of Pharmacy, 2022
Media Excellence Award, University of Florida, College of Pharmacy, 2022
Commencement Speaker, University of Georgia, College of Pharmacy, 2022
Frank A. Duckworth Eminent Scholar Chair in Drug Research and Development, 2022 – present
Fellow, Southeastern Conference Academic Consortium's Academic Leadership Development Program (SECU/ALDP), 2019-2020
Fellow, University of Florida Advanced Leadership for Academics and Professionals, 2019-2020
Outstanding Teaching Team Year 3, University of Florida, College of Pharmacy, 2019
Media Excellence Award, University of Florida, College of Pharmacy, 2018
Keynote speaker, Professional Commitment Ceremony, Ohio Northern University Raabe College of Pharmacy, Ada, OH – September 28, 2018.
Elected President of the American Association of Pharmaceutical Scientists (AAPS) 2016 – 2019
Member, American Foundation for Pharmaceutical Education, Board of Grants, 2015 – present
Speaker, TEDxUM (one of ten faculty selected from the University) – October 2015
Inaugural recipient of AAPS Drug Discovery and Development Interface (DDDI) Section Service Award, 2015
Member, United States Pharmacopeial Convention, AAPS Voting Delegate, 2015 – present
Fellow, American Association of Pharmaceutical Scientists (AAPS), 2014
Elected Member-At-Large, American Association of Pharmaceutical Scientists, 2013 – 2016
The University of Mississippi Faculty Achievement Award, 2010
Teacher of the Year, PY2 Class, School of Pharmacy, University of Mississippi, 2010
Faculty Service Award, School of Pharmacy, University of Mississippi, 2009
Dean's Advisory Committee Distinguished Teaching Scholar, School of Pharmacy, University of Mississippi, July 1, 2008 – June 30, 2011
Faculty Research Award, School of Pharmacy, University of Mississippi, 2007
Phi Kappa Phi, 2007
Teacher of the Year by the third year pharmacy class, University of Mississippi, 2006
Elected Vice-Chair of Drug Design and Discovery (DDD) section for the American Association of Pharmaceutical Scientists (AAPS), August 2005 – August 2011
Inaugural Dean's Advisory Committee Distinguished Teaching Scholar, School of Pharmacy, University of Mississippi, July 1, 2005 – June 30, 2008
American Association of Colleges of Pharmacy Academic Leadership Fellow, 2005 – 2006
Distinguished Alumnus of the Year, Phi Delta Chi, Alpha Upsilon Chapter, Ohio Northern University, Ada, OH, 2005
Teacher of the Year by third year pharmacy class, University of Mississippi, 2003
Recipient of AACP New Investigator Award, 2002
Recipient of Glaxo/Albert B. Prescott Leadership Award, 2002
Recipient of Training Fellow Award, National Institute on Drug Abuse, University of Minnesota, Minneapolis, Minnesota, 1998-2001
Recipient of University of Georgia, Medicinal Chemistry, Pre-Doctoral Fellowship, 1994-1998
Sigma Xi Research Society, 1998
Rho Chi Society (Pharmacy honor society), 1997
Recipient of Allen and Hanburys/Glaxo Pride in Pharmacy Award, 1994

Phi Lambda Sigma (Pharmacy leadership honor society), 1992

Mortar Board, 1992

Omicron Delta Kappa, 1992

Phi Delta Chi Outstanding Member of the Year Award, 1992

Recipient of Ohio Northern University Dean's Award, academic scholarship, 1989-1993

SERVICE AS SCIENTIFIC REFEREE

Invited National Academies of Sciences, Engineering, & Medicine (Ad-Hoc)

1. Chemistry Panel Meeting, Keck Center, Washington DC, November 29-30, 2018.

Invited National Institutes of Health Referee (Ad-Hoc)

1. National Institute on Drug Abuse – PAR-23-076 NIDA Center of Excellence Grant Program (P50) and PAR-23-049 NIDA Core “Center of Excellence” Grant Program (P30). February 26-27, 2024.
2. National Center for Advancing Translational Sciences – Contract Review on RFP 75N95023R00020 Chemistry, Manufacturing and Controls and Related Services for Development of Drug Substances. November 2-3, 2023. (Chair)
3. National Institute on Drug Abuse – Contract Review on RFP 75N95023R000 Pharmacokinetic and Pharmacodynamic Trials for Medication Development in SUD. April 5, 2023. (Chair)
4. National Institute on Drug Abuse – 2023 NIDA Loan Repayment, Special Emphasis Panel 2023/08 ZDA1 CEM-T (A1) 1, March 10, 2023.
5. National Institute on Drug Abuse – Contract Review on RFP 75N95022R00058 Production of Cannabis and Related Materials for Research. January 6, 2023.
6. National Institute on Drug Abuse – Special Emphasis Panel, RFA DA-22-020 (SBIR) and RFA DA-22-018 (STTR), Advancing Validated Drug Targets for Substance Use Disorders (R41/42/43/R44 – Clinical Trial Not Allowed), 2022/08 ZDA1 GXM-A (02) R, June 28, 2022.
7. National Institute on Drug Abuse – Contract Review on Synthesis and Distribution of Drugs of Abuse and Related Compounds, Special Emphasis Panel ZDA1 MXS-W (35), May 9, 2022. (Chair)
8. National Institute on Drug Abuse – 2022 NIDA Loan Repayment, Special Emphasis Panel 2022/08 ZDA1 JRB-A (31) 2, April 9, 2022.
9. National Institutes of Health Center for Scientific Review Special Emphasis Panel – PAR Panel: CounterACT-Countermeasures Against Chemical Threats: Exploratory applications. 2022/01 ZRG1 MDCN-B (55) R, October 28-29, 2021.
10. National Institute on Drug Abuse – Contract Review on Development & Manufacture of Pharmaceutical Products for the Treatment of Substance Abuse Disorders (N01DA-21-8956), ZDA1 SXC-G (32), June 25, 2021.
11. National Institute on Drug Abuse – Contract Review on In Vitro Metabolism and Non-clinical ADME Studies (N01DA-21-8957), ZDA1 SKM-D (33), June 15, 2021. (Chair)
12. National Institute on Drug Abuse – 2021 NIDA Loan Repayment, Special Emphasis Panel 2021/08 ZDA1 PXN-F (31) 2, April 16, 2021.
13. National Institutes of Health Center for Scientific Review Special Emphasis Panel – PAR Panel: CounterACT-Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence. 2021/05 ZRG1 MDCN-B (54) R, March 4-5, 2021.
14. National Institutes of Health Center for Scientific Review Special Emphasis Panel – PAR Panel: CounterACT-Countermeasures against Chemical Threats. 2021/05 ZRG1 MDCN-B (50) R, March 3, 2021
15. National Institute on Drug Abuse – 2020 NIDA Loan Repayment Program, Special Emphasis Panel 2020/08 ZDA1 TXW-S (32) 1, March 31, 2020.

16. National Institutes of Health Center for Scientific Review Special Emphasis Panel – PAR Panel: CounterACT-Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence. 2020/05 ZRG1 MDCN-B (54) R, March 6, 2020.
17. National Institutes of Health Center for Scientific Review Special Emphasis Panel – PAR Panel: CounterACT-Countermeasures against Chemical Threats. 2020/05 ZRG1 MDCN-B (50) R, March 5, 2020
18. National Institutes of Health National Center for Complementary & Integrative Health (NCCIH) – Technology Products for Natural Products Research (U24), Natural Products NMR Open Data Exchange (NP-NODE) Special Emphasis Panel 2020/01 ZAT1 AJT (17) R, January 6, 2020.
19. National Institutes of Health Center for Scientific Review Special Emphasis Panel – PAR18-721: Counter Act Exploratory Grants. 2020/21 ZRG1 MDCN-B (55) R, September 27, 2019.
20. National Institute on Drug Abuse – 2019 Contract Proposal Review, Special Emphasis Panel N01DA-19-8950 “Analytical Chemistry and Stability Testing of Treatment Drugs for Substance Use Disorders”. May 21, 2019.
21. National Institute on Drug Abuse – 2019 NIDA Loan Repayment, Special Emphasis Panel 2019/08 ZDA1 LXF-L (31) S, April 8, 2019.
22. National Institute of Allergy and Infectious Disease – Special Emphasis Panel RFA AI-17-042, Centers of Excellence for Translational Research (CETR) (U19), 2019/01 ZAI1 LG-M (J2) 1, October 11-12, 2018.
23. National Institute of Allergy and Infectious Disease – Special Emphasis Panel RFA AI-17-042, Centers of Excellence for Translational Research (CETR) (U19), 2019/01 ZAI1 LG-M (J1) 1, September 27-28, 2018.
24. National Institute of Neurological Disorders and Stroke – PAR15-315: CounterACT Exploratory Grants. 2018/08 ZRG1 MDCN-B (55) R, June 21, 2018.
25. National Institute on Drug Abuse – Cutting-Edge Basic Research Awards (CEBRA) (R21) Program 2018/05 ZDA1 SXM-M (16) S, March 21, 2018.
26. National Institute on Drug Abuse – Special Emphasis Panel 2018/08 ZDA1 LXF-L (31) S, March 20, 2018.
27. National Institute on Drug Abuse – Cutting-Edge Basic Research Awards (CEBRA) (R21) Program 2018/01 ZDA1 SXT-P (06) S, November 29, 2017. (served as co-chair)
28. National Institutes of Health – Center for Scientific Review Special Emphasis Panel 2017/10 ZRG1 BCMB-W (50) R, PAR Panel: Chemical Discovery for Substance Use Disorders. July 12, 2017.
29. National Institute on Drug Abuse – Cutting-Edge Basic Research Awards (CEBRA) Program (R21) 2017/05 ZDA1 GXM-A (13) S, March 27, 2017.
30. National Institute on Drug Abuse – Special Emphasis Panel 2017/08 ZDA1 LXF-L (31) S, March 26, 2017.
31. National Institute on Drug Abuse – PAR panel: Chemical Discovery for Substance Use Disorders 2017/05 ZRG1 BCMB-U (50) R, March 7, 2017.
32. National Institute on Drug Abuse – Contract Review on Non-clinical ADME Studies (N01DA-16-8931), July 13, 2016.
33. National Institute of Allergy and Infectious Disease – Discovery/Development of Novel Therapeutics for Eukaryotic Pathogens R21/R33 2016/10 ZAI1 LR-M (S1) 1, May 10-12, 2016.
34. National Institute on Drug Abuse – Special Emphasis Panel 2016/08 ZDA1 LXF-L (31) S, March 15, 2016.

35. National Center for Complementary and Integrative Health – Clinical Research on Natural Products (R21 and R33) Special Emphasis Panel 2016/01 ZAT1 SM (38) S, November 4, 2015.
36. National Institute on Drug Abuse – Special Emphasis Panel 2015/08 ZDA1 LXF-L (31) S, April 5, 2015.
37. National Institute on Drug Abuse – Cutting-Edge Basic Research Awards (CEBRA) Program 2015/05 ZDA1 JXR-G (10) S, April 2, 2015.
38. National Institute of Allergy and Infectious Disease – Development of Novel Therapeutics for Select Pathogens (R21/R33), Gram-Negative Therapeutics (ZAI1-LR-M-M1), March 11-13, 2015.
39. National Institute of Allergy and Infectious Disease – Development of Novel Therapeutics for Select Pathogens (R21/R33), Influenza Therapeutics (ZAI1-LR-M-M2), March 9-10, 2015.
40. National Center for Complementary and Alternative Medicine – Special Emphasis Panel U41 Centers for Advancing Natural Products Innovation and Technology Centers (CANPIT), ZAT1 SM (35), December 19, 2014.
41. National Center for Complementary and Alternative Medicine – Special Emphasis Panel P50 Botanical Dietary Supplement Research Centers (BDSRC), ZAT1 SM (34) P, December 17-18, 2014.
42. National Institute on Drug Abuse – Special Emphasis Panel Contract Review on GMP Synthesis of Bulk Drug Substances (N01DA-15-8915), August 28, 2014.
43. National Institute on Drug Abuse – Special Emphasis Panel 2014/08 ZDA1 LXF-L (36) 1, March 30, 2014.
44. National Institute on Drug Abuse – Cutting-Edge Basic Research Awards (CEBRA) Program 2014/05 ZDA1 GXM-A (09) S, March 19, 2014.
45. National Institute on Drug Abuse – Contract Review on Non-clinical ADME Studies (N01DA-14-8916), March 11, 2014.
46. National Institute of Allergy and Infectious Disease – Center of Excellence for Translational Research (Teleconference) 2014/01 ZAI1 LR-M (J1) 1, September 17-19, 2013.
47. National Center for Advancing Translational Sciences (NCATS) – NCATS Preclinical Drug Development Review Group 2013/05 ZTR1 DPI-8 (01) TRND – 4. March 20-21, 2013.
48. National Institute on Drug Abuse – Special Emphasis Panel 2013/08 ZDA1 LXF-L (01) 1, March 18, 2013.
49. National Institute on Drug Abuse – Special Emphasis Panel ZDA1 LXF-L (01) 1, March 5, 2012.
50. National Institute on Drug Abuse – Special Emphasis Panel ZDA1 JXR-D (09) 1. RFA 12-005 Medications Development Program Projects for Substance-Related Disorders (P01), October 18-19, 2011.
51. National Institute on Drug Abuse – Special Emphasis Panel ZDA1 JXR-D (06). RFA 12-001 New Molecular Entities to Treat Substance Use Disorders, May 24, 2011.
52. National Institute on Drug Abuse – Special Emphasis Panel ZDA1 LXF-L (01), March 22, 2011.
53. National Institute of Mental Health – National Cooperative Drug Discovery sand Development Groups (NCDDDG) Special Emphasis Panel ZMH1 ERB-C (04), March 10, 2011.
54. National Institutes of Health Center for Scientific Review – Drug Discovery Special Emphasis Panel/Scientific Review Group 2011/01 ZRG1 MDCN-B (91) S, November 9-10, 2010.

55. National Institute of Diabetes and Digestive and Kidney Diseases – Cystic Fibrosis Research and Translational Core Centers ZDK1 GRB-W (M2). April 7-8, 2010.
56. National Institute on Drug Abuse – Special Emphasis Panel ZDA1 LXF-L (01), March 21, 2010.
57. National Institute on Drug Abuse – Member Conflict: Drug Discovery Panel ZRG1 MDCN-B (02), March 9-10, 2010.
58. National Institute of Mental Health – National Cooperative Drug Discovery sand Development Groups (NCDDDG) Special Emphasis Panel ZMH1 ERB-C (03), March 1, 2010.
59. National Institute of Allergy and Infectious Disease – Special Emphasis Panel ZAI1 LR-M (M1) – Partnerships for Development of Therapeutics and Diagnostics for Drug-Resistant Bacteria and Eukaryotic Parasites (R01 and R43/44), January 26-27, 2010.
60. National Institute on Drug Abuse – SBIR contract review Panel RFC No. N43DA-10-7774 – Rapid and sensitive method for the determination of Nicotine and its metabolites in biological fluids, January 12-14, 2010.
61. National Institute on Drug Abuse – SBIR contract review panel RFC No. N43DA-10-2218 – New Technologies: Integrating Data From Prescription Monitoring Program(s) to Current Clinical Practice, December 16, 2009.
62. National Institutes of Health Center for Scientific Review – Drug Discovery for Neurodegenerative Diseases Special Emphasis Panel ZRG1 MDCN-B (91) S, November 3-4, 2009.
63. National Institutes of Health Chemical and Bioanalytical Sciences Fellowship Study Section (F04A), June 18-19, 2009.
64. National Institute on Drug Abuse – Contract Review on GMP Synthesis of Bulk Drug Substances (N01DA-9-8881), May 13, 2009.
65. National Institute on Drug Abuse – Special Emphasis Panel ZDA1 LXF-L (01), March 30, 2009.
66. National Institutes of Health Center for Scientific Review – Drug Discovery for Neurodegenerative Diseases Special Emphasis Panel ZRG1 MDCN-B (91), February 19-20, 2009.
67. National Institute on Drug Abuse – Contract Review on Non-clinical ADME Studies (N01DA-9-8883), December 11, 2008.
68. National Institute on Drug Abuse – Contract Review on the quantification of drugs of abuse and related substances in biological specimens (N01DA-9-7767), August 6, 2008.
69. National Institutes of Health Chemical and Bioanalytical Sciences Fellowship Study Section (F04A) ZRG1 F04A-T (20) L, June 26, 2008.
70. National Institute for Research Resources – Science Education Partnership Award (SEPA) Special Emphasis Panel ZRR1 SEPA-9 01, March 2007.
71. National Institute for Research Resources – Science Education Partnership Award (SEPA) Special Emphasis Panel ZRR1 SEPA-9 01, March 2006.
72. National Institute of Allergy and Infectious Disease – Special Emphasis Panel ZAI-1-LR-M-M1, January/February 2006.
73. National Institute of Diabetes and Digestive and Kidney Diseases – Special Emphasis Panel ZDK1 GRB-6 (M1), April 19, 2005.
74. National Institute of Allergy and Infectious Disease-sponsored RFA, 2004.

Invited Department of Defense (DoD) Referee

1. FY20 Chronic Pain Management Research Program (CPMRP) Investigator-Initiated Research Award (IIRA) – January 6-7, 2021 (contact Mamta Naidu Mamta.Naidu@gdit.com)

Invited Austrian Science Fund (FWF) Referee

Translational Research Programme (TRP) – November 27, 2009 (contact Silvia Spitzer Silvia.Spitzer@fwf.ac.at)

Invited Neurological Foundation of New Zealand Referee

Neurological Foundation Peer Review – October 25, 2012 (contact Douglas Ormrod douglas.ormrod@neurological.org.nz)

Neurological Foundation Peer Review – May 17, 2012 (contact Douglas Ormrod douglas.ormrod@neurological.org.nz)

Invited National Research Foundation of South Africa

Research and Innovation Support and Advancement Peer Review – October 3, 2012 (contact Nosisa Dube nosisa.dube@nrf.ac.za)

Invited San Antonio Partnership for Precision Therapeutics

Pilot Grant Proposal Peer Review – November 8, 2019 (contact Liz Tullis ltullis@txbiomed.org)

Pilot Grant Proposal Peer Review – October 26, 2020 (contact Liz Tullis ltullis@txbiomed.org)

Pilot Grant Proposal Peer Review – July, 2021 (contact Liz Tullis ltullis@txbiomed.org)

Invited Hetzier Foundation for Addiction Research (<https://hetzler-stiftung.de/>)

Pilot Grant Proposal Peer Review – February 25, 2022 (contact Tilo Grosser tilo.grosser@uni-bielefeld.de)

Invited National Science Centre, Poland (<http://www.ncn.gov.pl>)

Funding scheme: OPUS-23; Panel: NZ7 (Diagnostic tools, therapies and public health) – October 5, 2022 (contact Monika Pobiega monika.pobiega@ncn.gov.pl)

Invited Journal Referee

Medicinal Chemistry Research 1998 – present

Expert Opinion on Therapeutic Patents, 1998

Journal of Medicinal Chemistry 1999 – present

Biopolymers (Peptide Science), 2003 – present
Current Medicinal Chemistry, 2003 – present
Journal of Natural Products, 2003 – present
Bioorganic & Medicinal Chemistry Letters, 2004 – present
Molecules, 2004 – present
Neurochemical Research, 2004 – present
Journal of Pharmacy & Pharmaceutical Sciences, 2004 – present
Current Topics in Medicinal Chemistry, 2004 – present
Synapse, 2005 – present
Life Sciences, 2005 – present
Peptides, 2005 – present
Organic Letters, 2005 – present
Journal of Combinatorial Chemistry, 2005 – present
Proceedings of the National Academy of Science, USA, 2005 – present
Letters in Organic Chemistry, 2006
Chimica Oggi (Chemistry Today), 2006
Journal of Pharmacy and Pharmacology, 2006
Combinatorial Chemistry and High Throughput Screening, 2006
American Journal of Pharmaceutical Education, 2006 – present
Tetrahedron, 2007 – present
Archiv der Pharmazie, 2007 – present
Chemical Reviews, 2007 – present
Tetrahedron Letters, 2007 – present
Journal of Pharmacology and Experimental Therapeutics, 2007 – present
The Open Medicinal Chemistry Journal, 2008 – present
Current Bioactive Compounds, 2008 – present
Pharmacology, Biochemistry and Behavior, 2008 – present
Journal of Computer Information and Modeling, 2008 – present
British Journal of Pharmacology, 2008 – present
Bioorganic Medicinal Chemistry, 2008 – present
Molecular Pharmaceutics, 2008 – present
Journal of the American Chemical Society, 2008 – present
Neuropsychopharmacology, 2008 – present
Synthesis, 2008 – present
Future Medicinal Chemistry, 2009 – present
Protein and Peptide Letters, 2009 – present
Journal of Computer-Aided Molecular Design, 2009 – present
Journal of Molecular Graphics and Modeling, 2009 – present
BMC Research Notes, 2009 – present
Neuroscience Letters, 2009 – present
ACS Chemical Neuroscience, 2009 – present
Journal of Structural Biology, 2009 – 2010
ACS Medicinal Chemistry Letters, 2010 – present
Current Pharmaceutical Design, 2010 – present
ACS Combinatorial Science, 2010 – present
The Journal of Physical Chemistry, 2011 – present
Journal of Antibiotics, 2011
European Journal of Medicinal Chemistry, 2011 – present

E-Journal of Chemistry, 2012
Neuroscience & Biobehavioral Reviews, 2012
PLOS ONE, 2012
Journal of Pharmaceutical Sciences, 2014
Forensic Science International, 2014
Zeitschrift für Naturforschung C, 2014
ChemMedChem, 2015 – present
Journal of Ethnopharmacology, 2018 – present
Journal of Psychoactive Drugs, 2019 – present
Scientific Reports, 2020
ACS Omega, 2020
AAPS Journal, 2020 – present
Human Psychopharmacology: Clinical and Experimental, 2020
Nature Communications, 2021
ACS Pharmacology & Translational Sciences, 2022 – present
Addiction Neuroscience, 2022

Editorial Appointments

New Trends Editor, Medicinal Chemistry Research, Springer, 2002 – 2010
Senior Editorial Board, Molecular Conceptor, Synergix, Ltd., 2005 – Present
Editorial Advisory Board, Current Topics in Medicinal Chemistry, Bentham, 2006 – 2009
Editorial Board, Pharmacologyonline, 2006 – Present
Editorial Board, Perspectives in Medicinal Chemistry, Libertas Academica, 2007 – Present
Editorial Board, The Open Medicinal Chemistry, Bentham, 2007 – 2017
Editorial Board, The Open Enzyme Inhibition Journal, Bentham, 2008 – 2011
Editorial Board, Current Bioactive Compounds, Bentham, 2008 – 2015
Editorial Board, Future Medicinal Chemistry, Future Science Group, 2008 – Present
Senior Editor, Medicinal Chemistry Research, Springer, 2011 – 2019
Editorial Advisory Board, Journal of Medicinal Chemistry, ACS Publications, 2011 – Present
Guest Editor, Current Topics in Medicinal Chemistry, Bentham, 2011
Editorial Board, World Journal of Pharmacology, Baishideng Publishing Group, 2011 – Present
Associate Editor (Ad Hoc), AAPS PharmSci Tech, AAPS Publishing, 2011
Editorial Advisory Board, Letters in Drug Design and Discovery, Bentham, 2012 – 2015
Editorial Board, Scientifica Pharmaceuticals, Hindawi Publishing Corporation, 2012 – 2017
Editorial Board of Referees, Arkivoc Journal, <http://www.arkat-usa.org>, 2012 – Present
Editor-In-Chief (Ad Hoc), AAPS PharmSci Tech, AAPS Publishing, 2012
Review Editor, Frontiers in Neuroscience, 2015 – Present
Editorial Advisory Board, AAPS Open, SpringerNature, 2019 – Present
Editorial Advisory Board, ACS Pharmacology & Translational Sciences, 2020 – Present

Expert Witness Legal Consultancy

09/2007 – 03/2008	Sterne, Kessler, Goldstein & Fox, Washington, DC
11/2012 – 4/2013	Kramer, Levin, Naftalis, & Frankel LLP, New York, NY
03/2014 – present	IMS Expert Services, Pensacola, FL
03/2014 – 09/2015	Dechert LLP, Silicon Valley, CA
03/2014 – present	Palm Beach Law, PLLC, Delray Beach, FL
11/2017 – present	Swope, Rodante, P.A., Tampa, FL

10/2019 – 11/2019	Office of the Ohio Public Defender, Columbus, OH
06/2021 – 12/2021	Office of the Federal Public Defender, District of Nevada, Las Vegas, NV
10/2021 – present	AbbVie Inc.
04/2023 – present	Goodwin Procter LLP, Santa Monica, CA
06/2023 – present	JohnC. Mallios & Associates, Waxahachie, TX

Scientific Consultancy

12/2011	West Virginia University, School of Pharmacy
06/2017 – present	United States Food and Drug Administration (US FDA), Drug Safety and Risk Management (DSaRM) Advisory Committee
11/2021 – present	Member, Scientific Advisory Board, Forbes & Manhattan, Inc.
12/2021 – present	Director of Medical Innovation, Novium Wellness
04/2023 – present	Member, Scientific Advisory Board, Nuka Enterprises, LLC

PROFESSIONAL/COMMUNITY SERVICE

Professional Service

International Pharmaceutical Federation (FIP)

Co-chair, Drug Design and Discovery Special Interest Group, 2015 – 2019

Sigma Xi, Ole Miss Chapter

President Elect, 2006 – 2008

President, 2008 – 2010

Pharmacy Leadership and Education Institute, Glaxo/Smith Kline Albert Prescott Award
selection committee, 2002 – 2006

American Association of Pharmaceutical Scientists (AAPS), Drug Design and Discovery Section
(formerly Medicinal and Natural Products Section), 1997 – 2017

National Biotechnology Conference Planning Committee, 2003 – 2004

Vice-Chair, DDD section, 2005 – 2006

Chair-Elect, DDD section, 2006 – 2007

Annual Meeting Planning Committee, 2006 – 2007

Chair, DDD section, 2007 – 2009

Nominations committee, 2007 – 2009

Past-Chair, DDD Section 2009 – 2010

Program Coordination Committee, 2019 – 2010

AAPS D3I committee/focus group, 2008 – present

American Association of Pharmaceutical Scientists (AAPS) Publications Committee

Chair-Elect, 2010 – 2011

Chair, 2011 – 2012

Past Chair, 2012 – 2013

American Association of Pharmaceutical Scientists (AAPS) Annual Meeting Planning
Committee

Drug Design and Discovery (DDD) Section representative, 2006 – 2007

Co-Chair, 2011 – 2012

Chair, 2012 – 2013

Past Chair, 2013 – 2014

American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference
Planning Committee, DDD Section representative, 2003 – 2004

American Association of Pharmaceutical Scientists (AAPS) Executive Council

Member-At-Large, 2013 – 2016

President-Elect, 2016 – 2017

President, 2017 – 2018

Immediate Past-President, 2018-2019

American Chemical Society Local Ole Miss Section Secretary, 2003 – 2004

UNIVERSITY ADMINISTRATION, COMMITTEES AND SERVICE

University of Florida, College of Pharmacy, Gainesville, Florida

Faculty Governance Council, 2023 – present (ex-officio)

Associate Dean for Faculty Development, 2023 – present

Diversity and Inclusion Committee, 2020 – present

Tenure and Promotion Committee, 2019 – present (**Chair**, 2020 – 2023, ex-officio 2023 - present)

Curriculum Committee, 2017 – 2019

Department of Pharmacodynamics Faculty Search Committee, 2017

Department of Medicinal Chemistry Faculty Search Committee, 2017

University of Mississippi

Office of Research and Sponsored Programs, Faculty Fellow, 2016

Chancellor's Standing Committee, University Research Board, School of Pharmacy Representative (alternate), 2013 – 2016

UM Southeastern Conference Faculty Achievement Award Selection Committee, 2012 – 2016

UM Faculty Achievement Award Selection Committee, 2012 – 2016

Chancellor's Standing Committee, Academic Freedom and Responsibility, 2011 – 2014

Chair, 2013-2014

Task Force on the UM World Science Festival, 2010 – 2011

Chancellor's Standing Committee, Graduate Council, 2009 – 2013

UM Competes Task Force, School of Pharmacy Representative, 2008

Sigma Xi, Ole Miss Chapter, President, 2008 – 2010

Sigma Xi, Ole Miss Chapter, President Elect, 2006 – 2008

Alcohol Task Force, 2006 – 2007

Vivarium Task Force, 2005

Faculty Senate, 2003 – 2005, **Chair**, University-wide elections committee, 2004 – 2005

National Center for Natural Products Research Assoc. Director Search Committee, 2003 – 2004

Faculty Achievement Award Selection Committee, 2002

Who's Who selection committee, 2001 – 2003

Chancellor's Committee on Health and Safety, Chemical Safety Subcommittee, 2001 – 2004

University of Mississippi, School of Pharmacy

BioMolecular Sciences, Faculty Search Committee Chair, Neuropharmacology, 2015 – 2016

BioMolecular Sciences, Faculty Search Committee Member, Medicinal Chemistry, 2015 – 2016

Dean's Office, Grants Management Specialist Search Committee, 2014

BioMolecular Sciences, R & D Scientist Search Committee, 2014

Dean's Office, Accountant I Search Committee, 2014

Promotion/Tenure Track Ad Hoc Committee, Department of BioMolecular Sciences, 2014

Medicinal Chemistry Faculty Search Committee, 2013

Curriculum Committee, 2012 – 2016, **Chair**, 2014 – 2016
Joseph Sam Alumni Award Selection Committee, 2011 – 2016
Research and Graduate Affairs, 2008 – 2014
Faculty Council, 2008 – 2010
Continuing Education, Lecture, and Alumni Activities, **Vice-Chair**, 2007 – 2008
Curriculum Subcommittee of Strategic Planning Committee, 2006 – 2007
Faculty Council, **Chair**, 2006 – 2007
Medicinal Chemistry Chair Search Committee, 2005 – 2006
Scholastic Standards Committee, 2005 – 2007
Pharmacology Faculty Search Committee, 2005
Mission, Planning, and Assessment Subcommittee, ACPE accreditation team, 2004 – 2006
Faculty Task Force on Faculty Governance, 2004 – 2005
Coy Waller Distinguished Lecture Committee, 2004
Faculty Council, **Vice-Chair**, 2004 – 2006
Pharmaceutics Chair Search Committee, 2003 – 2005
Medicinal Chemistry Faculty Search Committee, 2003 – 2004
Medicinal Chemistry Faculty Search Committee, 2002 – 2003
Early-Entry Program Interviewer, 2003 – 2016
Faculty-Student Affairs Committee, 2001 – 2004
Honors and Awards Committee, **Chair**, 2001 – 2003
Curriculum Committee, 2001 – 2005
Drug abuse advisory council, and Utah school advisor 2002 – 2016

University of Georgia, College of Pharmacy

Dean-Graduate Student Relations Committee, 1993
Graduate Student Representative on Faculty Search Committee, 1991
Research and Seminar Committee, Student Member, 1991 – 1992

Ohio Northern University

Student Senate, College of Pharmacy Representative, 1991 – 1993

Ohio Northern University, College of Pharmacy

Dean Search Committee, Student Representative, 1991
Pharmacy Council, President, 1991 – 1992
Drug Abuse Awareness Team, 1991

PRESENTATIONS

INVITED PRESENTATIONS

International Invited Presentations

- 8/23 **McCurdy, C.R.** The Science of Kratom. The 7th Current Drug Development International Conference 2023 & 1st World Kratom Congress. The (basic) Science of Kratom. **Keynote address.** Phuket, Thailand. August 23-25, 2023.
- 02/23 **McCurdy, C.R.** A Non-Opioid Theranostic Approach to Pain Relief. Fifth International Conference on PharmScience Research & Development. Las Vegas, NV. February 21-24, 2023.
- 9/22 **McCurdy, C.R.** Kratom: Ethnopharmacology, Chemistry, and Human Uses. International Brain Research Organization (IBRO)-ARPC School on Neuroprotective Potential on Medicinal Plants and Phytochemicals in Neurodegenerative Disorders. **Keynote address.** Banaras Hindu University, Varanasi, India. September 12-18, 2022.
- 5/22 **McCurdy, C.R.** Kratom (*Mitragyna speciosa*): Recent Advances in Understanding the Chemistry, Pharmacology, and Human Uses. Ethnopharmacologic Search for Psychoactive Drugs 55 years of Research (ESPD55). St. Giles House, East Dorset, England. May 23-26, 2022. Live Streamed on www.espd55.com and Facebook.
- 10/20 **McCurdy, C.R.** Understanding Kratom (*Mitragyna speciosa*): Chemistry, Pharmacology, and Therapeutic Potential. Recent Trends in Neuroscience Research, International Webinar Series, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, Karnataka, India. October 23, 2020.
- 08/20 **McCurdy, C.R.** *Mitragyna speciosa*: What Science is Telling us About Kratom. American Chemical Society Webinar Series. August 23, 2020.
- 06/19 **McCurdy, C.R.;** McMahon, L.R. Kratom Research at the University of Florida. 12th Global Gator Symposium. Reims, France. June 28, 2019.
- 02/19 **McCurdy, C.R.** Welcome and introductory remarks, Kratom since we last met. 2nd International Symposium on Kratom/Ketum. Orlando, FL, USA. February 8-10, 2019.
- 05/18 **McCurdy, C.R.** Clinical Translation of a Sigma Receptor Antagonist as a Diagnostic Agent for Nerve Damage. Fudan University, Shanghai, China. June 2, 2018.
- 05/18 **McCurdy, C.R.** Clinical Translation of a Sigma Receptor Antagonist as a Diagnostic Agent for Nerve Damage. INSIGHT 2018, Pharmaceutical Sciences

Across Borders 3rd Annual Asia-Pacific Research Symposium. **Keynote address.** China Pharmaceutical University, Nanjing, China. May 26-27, 2018.

- 05/18 **McCurdy, C.R.** Sigma Receptor Ligands for Treatment and Diagnosis of Pain: Translation from Lab to Human Trials. Invited special lecture Kasturba Medical College, Mangalore, Manipal, India. May, 22, 2018.
- 08/17 **McCurdy, C.R.** Sigma Receptor Ligands: From Discovery to Clinical Translation. 1st International Brain Research Organization (IBRO)-ARPC Banasthali School of Neuroscience. **Keynote address.** Banasthali University, Jaipur, Rajasthan, India. August 21-26, 2017.
- 06/17 **McCurdy, C.R.** Kratom (*Mitragyna speciosa*) as a potential therapy for opioid dependence. Ethnopharmacologic Search for Psychoactive Drugs II: 50 years of Research (1967 – 2017). Tyringham Hall, Buckinghamshire, England. June 6-8, 2017. Also Live Streamed on Facebook.
- 04/17 **McCurdy, C.R.** Potential of ketum for pain treatment and opioid withdrawal symptoms in mice. International Symposium on Ketum. Penang, Malaysia. April 5-7, 2017.
- 07/16 **McCurdy, C.R.** Sigma receptor antagonists potentiate the analgesic effects of cannabinoid receptor agonists. Hungarian Academy of Sciences. Budapest, Hungary. July 4, 2016.
- 06/16 **McCurdy, C.R.** Sigma receptor blockade potentiates the analgesic effects of cannabinoids. 26th Annual Symposium of the International Cannabinoid Research Society. Bukovina, Poland. Oral presentation 21, June 27, 2016.
- 06/15 **McCurdy, C.R.** Sigma receptor antagonists in peripheral pain: Potential for improved diagnosis and pharmacotherapy with significantly reduced CNS liabilities. 46th International Narcotics Research Conference (INRC). Session 2 – “Advances in Therapeutic Design”. Phoenix, AZ. June 15-19, 2015.
- 12/11 **McCurdy, C.R.** The Other Side of the Desk: A Career in Academia. American Association of Pharmaceutical Scientists, Student-Postdoctoral Outreach and Development Webinar presentation (SPOD-4). December 8, 2011. (archived at <http://www.aaps.org/webinars>)
- 01/11 **McCurdy, C.R.** Investigations of *Mitragyna speciosa* as a potential treatment for Opioid Withdrawal Syndrome. Recent Advances in Pharmaceutical Research. Beni-Sueif University. Beni-Sueif, Egypt. January 12, 2011.
- 02/10 **McCurdy, C.R.** Development of highly selective sigma-2 receptor ligands. 2nd International Conference on Drug Design and Discovery, Dubai, United Arab Emirates (UAE). February 1-4, 2010 (WITHDREW PARTICIPATION).

- 09/09 **McCurdy, C.R.** Sigma Receptors as Targets for Cocaine and Methamphetamine Pharmacotherapies. Universidade of São Paulo, Faculdade de Ciências Farmacêuticas de Ribeirão Preto. Ribeirão Preto, Brazil. September 10, 2009.
- 09/09 **McCurdy, C.R.** Characterization of the opioid withdrawal effects of *Mitragyna speciosa*, 7th International Congress of Pharmaceutical Sciences (CIFARP), Centro de Convenções Ribeirão Preto SP Brazil, September 6-9, 2009.
- 07/09 **McCurdy, C.R.** Sigma receptors: applications to drug design. University of Bologna Summer School, Bologna, Italy, July 6-10, 2009.
- 06/09 **McCurdy, C.R.** Understanding sigma receptor ligand interactions. 71st Annual Meeting of The College on Problems of Drug Dependence (CPDD), Reno, NV, June 20-25, 2009.
- 11/08 **McCurdy, C.R.** Development of Selective Sigma Receptor Ligands. 2009 Annual Meeting of the American Association of Pharmaceutical Scientists, Atlanta, GA, November 16-20, 2008.
- 11/08 **McCurdy, C.R.** Combining Target-based and Ligand-based Virtual Screening to Identify New Leads. 2009 Annual Meeting of the American Association of Pharmaceutical Scientists, Atlanta, GA, November 16-20, 2008.
- 09/08 **McCurdy, C.R.** Design and Application of Selective Sigma Ligands. Université Catholique de Louvain, Brussels, Belgium, September 9, 2008.
- 06/08 **McCurdy, C.R.** Discovery of a selective sigma-2 receptor ligand and the potential involvement of sigma-2 receptors in cocaine toxicity. 70th Annual Meeting of The College on Problems of Drug Dependence (CPDD), San Juan, Puerto Rico, June 14-19, 2008.
- 02/08 **McCurdy, C.R.** Sigma Receptor Ligands as Pharmacotherapy for Psychostimulant Abuse. 1st International Conference on Drug Design and Discovery, Dubai, United Arab Emirates (UAE). February 4-7, 2008.
- 07/07 **McCurdy, C.R.** Salvinorin A Binding Mode at Kappa Opioid Receptors and Reversal of Actions by Kappa Antagonists. International Narcotics Research Conference (INRC), Berlin, Germany, July 8-13, 2007.
- 06/07 **McCurdy, C.R.** New approaches to the treatment of psychostimulant abuse. Peking Union Medical College, Chinese Academy of Medical Science, Institute of Materia Medica, Beijing, China, June 1, 2007.
- 04/07 Singh, N.; **McCurdy, C.R.** Delineating a powerful virtual screening protocol for G-protein coupled receptors: Application to a selective kappa opioid receptor agonist, salvinorin A. Pharmaceutical Sciences World Congress, Amsterdam, Netherlands, April 22-25, 2007.

- 06/04 **McCurdy, C.R.** Novel templates with affinity for opioid receptors. Institut de Chimie Pharmaceutique Albert Lespagnol, Universite de Lille 2, Lille, France, June 10, 2004.
- 06/04 **McCurdy, C.R.** Salvinorin A, A Structurally Novel Opioid Lead. Universite Paul Sabatier, Toulouse III, CNRS, Toulouse, France, June 8, 2004.
- 06/04 **McCurdy, C.R.** Non-nitrogenous kappa opioid receptor ligands based on Salvinorin A, a unique and naturally occurring opiate lead. Journées Franco Belges, Luxembourg, June 3, 2004.
- 06/04 **McCurdy, C.R.** Parallel Synthesis of Spirohydantoin Libraries. Universite Catholique de Louvain, Brussels, Belgium, June 1, 2004.
- 07/03 **McCurdy, C.R.** Design and application of reporter affinity labels. Universita di Catania, Catania, Italy. July 14, 2003.

National Invited Presentations

- 10/22 **McCurdy, C.R.** How Close is a Cure for Pain? Dean's Distinguished Lecture, Rowan University, Glassboro, NJ. October 7, 2022.
- 10/22 **McCurdy, C.R.** Kratom 101: History, Chemistry, and Pharmacology. Camille and Henri Dreyfus Lecture, Rowan University, Glassboro, NJ. October 6, 2022.
- 09/22 **McCurdy, C.R.** Novel Treatment Approaches for Pain: Opioid Partial Agonists and Other Targets. 2022 American College of Clinical Pharmacology Annual Meeting. Trends in Drug Development Seminar, Bethesda, MD. September 24, 2022.
- 04/22 **McCurdy, C.R.** Can a controversial tree help end the opioid crisis? National Center for Complementary and Integrative Health (NCCIH), National Institutes of Health (NIH), Bethesda, MD. April 25, 2022.
- 03/22 **McCurdy, C.R.** Can we end the opioid crisis at the gas station? Department of Pharmaceutical Sciences Seminar Series, University of Tennessee College of Pharmacy, Memphis, TN. March 1, 2022.
- 02/22 **McCurdy, C.R.** Kratom (*Mitragyna speciosa*): A complex symphony of alkaloids that may help the opioid crisis. Medicinal Chemistry Seminar Series. University of Minnesota College of Pharmacy, Minneapolis, MN. February 15, 2022.
- 11/21 **McCurdy, C.R.** AAPS-ULM Student Chapter 4th Annual Research Symposium Keynote Speaker. University of Louisiana at Monroe College of Pharmacy, Monroe, LA. November 1, 2021.

- 08/21 **McCurdy, C.R.** TBD. Keynote Speaker for annual NIGMS-Funded Systems Pharmacology and Toxicology (SPaT) T32 Symposium. University of Arkansas for Medical Sciences (UAMS), Little Rock, AR. August 13, 2021.
- 06/21 **McCurdy, C.R.** Kratom (*Mitragyna speciosa*): What science is revealing about this controversial supplement. United States Food and Drug Administration, Center for Drug Evaluation and Research, Botanical Drug Seminar Series. June 3, 2021. – PRESENTED VIRTUALLY
- 04/21 **McCurdy, C.R.** Kratom (*Mitragyna speciosa*): Could the controversial Herb Help End the Opioid Crisis? Emory University School of Medicine, Atlanta, GA. April 6, 2021. – PRESENTED VIRTUALLY
- 03/21 **McCurdy, C.R.** The Science of Kratom: what we know today. Tennessee Association of Alcohol, Drug & other Addiction Services (TAADAS). Nashville, TN. March 26, 2021. – PRESENTED VIRTUALLY
- 02/21 **McCurdy, C.R.** My career journey from dispensing drugs to developing them. Rowan University **Dreyfus Lectureship – Part 2**. Rowan University, Glassboro, NJ. February 12, 2021. – PRESENTED VIRTUALLY
- 02/21 **McCurdy, C.R.** Kratom Science. Lipscomb University. February 9, 2021. – PRESENTED VIRTUALLY
- 01/21 **McCurdy, C.R.;** McMahon, L.R. Chemistry and Pharmacology of *Mitragyna speciosa* (kratom). American Society of Pharmacognosy Webinar series. January 21, 2021. – PRESENTED VIRTUALLY
- 11/20 **McCurdy, C.R.** Kratom Science: Where We Stand Today. Kratom Leadership Summit, Tampa Airport Marriott, Tampa, FL. November 12-13, 2020. – PRESENTED VIRTUALLY
- 09/20 **McCurdy, C.R.** Translation of a Sigma-1 Receptor Ligand into Human Clinical Trials for Diagnosis of Nerve Damage and Potential for a non-Opioid Analgesic. School of Pharmacy, Virginia Commonwealth University, Richmond, VA. September 25, 2020 – VIRTUAL VISIT
- 01/20 **McCurdy, C.R.** Kratom – Potential Drug of Abuse or Useful Analgesic Without Opioid-Like Side-Effects? Winter Conference on Brain Research. Big Sky, MT. January 26, 2020
- 11/19 **McCurdy, C.R.** Rowan University **Dreyfus Lectureship**. Rowan University, Glassboro, NJ. November 14-15, 2019.
- 10/19 **McCurdy, C.R.** University of Missouri Kansas City Dean's Forum. Kansas City, MO. October 24-25, 2019. **Keynote Lecture**

- 08/19 **McCurdy, C.R.** Kratom: History and Phytochemistry. Chemistry & Pharmacology of Drug Abuse Conference. Northeastern University, Boston, MA. August 1-2, 2019.
- 04/19 **McCurdy, C.R.** *Mitragyna speciosa*: Phytochemistry in Plants and Biotransformation in Animals. Team Science: from Molecules to Test Tubes to Behavior. ASPET Annual Meeting at Experimental Biology 2019. Orlando, FL. April 9, 2019.
- 06/18 **McCurdy, C.R.** Visualizing Pain to Develop Better Treatments. 2018 Drug Discovery and Development Colloquium. University of Kentucky College of Pharmacy, Lexington, KY. June 22, 2018. **Keynote Lecture**
- 06/18 **McCurdy, C.R.** History, chemistry and pharmacology of Kratom. College on Problems of Drug Dependence 80th Annual Meeting. Symposium XX “Kratom: Bitter Narcotic or Sweet Medicine for Pain and Opioid Addiction?” San Diego, CA. June 14, 2018.
- 12/17 **McCurdy, C.R.** Something on Sigma and Translational Medicine. American Physician Scientists Association (APSA) Annual MD/PhD Symposia, University of Arkansas for Medical Sciences, Little Rock, AR December 6, 2017. **Keynote Lecture**
- 10/17 **McCurdy, C.R.** Translation of Sigma Receptor Ligands from Conception to the Clinic. Long School of Medicine, Department of Pharmacology, UT Health San Antonio, San Antonio, TX (October 11, 2017)
- 10/17 **McCurdy, C.R.** Chalk-Talk “Soft Skills” NIDA T32 training grant
- 10/17 **McCurdy, C.R.** Sigma receptor ligands: From Discovery to Human Clinical Translation. College of Medicine, Department of Neuroscience, McKnight Brain Institute, University of Florida, Gainesville, FL (October 5, 2017)
- 9/17 **McCurdy, C.R.** Kratom (*Mitragyna speciosa*) as a Potential Treatment for Opioid Dependence. UF Drug Discovery Symposium, Center for Natural Products, Drug Discovery & Development (CNP3), Gainesville, FL. September 21-22, 2017.
- 3/17 **McCurdy, C.R.** Development and clinical translation of sigma receptor ligands as diagnostics and therapeutics for pain. 2017 Behavior, Biology, and Chemistry: Translational Research in Addiction. San Antonio, TX. March 4-5, 2017. **Special Lecture**
- 1/16 **McCurdy, C.R.** Targeting Sigma Receptors to Diagnose and Treat Peripheral Pain. College of Pharmacy, Department of Medicinal Chemistry, University of Florida, Gainesville, FL (January 5, 2016)

- 12/15 **McCurdy, C.R.** Improving the diagnosis and treatment of peripheral pain. College of Pharmacy, Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR (December 4, 2015)
- 9/15 **McCurdy, C.R.** Sigma Receptor Antagonists for Peripheral Pain. College of Pharmacy, Center for Drug Design, University of Minnesota, Minneapolis, MN (September 16, 2015)
- 1/15 **McCurdy, C.R.** Chemical Dependency Awareness Day Lecture, Mylan School of Pharmacy, Duquesne University, Pittsburgh, PA (January 7, 2015)
- 12/14 **McCurdy, C.R.** Developing Pharmacotherapy for Psychostimulant Abuse and Peripheral Pain. University of Mississippi Medical Center, Jackson, MS (December 11, 2014)
- 12/14 **McCurdy, C.R.** Development of Highly Selective Sigma Receptor Ligands for CNS Disorders. Department of Medicinal and Natural Products Chemistry Seminar Series, College of Pharmacy, University of Iowa, Iowa City, IA (December 9, 2014)
- 06/14 **McCurdy, C.R.** Development and Preclinical Efficacy of a Dual Sigma Receptor Antagonist/Dopamine Uptake Inhibitor, CM699, as a Medication for Stimulant Abuse. Featured Speaker, Drug Discovery and Development Colloquium 2014. University of Arkansas for Medical Sciences, Little Rock, AR. (June 20, 2014)
- 12/13 **McCurdy, C.R.** The Utilization of Natural Products as Potential Treatments for Drug Abuse and Addiction, Division of Clinical Chemistry/Hematology, University of Pittsburgh Medical Center Presbyterian-Shadyside. Pittsburgh, PA. (December 17, 2013)
- 03/13 **McCurdy, C.R.** The Role of Sigma-1 Receptors in Cocaine Self-Administration. Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University Medical Center, Stanford, CA. (March 12, 2013).
- 11/12 **McCurdy, C.R.** Medicinal Chemistry Careers as a Pharmacist. Ohio Northern University, Raabe College of Pharmacy, Ada, OH. (November 7, 2012).
- 05/12 **McCurdy, C.R.** Targeting Sigma Receptors - Insights to blocking the actions of psychostimulants and CNS disorders. University of Georgia, Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, Athens, GA. (May 9, 2012)
- 04/12 **McCurdy, C.R.** Towards the Development of a Botanical Drug Product for Opioid Withdrawal Syndrome. University of Georgia Symposium on Pharmaceutical Development. The Classic Center, Athens, GA. (April 19, 2012)

- 06/11 **McCurdy, C.R.** Sigma Receptors: Targeting an Enigma? Philip S. Portoghese Symposium - Recognizing 50 years of Teaching, Research and Service. University of Minnesota, College of Pharmacy, Minneapolis, MN. (June 2, 2011)
- 4/11 **McCurdy, C.R.** Investigations of Kratom (*Mitragyna speciosa*) as a potential herbal drug for opioid withdrawal. West Virginia University, School of Pharmacy, AAPS Visiting Scholar Speaker, Morgantown, WV. (April 7, 2011)
- 12/10 **McCurdy, C.R.** *Mitragyna speciosa* (Kratom): Development of a botanical product for opioid addiction. Duquesne University, Mylan School of Pharmacy, Graduate School of Pharmaceutical Sciences, Pittsburgh, PA. (December 1, 2010)
- 09/10 **McCurdy, C.R.** Investigations of Kratom (*Mitragyna speciosa*) as a potential herbal drug for opioid withdrawal. West Virginia University, School of Pharmacy Research Day, Keynote Speaker, Morgantown, WV. (September 30, 2010) (Rescheduled – personal health issue)
- 04/10 **McCurdy, C.R.** Highly Selective Sigma Receptor Ligands as Antipsychostimulants. University of Tennessee Health Science Center, Department of Pharmaceutical Sciences Seminar Series, Memphis, TN. (April 12, 2010)
- 11/09 **McCurdy, C.R.** Development of Highly Selective Sigma-2 Receptor Ligands. Department of Health & Human Services, National Institutes of Health, National Institute on Drug Abuse, Intramural Research Program Seminar Series. Baltimore, MD (November 17, 2009)
- 01/09 **McCurdy, C.R.** Drug Design of Potential Treatments for Cocaine and Methamphetamine Abuse. The University of Georgia, Department of Chemistry, Athens, GA (January 15, 2009)
- 05/08 **McCurdy, C.R.** Design of a highly selective sigma-2 receptor ligand with cocaine antagonist activity. University of Maryland School of Pharmacy, Baltimore, MD. (May 28, 2008)
- 04/08 **McCurdy, C.R.** *Mitragyna speciosa*. 4th Interim American Society of Pharmacognosy Meeting, National Center for Natural Products Research, Oxford, MS. (April 12-16, 2008)
- 12/07 **McCurdy, C.R.** Sigma Receptor Antagonists with Anti-Psychostimulant Activity, McLean Hospital, Harvard Medical School, Belmont, MA. (December 17, 2007)
- 09/07 **McCurdy, C.R.** Sigma Receptor Antagonists as Potential Pharmacotherapy for Psychostimulant Abuse, University of Kentucky, College of Pharmacy, Lexington, KY. (September 28, 2007)

- 09/07 **McCurdy, C.R.** Guest Speaker, Contemporary Pharmacy Practice Course, Ohio Northern University, College of Pharmacy, Ada, OH. (September 26, 2007)
- 09/07 **McCurdy, C.R.** Pharmacotherapy Development for Cocaine and Methamphetamine Abuse. Ohio Northern University, College of Pharmacy, Ada, OH. (September 26, 2007)
- 04/07 **McCurdy, C.R.** Novel Pharmacological Interventions for Psychostimulant Abuse: Answering NIDAs Call. University of Minnesota National Institute on Drug Abuse Training Grant Retreat. Minneapolis, MN. (April 9, 2007).
- 02/07 **McCurdy, C.R.** Targeting Sigma Receptors for the Treatment of Cocaine Abuse. University of Arkansas, College of Pharmacy, Little Rock, AR. (February 9, 2007).
- 12/06 **McCurdy, C.R.** A New Approach to Pharmacotherapies for Psychostimulant Abuse. Southern Illinois University Edwardsville, Department of Pharmaceutical Sciences, School of Pharmacy, Edwardsville, IL. (December 8, 2006).
- 10/06 **McCurdy, C.R.** Sigma Receptor Antagonists: Potential Pharmacotherapy for Psychostimulant Abuse. University of Houston, Department of Pharmaceutical Sciences, Houston, TX. (October 3, 2006)
- 10/05 Singh, N.; Cheve, G.; **McCurdy, C.R.** Comparative Protein Modeling of 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase Enzyme from *Plasmodium falciparum*: Structural and Docking Analysis. American Chemical Society Prospectives: Advances in Structure-Based Drug Discovery, October 16-19, Philadelphia, PA.
- 10/05 **McCurdy, C.R.** Sigma Receptor Ligands. University of Minnesota, College of Pharmacy, Department of Medicinal Chemistry, Minneapolis, MN. (October 18, 2005)
- 11/04 **McCurdy, C.R.**, Scully, S.S. "Natural Products (Naturceuticals) with Analgesic Properties", NIDA-AAPS Naturceuticals (Natural Products), Nutraceuticals, Herbal Botanicals, and Psychoactives: Drug Discovery and Drug-Drug Interactions. November 5-7, 2004. Baltimore, MD.
- 05/04 **McCurdy, C.R.** "Medicinal Chemistry Research: Keys to the Future", Ohio Northern University, College of Pharmacy, Ada, OH.
- 04/04 **McCurdy, C.R.** "Efforts to Understand Opioid Receptor Selectivity", Department of Medicinal Chemistry, University of Florida, College of Pharmacy, Gainesville, FL.
- 03/04 **McCurdy, C.R.** "Drug Discovery Processes and the Art of Medicinal Chemistry" University of Florida, College of Dentistry, Comprehensive Center for Pain Research, Gainesville, FL.

- 03/01 **McCurdy, C.R.** "Naphthalene Dicarboxaldehyde Derivatives of Opiate Antagonists as Reporter Affinity Labels: A New Concept in Medicinal Chemistry." University of Mississippi, School of Pharmacy, University, MS.
- 02/01 **McCurdy, C.R.** "Reporter Affinity Labels: A New Concept in Medicinal Chemistry." University of the Pacific, College of Pharmacy, Stockton, CA.
- 03/98 **McCurdy, C.R.** "Synthesis and biological activity of lobeline analogs with selective activation of neuronal nicotinic receptors containing the β -4 subunit. University of Minnesota, College of Pharmacy, Minneapolis, MN.
- 09/97 Beach, J.W.; **McCurdy, C.R.**; Terry Jr., A.V.; Cosford, N. "Nicotinic agonists based on lobeline, synthesis and biological evaluation. 214th ACS National Meeting, Las Vegas, NV.

PRESENTATIONS (Not published as abstracts)

National/International Presentations

- 07/16 Mottinelli, M.; Journigan, V.B.; Mesangeau, C.; Cutler, S.J.; Eans, S.O.; Medina, J.M.; McLaughlin, J.P.; **McCurdy, C.R.** New Biphenylmethylenepiperidine Derivatives as Dual Opioid-NPFF Ligands: In Vitro and In Vivo Evaluation. International Narcotics Research Conference, Bath, United Kingdom, July 11-14, 2016. M1.13
- 10/15 Mavlyutov, T.A.; Yao, A.; Chu, U.; Chu, M.; Zhao, L.; Yang, H.; **McCurdy, C.R.**; Ruoho, A.E.; Guo, L.-W. Role of sigma receptors in the viability of retinal pigment epithelial cells – studies using the crispr-cas9 system. Neuroscience 2015, Society for Neuroscience, Chicago, IL, October 17-21, 2015. 58.10/J21
- 10/15 Ruoho, A.E.; Mavlyutov, T.A.; Chu, U.B.; Chu, M.; Zhao, L.; Yang, H.; **McCurdy, C.R.**; Guo, L.-W. Sigma-2 receptor 18 kDa and PGRMC1 are distinct gene products. Neuroscience 2015, Society for Neuroscience, Chicago, IL, October 17-21, 2015. 555.03
- 10/15 Nicholson, H.E.; Mesangeau, C.; **McCurdy, C.R.**; Bowen, W.D. A potential neuroprotective function for the sigma-2 receptor. Neuroscience 2015, Society for Neuroscience, Chicago, IL, October 17-21, 2015. 555.07
- 06/15 McLaughlin, J.P.; Eans, S.O.; Medina, J.M.; Ganno, M.L.; Journigan, V.B.; Cutler, S.J.; **McCurdy, C.R.** Neuropeptide FF (NPFF)-induced hyperalgesia and acute opioid antinociceptive tolerance is prevented by VBJ-192, a dual-activity mu-opioid receptor (MOR) agonist-NPFF receptor antagonist. 46th International Narcotics Research Conference (INRC). Phoenix, AZ. June 15-19, 2015. Poster #68.

- 11/14 Hiranita, T.; Kopajtic, T.A.; Mesangeau, C.; **McCurdy, C.R.**; Katz, J.L. Self-administration of the sigma-receptor agonist, DTG, in experimentally naïve rats. Neuroscience 2014, Society for Neuroscience, Washington DC, November 15-19, 2014. 812.02/BB23
- 11/14 Nicholson, H.E.; Weledji, N.T.; Mesangeau, C.; **McCurdy, C.R.**; Bowen, W.D. Metabolism stimulation by CM-769: A novel function for the sigma-2 receptor. Neuroscience 2014, Society for Neuroscience, Washington DC, November 15-19, 2014. 299.17/B31
- 11/14 Alsharif, W.; Kopajtic, T.; Kandasamy, M.; Avery, B.A.; Hiranita, T.; Katz, J.L.; **McCurdy, C.R.** Analogs of the Dual Sigma Receptor Antagonist Dopamine Uptake Inhibitor, CM699, as Potential Pharmacotherapy for Stimulant Abuse. 2014 American Association of Pharmaceutical Scientists Annual Meeting, San Diego, CA. November 2-6, 2014. Poster # T3020. **AAPS DDI Graduate Student Research Award Presentation**
- 07/14 **McCurdy, C.R.**; Journigan, V.B.; Mesangeau, C.; Kapanda, C.N.; Cutler, S.J.; Eans, S.O.; Ganno, M.L.; Mollereau, C.; McLaughlin, J.P. Synthesis and Evaluation of Dual-Activity Opioid-NPFF Ligands for Receptor Affinity, Antinociception and Tolerance Liabilities. 45th meeting of the International Narcotics Research Conference 2014. Montreal, Quebec, Canada. July 13-18, 2014. Poster #25.
- 06/14 **McCurdy, C.R.**; Mesangeau, C.; Hiranita, T.; Lopez, J.; Brellenthin, A.; Kopajtic, T.; Coggiano, M.; Alsharif, W.; Jamalapuram, S.; Tsai, S.-Y.; Avery, B.A.; Su, T.-P.; Tanda, G.; Katz, J.L. Development and Preclinical Efficacy of a Dual Sigma Receptor Antagonist/Dopamine Uptake Inhibitor, CM699, as Potential Pharmacotherapy for Stimulant Abuse. Drug Discovery and Development Colloquium 2014, Little Rock, AR, June 20-21, 2014. **Featured Speaker Address.**
- 06/14 Alsharif, W.; Kopajtic, T.; Kandasamy, M.; Avery, B.A.; Hiranita, T.; Katz, J.L.; **McCurdy, C.R.** Analogs of the Dual Sigma Receptor Antagonist/Dopamine Uptake Inhibitor, CM699, as Potential Pharmacotherapy for Stimulant Abuse. Drug Discovery and Development Colloquium 2014, Little Rock, AR, June 20-21, 2014. Poster # 6.
- 06/14 Alsharif, W.; Comeau, A.; Mesangeau, C.; Bowen, W.D.; **McCurdy, C.R.** Development of Selective Irreversible Ligands for Sigma-2 Receptors. Drug Discovery and Development Colloquium 2014, Little Rock, AR, June 20-21, 2014. Oral Presentation.
- 06/14 **McCurdy, C.R.**; Journigan, V.B.; Mesangeau, C.; Kapanda, C.N.; Cutler, S.J.; Eans, S.O.; Ganno, M.L.; Mollereau, C.; McLaughlin, J.P. Synthesis and Evaluation of Dual-Activity Opioid-NPFF Ligands for Receptor Affinity, Antinociception and Tolerance Liabilities. NIH, NIGMS Fifth Biennial National

IDEA Symposium of Biomedical Research Excellence (NISBRE), Washington, DC, June 16-18.

- 06/14 Avery, B.A.; Jamalapuram, S.; **McCurdy, C.R.** Determination of CM699, a Sigma Receptor Ligand, in Rat Plasma by UPLC/MS and its Application to a Pharmacokinetic Study. NIH, NIGMS Fifth Biennial National IDEA Symposium of Biomedical Research Excellence (NISBRE), Washington, DC, June 16-18.
- 04/14 Katz, J.L.; Hiranita, T.; Lopez, J.; Brellenthin, A.; Mesangeau, C.; Alsharif, W.; Kopajtic, T.; Coggiano, M.; Jamalapuram, S.; Tsai, S.-Y.; Avery, B.A.; Su, T.-P.; Tanda, G.; **McCurdy C.R.** Preclinical Efficacy of the Dual Sigma Receptor Antagonist Dopamine Uptake Inhibitor, CM699, as a Medication for Stimulant Abuse. Experimental Biology 2014, San Diego, CA, April 26-30, 2014. 803.3/D382. Featured on the blog DRUG MONKEY April 28, 2014 <http://scientopia.org/blogs/drugmonkey/2014/04/28/will-a-dual-sigma-receptor-antagonist-dopamine-transporter-inhibitor-treat-stimulant-abuse/>
- 04/14 Hiranita, T.; Kopajtic, T.; Mesangeau, C.; Narayanan, S.; **McCurdy, C.R.**; Katz, J.L. The Dopamine Uptake Inhibitor, WIN 35,428 Has Sigma2 Receptor Agonist Effects that Contribute to its Self-Administration. Experimental Biology 2014, San Diego, CA, April 26-30, 2014. 14-3880-EB
- 11/13 Avery, B.A.; Jamalapuram, S.; Mesangeau, C.; Alsharif, W.; **McCurdy, C.R.** Determination of CM699, a Sigma Receptor Ligand, in Rat Plasma by Ultra Performance Liquid Chromatography Mass Spectrometry and its Application to a Pharmacokinetic Study. 2013 Annual Meeting of the American Association of Pharmaceutical Scientists, San Antonio, TX, November 10-14, 2013. W4298
- 11/13 **McCurdy, C.R.**; Alsharif, W.; Comeau, A.; Mesangeau, C.; Bowen, W.D. Synthesis and Identification of Novel and Selective Irreversible Sigma-2 Ligands. 2013 Annual Meeting of the American Association of Pharmaceutical Scientists, San Antonio, TX, November 10-14, 2013. M1005
- 11/13 Nicholson, H.; Comeau, A.; Mesangeau, C.; **McCurdy, C.R.**; Bowen, W.D. Irreversible modulators of sigma-2 receptor function: Isothiocyanate derivatives of SN-79. Neuroscience 2013, Society for Neuroscience, San Diego, CA, November 9-13, 2013. 63.03/EE9
- 11/13 Matsumoto, R.R.; Robson, M.J.; **McCurdy, C.R.**; Coop, A.; Kaushal, N. Amphetamine and Related Drugs: Neural Mechanisms of Action. Neuroscience 2013, Society for Neuroscience, San Diego, CA, November 9-13, 2013. Nanosymposium 213; 213.07
- 04/13 Nicholson, H.; Comeau, A.; Mesangeau, C.; **McCurdy, C.R.**; Bowen, W.D. Development of selective irreversible antagonists for sigma-2 receptors. American Association for Cancer Research 2013 Annual Meeting, Washington, DC, April 6-10, 2013. 13-A-6261-AACR

- 10/12 Comeau, A.; Mesangeau, C.; **McCurdy, C.R.**; Bowen, W.D. Development of selective irreversible affinity ligands for sigma-2 receptors. Neuroscience 2012, Society for Neuroscience, New Orleans, LA, October 13-17, 2012. 61.13/N16
- 10/12 Matsumoto, R.R.; Seminerio, M.J.; Hansen, R.; Kaushal, N.; **McCurdy, C.R.**; Zhang, H.-T. The evaluation of AZ66, an optimized sigma receptor ligand, against methamphetamine-induced dopaminergic neurotoxicity and memory impairment in mice. Neuroscience 2012, Society for Neuroscience, New Orleans, LA, October 13-17, 2012. 354.31/T18
- 10/12 Robson, M.; **McCurdy, C.R.**; Matsumoto, R.R. Methamphetamine elicits PERK-mediated endoplasmic reticulum transcriptional responses in NG108-15 Cells. Neuroscience 2012, Society for Neuroscience, New Orleans, LA, October 13-17, 2012. 360.12/Z8
- 10/12 Hiranita, T.; Mereu, M.; Tanda, G.; Kopajtic, T.A.; Mesangeau, C.; **McCurdy, C.R.**; Katz, J.L. Combined dopamine transporter and σ receptor actions: Effects of σ receptor subtype. Neuroscience 2012, Society for Neuroscience, New Orleans, LA, October 13-17, 2012. 561.19/U19
- 10/12 Alsharif, W.; Mesangeau, C.; Matsumoto, R.R.; Seminerio, M.J.; Robson, M.; Poupaert, J.H.; Amata, E.; **McCurdy, C.R.** Preparation and evaluation of a series of indoles as sigma receptor ligands. 2012 Annual Meeting of the American Association of Pharmaceutical Scientists, Chicago, IL, October 14-18, 2012.
- 10/12 Avery, B.A.; Vuppala, P.K.; Jamalapuram, S.; Furr, E.B.; **McCurdy, C.R.** Determination of 7-hydroxymitragyine, a μ -opioid receptor agonist, in rat plasma by UPLC/MS/MS and its application to a pharmacokinetic study. 2012 Annual Meeting of the American Association of Pharmaceutical Scientists, Chicago, IL, October 14-18, 2012.
- 10/12 Avery, B.A.; Vuppala, P.K.; Jamalapuram, S.; Furr, E.B.; **McCurdy, C.R.** Pharmacokinetics of 7-hydroxymitragyine, a μ -opioid receptor agonist, in male Sprague Dawley rats. 2012 Annual Meeting of the American Association of Pharmaceutical Scientists, Chicago, IL, October 14-18, 2012.
- 08/12 Shih, J.; Xie, J.J.; Mesangeau, C.; Fazio, N.; Seminerio, M.; Xu, Y.; Matsumoto, R.R.; **McCurdy, C.R.** Investigation of piperazine derivatives as sigma receptor ligands with methamphetamine antagonist activity. 244th American Chemical Society National Meeting, Philadelphia, PA, August 19-23, 2012. MEDI-372.
- 08/12 Xie, J.J.; Shih, J.; Mesangeau, C.; Seminerio, M.; Xu, Y.; Matsumoto, R.R.; **McCurdy, C.R.** Selective sigma-2 receptor ligands derived from tetrahydroisoquinoline. 244th American Chemical Society National Meeting, Philadelphia, PA, August 19-23, 2012. MEDI-373.
- 07/12 Avery, B.A.; Vuppala, P.K.; Jamalapuram, S.; Furr, E.B.; **McCurdy, C.R.** Pharmacokinetics of 7-hydroxymitragyine, a μ -opioid receptor agonist, in male

Sprague Dawley rats. 43rd International Narcotics Research Conference (INRC), Kansas City, MO, July 15-20, 2012.

- 10/11 Jamalapuram, S.; Vuppala, P.K.; Mesangeau, C.; **McCurdy, C.R.**; Avery, B.A. In Vitro Metabolic Stability and Pharmacokinetics in Lead Optimization of Novel Sigma Receptor Ligands. 2011 Annual Meeting of the American Association of Pharmaceutical Scientists, Washington, DC, October 23-27, 2011.
- 10/11 Jamalapuram, S.; Vuppala, P.K.; Mesangeau, C.; **McCurdy, C.R.**; Avery, B.A. Determination of AZ66, a Metabolically Stable Sigma Receptor Ligand, in Rat Plasma by Ultra-Performance Liquid Chromatography Mass Spectrometry and its Application to Pharmacokinetic Study. 2011 Annual Meeting of the American Association of Pharmaceutical Scientists, Washington, DC, October 23-27, 2011.
***AWARDED AN APQ SECTION TRAVEL GRANT**
- 10/11 Vuppala, P.K.; Jamalapuram, S.; Mesangeau, C.; **McCurdy, C.R.**; Avery, B.A. Preclinical Characterization of CM301, a Novel and High Affinity Sigma-1 Receptor Ligand with Potent Anti-Cocaine Actions. 2011 Annual Meeting of the American Association of Pharmaceutical Scientists, Washington, DC, October 23-27, 2011.
- 10/11 Vuppala, P.K.; Jamalapuram, S.; Mesangeau, C.; **McCurdy, C.R.**; Avery, B.A. Metabolism of CM304, a Novel Highly Selective Sigma-1 Receptor Antagonist with Potent Anti-Cocaine Actions, in Mouse, Rat and Human Liver Microsomes and Characterization of Metabolites by UPLC/MS/MS. 2011 Annual Meeting of the American Association of Pharmaceutical Scientists, Washington, DC, October 23-27, 2011.
- 11/10 Vinnakota, H.; Mesangeau, C.; **McCurdy, C.R.**; Avery, B.A. Pharmacokinetic and Tissue Distribution Studies of SN79, a Sigma-2 Receptor Ligand, in Rats using UPLC/MS/MS. 2010 FIP Pharmaceutical Sciences World Congress / Annual Meeting of the American Association of Pharmaceutical Scientists, New Orleans, LA, November 14-18, 2010.
- 11/10 Vinnakota, H.; Mesangeau, C.; **McCurdy, C.R.**; Avery, B.A. Method Development and Validation of a Novel Sigma-2 Receptor Ligand (SN79) in Rat Plasma by UPLC/MS/MS and its Application to Pharmacokinetics in Rats. 2010 FIP Pharmaceutical Sciences World Congress / Annual Meeting of the American Association of Pharmaceutical Scientists, New Orleans, LA, November 14-18, 2010.
- 11/10 Jamalapuram, S.; Vuppala, P.K.; Mesangeau, C.; **McCurdy, C.R.**; Avery, B.A. Determination of CM156, a Selective Sigma Receptor Ligand, in Rat Plasma by Ultra-Performance Liquid Chromatography Mass Spectrometry and its Application to Pharmacokinetic Study. 2010 FIP Pharmaceutical Sciences World Congress / Annual Meeting of the American Association of Pharmaceutical Scientists, New Orleans, LA, November 14-18, 2010.

- 11/10 Boddu, S.P.; Furr, E.B.; Cutler, S.J.; **McCurdy, C.R.**; Avery, B.A. Pharmacokinetics of Kratom Tea Extracts in Sprague Dawley Rats. 2010 FIP Pharmaceutical Sciences World Congress / Annual Meeting of the American Association of Pharmaceutical Scientists, New Orleans, LA, November 14-18, 2010.
- 09/10 James, M.; Shen, B.; Nielsen, C.; Zavaleta, C.; Berganos, R.A.; Mesangeau, C.; Gambhir, S.S.; **McCurdy, C.R.**; Chin, F.T. A New Ultra Selective PET Probe for Imaging Sigma-1 Receptors in Living Subjects. 2010 World Molecular Imaging Congress, Kyoto, Japan, September 8-11, 2010.
- 09/10 Shen, B.; Leblanc, G.; Subbarayan, M.; Berganos, R.A.; Mesangeau, C.; **McCurdy, C.R.**; Gambhir, S.S.; Chin, F.T. A Small Microwave Unit to Enhance Commercial Radiochemistry Modules for Making ^{18}F -labeled Imaging Agents. 2010 World Molecular Imaging Congress, Kyoto, Japan, September 8-11, 2010.
- 07/10 James, M.L.; Shen, B.; Zavaleta, C.; Nielsen, C.H.; Berganos, R.A.; Mesangeau, C.; Shaikh, J.; Gambhir, S.S.; Matsumoto, R.R.; **McCurdy, C.R.**; Chin, F.T. [^{18}F]FTC-146: A Novel and Highly Selective PET Ligand for Visualizing Sigma-1 Receptors in Living Subjects. 2010 Neuroreceptor Mapping Congress, Glasgow, Scotland, July 22-24, 2010.
- 07/10 El-Alfy, A.; Wilson, L.; Furr, E.B.; Song, Y.; Cutler, S.J.; Boddu, S.P.; Avery, B.A.; Boyer, E.W.; **McCurdy, C.R.** Blockade of Opioid Withdrawal Syndrome by Orally Administered Lyophilized Kratom (*Mitragyna speciosa*) Tea and Mitragynine in Mice. 41st International Narcotics Research Conference (INRC), Malmo, Sweden, July 11-16, 2010.
- 07/10 Avery, B.A.; Boddu, S.P.; Furr, E.B.; Cutler, S.J.; **McCurdy, C.R.** Pharmacokinetics of Kratom Tea Extracts in Sprague Dawley Rats. 41st International Narcotics Research Conference (INRC), Malmo, Sweden, July 11-16, 2010.
- 03/10 Abdelazeem, A.H.; Mesangeau, C.; Khan, S.; Sufka, K.J.; White, S.W.; Abbas, S.E.S.; Poupaert, J.H.; **McCurdy, C.R.** Design, Synthesis and Biological Evaluation of 2-(3*H*)-benzoxazolone and 2-(3*H*)-benzothiazolone dimers as potential anti-inflammatory agents. 239th ACS National Meeting, San Francisco, CA, March 21-25, 2010.
- 11/09 Vinnakota, H.; Vuppala, P.; Leon, J.F.; Furr, E.B.; Adkins, J.E.; Cutler, S.J.; **McCurdy, C.R.**; Avery, B.A. Pharmacokinetic and Tissue Distribution Studies of Mitragynine, A Naturally Occurring Opioid Agonist, In Rats Using UPLC/MS/MS. 2009 Annual Meeting of the American Association of Pharmaceutical Scientists, Los Angeles, CA, November 8-12, 2009.
- 7/09 **McCurdy, C.R.**; Habib, E.; Leon, J.F.; Adkins, J.E.; Furr, E.B.; Polgar, W.E.; Toll, L.; Cutler, S.J. Chemical and Pharmacological Characterization of Kratom

- (*Mitragyna speciosa*). 40th International Narcotics Research Conference (INRC), Portland, OR, July 12-16, 2009.
- 7/09 El-Alfy, A.; Wilson, L.; Furr, E.B.; Adkins, J.E.; Leon, J.F.; Cutler, S.J.; **McCurdy, C.R.** Characterization of the Neurobehavioral Effects of Kratom (*Mitragyna speciosa*). 40th International Narcotics Research Conference (INRC), Portland, OR, July 12-16, 2009.
- 7/09 Avery, B.A.; Vinnikota, H.; Leon, J.F.; Furr, E.B.; Adkins, J.E.; Cutler, S.J.; **McCurdy, C.R.** Pharmacokinetic and Tissue Distribution Studies of Mitragynine, a Naturally Occurring Opioid Agonist, in Rats using UPLC/MS/MS. 40th International Narcotics Research Conference (INRC), Portland, OR, July 12-16, 2009.
- 3/09 Kaushal, N.; Croom, C.; Shaikh, J.; Narayanan, S.; Mesangeau, C.; Poupaert, J.H.; **McCurdy, C.R.**; Matsumoto, R.R. SN79, a novel sigma-2 receptor antagonists, attenuates the behavioral effects of cocaine in mice. Behavior, Biology and Chemistry: Translational Research in Addiction, University of Texas Health Science Center, San Antonio, TX, March 20-22, 2009.
- 11/08 Nolan, T.L.; Singh, N.; **McCurdy, C.R.** New potential leads for the development of kappa opioid ligands using a hybrid virtual screening approach. 2008 Annual Meeting of the American Association of Pharmaceutical Scientists, Atlanta, GA, November 16-20, 2008.
- 7/08 Yekkiral, A.S.; Lunzer, M.M.; **McCurdy, C.R.**; Powers, M.D.; Roerig, S.C.; Portoghese, P.S. NNTA, a Selective Activator of Heterodimeric Mu/Kappa Opioid Receptors Produces no Tolerance or Physical Dependence in Mice. 39th International Narcotics Research Conference (INRC), Charleston, SC, July 13-18, 2008.
- 06/08 Cui, J.; Leon, J.F.; Mesangeau, C.; Peres, B.; Adkins, J.E.; Furr, E.B.; Arribas, M.; Nolan, T.L.; Cutler, S.J.; Polgar, W.E.; Toll, L.; **McCurdy, C.R.** Studies on the determination of the pharmacophoric elements of the naturally occurring opioid receptor agonist, mitragynine and related alkaloids from *Mitragyna speciosa*. 70th Annual Meeting of The College on Problems of Drug Dependence (CPDD), San Juan, Puerto Rico, June 14-19, 2008.
- 11/07 Narayanan, S.; Mesangeau, C.; Shaikh, J.; Yu, J.; Diers, J.A.; Matsumoto, R.R.; Poupaert, J.H.; **McCurdy, C.R.** Novel Pharmacologic Interventions for Cocaine Abuse. 2007 Annual Meeting of the American Association of Pharmaceutical Scientists, San Diego, CA, November 11-15, 2007. **AWARDED podium presentation in the 2007 AAPS Graduate Student Symposium in Drug Design and Discovery sponsored by Bristol-Myers Squibb**
- 11/07 Adkins, J.E.; Moraes, N.; White, N.; Tadlock, L.A.; Nieto, M.J.; **McCurdy, C.R.** HPLC method for determination of mitragynine, an indole alkaloid, in crude

extracts of *Mitragyna speciosa*. 2007 Annual Meeting of the American Association of Pharmaceutical Scientists, San Diego, CA, November 11-15, 2007.

- 11/07 Yekkiralala, A.S.; **McCurdy, C.R.**; Lunzer, M.M.; Powers, M.D.; Portoghese, P.S. Naphthoyl-b-naltrexamine (NNTA) selectively activates kappa/mu opioid receptor heterodimers: an insightful tool to study novel mechanisms of analgesia. Neuroscience 2007, Society for Neuroscience, San Diego, CA, November 3-8, 2007. 119.1. (oral presentation)
- 11/07 Shaikh, J.; Wilson, L.L.; Mesangeau, C.; **McCurdy, C.R.**; Poupaert, J.H.; Matsumoto, R.R. CM156, a novel sigma receptor ligand, attenuates the locomotor stimulant and neurotoxic effects of methamphetamine in mice. Neuroscience 2007, Society for Neuroscience, San Diego, CA, November 3-8, 2007. 173.5/GG19.
- 08/07 Narayanan, S.; Mesangeau, C.; Shaikh, J.; Matsumoto, R.R.; Poupaert, J.H.; **McCurdy, C.R.** Design, synthesis and evaluation of the first highly selective sigma-2 receptor ligand. 234th American Chemical Society National Meeting, Boston, MA, August 19-23, 2007. MEDI-335.
- 07/07 Adkins, J.; Moraes, N.; White, N.; Tadlock, L.A.; Nieto, M.J.; **McCurdy, C.R.** HPLC method for determination of mitragynine, an indole alkaloid, in crude extracts of *Mitragyna speciosa*. International Narcotics Research Conference (INRC), Berlin, Germany, July 8-13, 2007.
- 06/07 Matsumoto, R.R.; Wilson, L.L.; Mesangeau, C.; Diers, J.; Shaikh, J.; Poupaert, J.H.; **McCurdy, C.R.** CM156, a novel substituted piperazine, attenuates the behavioral effects of cocaine in mice. The College on Problems of Drug Dependence, Qubec, Canada, June 16-21, 2007.
- 03/07 Singh, N.; Mesangeau, C.; Narayanan, S.; Shaikh, J.; Matsumoto, R.R.; **McCurdy, C.R.** Development of the first predictive pharmacophore models for sigma-1 and sigma-2 receptor antagonists. 233rd American Chemical Society National Meeting, Chicago, IL, March 25-29, 2007. MEDI-292.
- 10/06 Adkins, J.E.; Tadlock, L.A.; Nieto, M.J.; **McCurdy, C.R.** Isolation, purification and identification of indole alkaloids from *Mitragyna speciosa* with simultaneous determination by LC methods. 2006 Annual Meeting of the American Association of Pharmaceutical Scientists, San Antonio, TX, October 29 – November 2, 2006.
- 10/06 Singh, N.; **McCurdy, C.R.** A 3D structure of 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase enzyme from *Mycobacterium tuberculosis*: Homology modeling and Docking analysis. 2006 Annual Meeting of the American Association of Pharmaceutical Scientists, San Antonio, TX, October 29 – November 2, 2006.

- 10/06 Narayanan, S.; Mesangeau, C.; Shaikh, J.; Yu, J.; Diers, J.A.; Matsumoto, R.R.; Poupaert, J.H.; **McCurdy, C.R.** Design, synthesis and biological evaluation of novel heterocyclic compounds as sigma receptor antagonists. 2006 Annual Meeting of the American Association of Pharmaceutical Scientists, San Antonio, TX, October 29 – November 2, 2006.
- 10/06 Shaikh, J.; Yu, J.; Diers, J.A.; Narayanan, S.; Mesangeau, C.; **McCurdy, C.R.**; Matsumoto, R.R. Evaluation of novel 2(3H)-benzoxazolones and 2(3H)-benzothiazolones against cocaine-induced behavior in mice. Neuroscience 2006, Society for Neuroscience, Atlanta, GA, October 14-18, 2006. 189.9/MM78.
- 09/06 Adkins, J.E.; Nieto, M.J.; **McCurdy, C.R.** Studies toward synthetically determining a pharmacophore of mitragynine, an indole alkaloid from *Mitragyna speciosa*: Removal of C-ring. 232nd American Chemical Society National Meeting, San Francisco, CA, September 10-14, 2006. MEDI-535.
- 09/06 Narayanan, S.; Mesangeau, C.; Shaikh, J.; Yu, J.; Diers, J.A.; Matsumoto, R.R.; Poupaert, J.H.; **McCurdy, C.R.** Design, synthesis and evaluation of original 2(3H)-benzoxazolones and 2(3H)-benzothiazolones as highly potent sigma receptor antagonists. 232nd American Chemical Society National Meeting, San Francisco, CA, September 10-14, 2006. MEDI-462.
- 09/06 Singh, N.; Cheve, G.; **McCurdy, C.R.** Three dimensional chemical-feature-based pharmacophore development for kappa opioid receptor agonist. 232nd American Chemical Society National Meeting, San Francisco, CA, September 10-14, 2006. MEDI-456.
- 03/06 Singh, N.; Cheve, G.; Narayanan, S.; Ferguson, D.M.; **McCurdy, C.R.** A Combined Ligand-Based and Target-Based Approach for the Identification of Novel Lead Structures: Application to Salvinorin A, a Selective Kappa Opioid Receptor Agonist. 213th American Chemical Society National Meeting, Atlanta, GA, March 26-31, 2006.
- 11/05 **McCurdy, C.R.**; Sufka, K.J.; Warnick, J.E.; Nieto, M.J. Salvinorin A, a kappa opioid receptor agonist, is an ultra short acting analgesic. 35th Annual Meeting of the Society for Neuroscience, Washington, DC, November 12-18, 2005.
- 07/05 **McCurdy, C.R.**; Sufka, K.J.; Warnick, J.E.; Nieto, M.J. Salvinorin A, a kappa opioid receptor agonist, is an ultrashort acting analgesic. 36th International Narcotics Research Conference, Annapolis, MD, July 10-15, 2005.
- 10/04 Warnick, J.E.; Feltenstein, M.W.; **McCurdy, C.R.**; Sufka, K.J. The role of opiate receptor subtypes in social attachment in young domestic fowl. 34th Annual Meeting of the Society for Neuroscience, San Diego, CA, Oct. 23-27, 2004. Program No. 762.2.
- 09/04 **McCurdy, C.R.**; Sufka, K.J.; Warnick, J.E.; Nieto, M.J. Salvinorin A, a kappa opioid receptor agonist, is a fast acting, potent analgesic. AAPS-NIDA

Symposium: Frontiers in Science: Drug Addiction-From Basic Research to Therapies. National Institutes of Health Campus, Bethesda, MD, September 9-11, 2004. Poster number 20.

- 03/04 Nieto, M.J.; Philip, A.E.; Mirbagheri, A.; **McCurdy, C.R.** Solution-Phase Parallel-Synthesis of Hydantoin Derivatives. 227th American Chemical Society National Meeting, Anaheim, CA, March 28-April 1. ORGN-337
- 03/04 Kane, B.E.; **McCurdy, C.R.**; Ferguson, D.M. Molecular Interactions of salvinorin A at the kappa opioid receptor. 227th American Chemical Society National Meeting, Anaheim, CA, March 28-April 1. MEDC-273
- 09/03 Zhang, Y.; **McCurdy, C.R.**; Portoghese, P.S. Synthesis and kinetic studies of agonist and antagonist reporter affinity labels for opioid receptors. 226th American Chemical Society National Meeting, New York, NY, September 7-11. MEDC-153.
- 07/03 Stewart, J.; Dayan, F.E.; **McCurdy, C.R.**; Zjawiony, J.K. Studies on the biosynthesis of the novel κ -opioid agonist, salvinorin A. 44th Annual Meeting of the American Society of pharmacognosy. Chapel Hill, NC, July 12-16.
- 07/03 **McCurdy, C.R.**; Nieto, M.; Kane, B.; Ferguson, D.M. Studies directed toward understanding the opioid receptor recognition of Salvinorin A, a non-nitrogenous natural product with kappa opioid receptor selectivity. 34th International Narcotics Research Conference, Perpignan, France, July 7-11, 2003.
- 07/03 Zhang, Y.; **McCurdy, C.R.**; Portoghese, P.S. Kinetic studies of covalent association of agonist and antagonist reporter affinity labels with opioid receptors. 34th International Narcotics Research Conference, Perpignan, France, July 7-11, 2003.
- 03/03 Vangapandu, S.; Phillip, A.; Stewart, J.D.; Zjawiony, J.; Avery, M.A.; **McCurdy, C.R.** Progress toward the total synthesis of salvinorin A: A potent, non-nitrogenous κ -opioid receptor selective agonist. 225th American Chemical Society National Meeting, New Orleans, LA, March 23-27. ORGN-421.
- 07/02 Zhang, Y.; **McCurdy, C.R.**; Metzger, T.G.; Portoghese, P.S. Studies of wild type and mutant mu opioid receptors with fluorogenic reporter affinity labels using flow cytometry: evidence for cross-linking K233 and C235. 33rd International Narcotics Research Conference, Pacific Grove, CA.
- 04/01 **McCurdy, C.R.**; LeBourdonnec, B.; El Kouhen, R.; Portoghese, P.S. Second generation reporter affinity labels: Naphthalene dicarboxaldehyde derivatives of β -naltrexamine. 221st ACS National Meeting, San Diego, CA.
- 03/00 **McCurdy, C.R.**; Jones, R.M.; Portoghese, P.S.; Investigation of phenolic bioisosterism in opioids: Synthesis and biological evaluation of 3-

methylsulfonamide analogues of naltrexone and oxymorphone. 219th ACS National Meeting, San Francisco, CA.

- 03/98 **McCurdy, C.R.**; Beach, J.W.; Smith, J.B.; Cutler, S.J. Behavioral and discriminative stimulus effects of cholinergic channel modulators. 215th ACS National Meeting, Dallas, TX.
- 06/98 Metting T.L., Burgio D.E., Terry Jr. A.V., Beach J.W. **McCurdy C.R.** and Allen D.D. Assessment of blood-brain barrier (BBB) choline transport inhibition by lobeline and arecoline derivatives using the *in situ* rat brain perfusion technique. Presentation at the Merck Undergraduate Research Seminar, Estes Park, CO.
- 04/97 **McCurdy, C.R.**; Venkateshwaran, T.G.; Stewart, J.T.; Beach, J.W. Chiral separations of lobeline analogs using high performance capillary electrophoresis and derivatized cyclodextrins as chiral additives. 213th ACS National Meeting, San Francisco, CA.
- 11/96 Carl, G.F.; Williamson, R.; Beach, J.W.; **McCurdy, C.R.**; Pauly, J.R.; Sparks, J.A.; Terry Jr., A.V. Lobeline and analogs exhibit differential agonist activity and sensitivity to antagonist blockade when compared to nicotine. Society for Neuroscience National Meeting, Washington, DC.
- 08/96 Beach, J.W.; **McCurdy, C.R.**; Terry Jr., A.V.; Pauly, J.R.; Boss, K.L. Nicotinic agonists based on lobeline. 212th ACS National Meeting, Orlando, FL.
- 08/95 Beach, J.W.; **McCurdy, C.R.**; Terry Jr., A.V.; Templeton, R.E. Analogues of lobeline as potential nicotinic agonists. 210th ACS National Meeting, Chicago, IL.

Regional Presentations

- 06/15 Alsharif, W.; Kopajtic, T.; Kandasamy, M.; Avery, B.A.; Hiranita, K.; Katz, J.L.; **McCurdy, C.R.** Synthesis, Biological Evaluation, and Metabolic Stability Enhancement of the dual Sigma Receptor Antagonist/DAT Inhibitor Agents as Potential Pharmacotherapy for Stimulant Abuse. Drug Discovery and Development Colloquium 2015, June 22-24, 2015, Oxford, MS
- 05/13 Gogineni, V.; Leon, J.F.; Wilson, L.L.; Avery, B.A.; **McCurdy, C.R.**; Cutler, S.J. *Mitragyna speciosa*: Isolation & Pharmacological Evaluation of the Indole Alkaloids. 40th Annual MALTO Medicinal Chemistry and Pharmacognosy Meeting, May 19-21, Little Rock, AR
- 05/12 Alsharif, W.; Mesangeau, C.; Amata, E.; Seminerio, M.J.; Robson, M.J.; Matsumoto, R.R.; Poupaert, J.H.; **McCurdy, C.R.** Synthesis and Pharmacological Evaluation of Indole-based Sigma Receptor Ligands. 39th Annual MALTO Medicinal Chemistry and Pharmacognosy meeting, May 20-22, Monroe, LA

- 09/11 El-Alfy, A.; Wilson, L.L.; Furr, E.B.; Boddu, S.P.; Avery, B.A.; Cutler, S.J.; Boyer, E.W.; **McCurdy, C.R.** Blockage of opioid withdrawal syndrome by orally administered lyophilized kratom (*Mitragyna speciosa*) tea and mitragynine in mice. NS19. 2011 South East Regional IDeA Meeting, September 22-24, 2011, New Orleans, LA (Poster and selected for invited **ORAL PODIUM** Presentation)
- 09/11 Avery, B.A.; Boddu, S.P.; Furr, E.B.; Cutler, S.J.; **McCurdy, C.R.** Pharmacokinetics of kratom tea (*Mitragyna speciosa*) extracts in Sprague Dawley rats. NS3. 2011 South East Regional IDeA Meeting, September 22-24, 2011, New Orleans, LA
- 09/07 Xu, Y.; Shaikh, J.; Viard, E.; Fishback, J.; Kaushal, N.; Mesangeau, C.; Narayanan, S.; Poupaert, J. H.; **McCurdy, C.R.**; Matsumoto, R.R. Synthesis and Evaluation of Subtype Selective Sigma Receptor Ligands From Substituted 2(3*H*)-Benzoxazolone and 2(3*H*)-Benzothiazolone Derivatives. 2007 South Central Chapter of the Society of Toxicology Meeting, September 27-28, 2007, Oxford, MS
- 05/07 Narayanan, S.; Mesangeau, C.; Shaikh, J.; Yu, J.; Diers, J.A.; Matsumoto, R.R.; Poupaert, J.H.; **McCurdy, C.R.** Design, synthesis and biological evaluation of novel sigma receptor antagonists as anti-cocaine agents. 34th Annual MALTO Medicinal Chemistry and Pharmacognosy meeting, May 20-22, 2007, Monroe, LA
- 05/07 Adkins, J.E.; Moraes, N.V.; While, N.; Tadlock, L.A.; Nieto, M.J.; **McCurdy, C.R.** HPLC Method Validation for Determination of Mitragynine, an Indole Alkaloid, in Crude Extracts of *Mitragyna speciosa*. 34th Annual MALTO Medicinal Chemistry and Pharmacognosy meeting, May 20-22, 2007, Monroe, LA
- 05/06 Singh, N.; Cheve, G.; **McCurdy, C.R.** Combination of Molecular Modeling, Site-Directed Mutagenesis, and SAR Studies to Delineate a Robust Virtual Screening Protocol: Application to Salvinorin A. 33rd Annual MALTO Medicinal Chemistry and Pharmacognosy meeting, May 21-23, 2006, Houston, TX
- 05/06 Vyas, N.; Mollereau, C.; Cheve, G.; **McCurdy, C.R.** Design, Synthesis and Biological Evaluation of Small Molecules for Neuropeptide FF Receptors. 33rd Annual MALTO Medicinal Chemistry and Pharmacognosy meeting, May 21-23, 2006, Houston, TX
- 11/05 Singh, N.; Cheve, G.; **McCurdy, C.R.** Probing the structure of 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase Enzyme from *Plasmodium falciparum*: Comparative Protein Modeling and Docking Studies. Southeast Regional American Chemical Society Meeting. November, 1-4, Memphis, TN.
- 05/05 Philip, A.E.; Geldenhuys, W.J.; Lockman, P.R.; McAfee, J.H.; Miller, B.L.; Allen, D.D.; **McCurdy, C.R.** Inhibition of Choline Uptake by N-cyclohexylcholine, a High Affinity Ligand for the Choline Transporter at the

Blood-Brain Barrier. 32nd Annual MALTO Medicinal Chemistry and Pharmacognosy meeting, May 22-24, Oxford, MS

- 05/05 Singh, N.; **McCurdy, C.R.** 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase: A Novel Target for Development of Broad-Spectrum Antimicrobial and Antiprotozoal Drug Candidates. 32nd Annual MALTO Medicinal Chemistry and Pharmacognosy meeting, May 22-24, Oxford, MS
- 05/04 Philip, A.E.; Nieto, M.J.; Mirbagheri, A.; Poupaert, J.H.; **McCurdy, C.R.** Application of Solution-Phase Parallel Synthesis to Preparation of Spirohydantoin Derivatives. 31st Annual MALTO meeting, University of Tennessee Health Sciences Center, Memphis, TN.
- 05/03 Philip, A.E.; McAfee, J.H.; Lockman, P.R.; Roder, K.E.; Allen, D.D.; **McCurdy, C.R.** Probing the structural requirements of the blood brain barrier choline transporter through synthetic choline analogues. 30th Annual MALTO meeting, University of Arkansas, Little Rock, AR.
- 04/02 Zhang, Y.; **McCurdy, C.R.**; Metzger, T.G.; Portoghese, P.S. Design of fluorogenic reporter affinity labels for kinetic studies of opioid receptor cross-linking using flow cytometry. 40th Annual MIKI Meeting, University of Illinois at Chicago, Chicago, IL
- 04/01 **McCurdy, C.R.**; Le Bourdonnec, B.; El Kouhen, R.; Portoghese, P.S. Second generation reporter affinity labels: analogs of β -Naltrexamine. 39th Annual MIKI Meeting, Minneapolis, MN
- 04/00 **McCurdy, C.R.**; Jones, R.M.; Portoghese, P.S. Investigation of phenolic bioisosterism in opiates. MIKI Meeting, Iowa City, IA
- 06/96 Venkateshwaran, T.G.; **McCurdy, C.R.**; Stewart, J.T.; Beach, J.W. Enantiomeric separation of lobeline analogues using capillary electrophoresis: Effects of cyclodextrin additives. South Eastern Regional Meeting of the American Association of Pharmaceutical Scientists, Research Triangle Park, NC.
- 05/95 **McCurdy, C.R.**; Beach, J.W.; Terry Jr.; Wargo, H.L.; Templeton, R.E. Synthesis and receptor binding of N-Substituted-2-styryl-1,2,3,6-tetrahydropyridine as a potential nicotinic agonists. 22nd Annual MALTO Meeting, Xavier University, New Orleans, LA.

Local Presentations

- 05/09 **McCurdy, C.R.** Utilization of Natural Products in the Treatment of Drug Abuse. NIH COBRE Community Outreach Program, The University of Mississippi, University, MS. (May 11, 2009)

- 03/09 **McCurdy, C.R.** Developing Treatments for Drug Abuse. Keynote Speaker. Mississippi Junior Science and Humanities Symposium. The University of Mississippi, University, MS. (March 8, 2009)
- 09/07 **McCurdy, C.R.** Sigma Receptors and Psychostimulants. Department of Pharmacognosy, School of Pharmacy, University of Mississippi, University, MS. (September 11, 2007)
- 03/07 Narayanan, S.; Mesangeau, C.; Shaikh, J.; Yu, J.; Diers, J.A.; Matsumoto, R.R.; Poupaert, J.H.; **McCurdy, C.R.** Design, Synthesis and Biological Evaluation of Novel Sigma Receptor Antagonists as Anti-Cocaine Agents. Sigma Xi Research Day, University of Mississippi, University, MS, March 26, 2007. (**AWARDED BEST POSTER IN TWO CATEGORIES**)
- 04/06 Singh, N.; Cheve, G.; Narayanan, S.; Ferguson, D.M.; **McCurdy, C.R.** . A Combined Ligand-Based and Target-Based Approach for the Identification of Novel Lead Structures: Application to Salvinorin A, a Selective Kappa Opioid Receptor Agonist. Sigma Xi Research Day, University of Mississippi, University, MS, April 4, 2006. (**AWARDED BEST POSTER**)
- 09/04 **McCurdy, C.R.**; Sufka, K.J.; Warnick, J.E.; Nieto, M.J. Antinociceptive Profile of Salvinorin A, a Structurally Unique Kappa Opioid Agonist. National Center for Natural Products Research, School of Pharmacy, Internal Poster Session. University of Mississippi, University, MS.
- 05/04 Warnick, J.E.; Feltenstein, M.W.; **McCurdy, C.R.**; Sufka, K.J. The Role of Opiate Receptor Subtypes in Social Attachment in Young Domestic Fowl. Sigma Xi Research Day, University of Mississippi, University, MS
- 05/04 Philip, A.E.; Nieto, M.J.; Mirbagheri, A.; Poupaert, J.H.; **McCurdy, C.R.** Application of Solution-Phase Parallel Synthesis to Preparation of Spirohydantoin Derivatives. Sigma Xi Research Day, University of Mississippi, University, MS.
- 05/02 Zhang, Y.; **McCurdy, C.R.**; Metzger, T.G.; Portoghese, P.S. Reporter Affinity Labels: A single-molecular fluorogenic probe to cross-link opioid receptors studied via flow cytometry. Chemical Biology, A Single Molecular Perspective – NIH Molecular Biophysics, Biotechnology, and Chemistry-Biology Interface Joint Training Grant Symposium, University of Minnesota, Minneapolis, MN
- 05/02 Zhang, Y.; **McCurdy, C.R.**; Metzger, T.G.; Portoghese, P.S. Kinetic studies of opioid receptors cross-linking with fluorogenic reporter affinity labels using flow cytometry. The 2nd Symposium on Targets and Cellular Mechanisms Involved in Drug Addiction, University of Minnesota, Minneapolis, MN
- 01/99 **McCurdy, C.R.**; Portoghese, P.S. Rational design and synthesis of δ -opioid receptor affinity labels. NIDA Neuroscience Training Grant Retreat, University of Minnesota, Minneapolis, MN.

- 10/96 Venkateshwaran, T.G.; **McCurdy, C.R.**; Stewart, J.T.; Beach, J.W. Enantiomeric separation of lobeline analogs using capillary electrophoresis. Graduate Research Day, University of Georgia, Athens, GA.
- 05/95 **McCurdy, C.R.**; Beach, J.W.; Terry Jr., A.V.; Wargo, H.L.; Templeton, R.E. Synthesis and nicotinic receptor binding of N-substituted-2-styryl-1,2,3,6-tetrahydropyridine. Graduate Research Day, University of Georgia, Athens, GA.

LECTURES AND TEACHING EXPERIENCE:

University of Florida, College of Pharmacy, Gainesville, FL

08/22-Present	PHA 6935: Advanced CNS Drug Design. (3 credit hours)
01/22-Present	HOS6932: Cultivation, Extraction, and Application of Medicinal Plants and their Bioactive Compounds. (3 credit hours, spring semesters).
12/20	PHA 5930: Seminar in Pharmacy Research (gave a 1 hour seminar to the class on kratom – December 2, 2020)
08/18-Present	PHA 6894: Intro to Graduate Studies (1 semester hour, fall and spring semesters). Teach 2 lectures in the course on leadership and another on communication.
01/18-Present	PHA 6467: Drug Design II. Graduate level course (3 credit hours, spring semesters). Teach 3 hours of lecture on CNS drug design.
01/18-Present	PHA 5080C: Patient Care 7: Brain and Behavior. Block 16. Professional Pharmacy Program Required Course (6 credit hours, spring semesters). Teach in 6 out of 9 modules.
08/17-Present	PHA 6447: Drug Design I. Graduate level course (3 credit hours, fall semesters). Course coordinator.
05/17-Present	PHA 6935: Life Cycle of a Drug. Graduate level course (3 semester hours, summer semesters). Course coordinator, teach one lecture

University of Mississippi, School of Pharmacy, University, MS

04/14-12/16	PHAR 332: Basic Pharmaceutics II. PY1 Professional Program Required Course. Taught one lecture on radiopharmaceuticals.
01/11-12/16	MEDC 418: Chemical Neuroscience Principles of Drugs of Abuse. PY2 Professional Pharmacy Elective course (1 semester hour, spring semesters).
01/07-12/16	MEDC 417: Medicinal Chemistry of Therapeutic Agents II. Undergraduate Level Professional Pharmacy Program. New course format in 2006-2007 to pharmacy program (3 semester hours, spring semesters).
01/07-12/16	MEDC 502: Advanced Medicinal Chemistry II. Graduate Level course (3 semester hours, spring semesters).
08/06-12/16	MEDC 416: Medicinal Chemistry of Therapeutic Agents I. Undergraduate Level Professional Pharmacy Program. New course format in 2006 to pharmacy program (3 semester hours, fall semesters)
08/06-12/16	MEDC 501: Advanced Medicinal Chemistry I. Graduate Level course. (3 semester hours, fall semesters)
01/04-05/09	MEDC 541/542: Special Topics in Medicinal Chemistry: Drugs, Society, and Human Behavior. Undergraduate/Graduate pharmacy elective (3 semester hours)
02/03-05/05	PHCY 201: Use and Misuse of Drugs. Undergraduate level University-Wide Elective. Gave 2 (75 minute) lectures on CNS Depressants and Hallucinogens. (3 semester hours)
01/03-05/06	MEDC 314: Principles of Medicinal Chemistry. Undergraduate Level Professional Pharmacy Program. Teaching. (3 semester hours).

01/03-05/06	MEDC 315: Principles of Medicinal Chemistry Laboratory. Undergraduate level professional Pharmacy Program. Developed new laboratory program and teaching. (1 semester hour).
08/02-12/05	MEDC 503: Medicinal Chemistry Research Methodology. Graduate level. Redesigned and taught course. (3 semester hours).
01/02-12/16	MEDC 713: Peripheral and Central Nervous System Agents. Graduate level. Developed and teaching course. (3 semester hours)
03/02-05/06	MEDC 412: Medicinal Chemistry. Gave 4 lectures on Narcotic analgesics. (3 semester hours)
01/02	PHCY 201: Use and Misuse of Drugs. Gave 2 (75 minute) lectures on Designer Drugs. (3 semester hours)

University of Georgia, College of Pharmacy, Athens, GA

09/97	PHR 404: Medicinal Chemistry II. Central Nervous System Agents. Course for 2nd year pharmacy students. I gave one lecture on Alzheimer's Disease and Acetylcholinesterase inhibitors.
04/97	PHR 305: Biochemistry of Drugs and Disease. Course for 1st year pharmacy students. I gave 3 lectures on vitamins.
01/95-05/95	Laboratory Instructor: PHR 311: Medicinal Chemistry Laboratory. Undergraduate Pharmacy students.

GRANT ACTIVITY

Pending

NIH UG3 NS127264-01A1, NINDS “Non-Addictive Sigma Ligands as Pain Therapeutics” Multiple PI (Christopher R. McCurdy and Jay P. McLaughlin). RFA NS-21-010 “HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain”. Submitted to NINDS program on October 14, 2022. Review Group: ZNS1 SRB-G(57) (**PENDING COUNCIL REVIEW**) Project Period: 06/01/2023 – 05/31/2028. Impact Score 43. Total costs submitted: **\$7,459,338**.

Currently Active as Principal Investigator

NIH UG3 DA058553-01, NIDA “Development of Sigma Receptor/DAT Dual-Targeting Compounds to Treat Stimulant Use Disorder” PI Jeffrey B. Reich, Sparian Biosciences, University of Florida Consortium PI (Christopher R. McCurdy). PAR20-092 Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3). Submitted to NIDA on August 31, 2022. Review Group: NIDA-L 11/09/2022. (**FUNDED**). Project Period: 08/15/2023 – 07/31/2025. Impact Score 31. Total costs submitted (UG3/UH3): **\$18,890,842** UG3 Phase awarded; Total costs funded: **\$6,903,733**. Total costs year 1: \$2,886,286. Total costs year 2: \$4,017,447.

NIH UH3 DA048353-01, NIDA “Opioid use disorders: UF Pharmacy medications discovery and development” Multiple PI (Christopher R. McCurdy and Lance R. McMahon). RFA DA19-02 “Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3)”. Submitted to NIDA program on September 30, 2020. (**FUNDED**). Project period: December 15, 2020 – November 30, 2024. UH3 phase awarded; Total costs funded: **\$4,334,043**. Total costs year 1: \$1,444,681. Total costs year 2: \$1,444,681. Total costs year 3: \$1,444,681. Year 4: No cost extension.

NIH R01 DA047855-01A1, NIDA “Kratom alkaloids: in vitro and in vivo pharmacological mechanisms” Multiple PI (Lance R. McMahon, Bonnie A. Avery, Christopher R. McCurdy) Submitted April 16, 2018 under continuous submission privilege. Review group: MNPS. Peer review June 14, 2018. (**FUNDED**). Project period: April 1, 2019 – March 31, 2025. Impact Score 32; 24th percentile. Total costs funded: **\$3,626,856**.

Currently Active as Co-Investigator

NIH R61/R33 DA056922-01A1, NIDA “Patterns and neurocognitive consequences of opioid-alcohol polysubstance use” Co-Investigator (Lori Knackstedt and Linda Cottler, MPI). (**FUNDED**). Project Period: 06/01/2023 – 05/31/2028. R61 Phase active. Peer review Impact Score 15. Total costs funded for R61 phase: **\$881,000**.

NIH R01 AG072714-01A1 “Effects of cannabis on age-related cognitive decline and Alzheimer’s disease pathology. Co-Investigator (Setlow, Barry – PI). Submitted XX. Review group: XX. (**FUNDED**). August 13, 2021 – May 31, 2026. Total costs funded: **\$2,998,063**.

Florida Department of Health grant # 21A11 “Effects of cannabis on Alzheimer’s disease-related pathology and cognitive decline”, Mechanism: Ed and Ethel Moore Alzheimer’s Disease Research Program 20-21 Funding Cycle. Co-Investigator (1% effort) (Setlow, Barry – PI). Submitted September 9, 2020. **(FUNDED)**. December 15, 2020. Project period: March 15, 2021 – March 14, 2023. Total cost **\$247,620**.

NIH R01 DA049470-01A1, NIDA “Opioid and cannabinoid interactions in pain and reward”, Co-Investigator (Neubert, John – PI). Submitted December 13, 2019. Project period: July 1, 2020 – June 30, 2025. Priority Score 30; 16th percentile. **(FUNDED)**. September 11, 2020.

NIH T32 GM136583-01, NIGMS “Chemistry-Biology Interface Training Program at the University of Florida”. Co-Investigator (Li, Chenglong – PI). **(FUNDED)**. July 1, 2020 – June 30, 2025. Total costs years 1-5: **\$800,510**.

Completed

DoD PR161310 Contract W81XWH-17-1-0557 “Sigma receptor ligands as non-opioid based pain management”. Principal Investigator (20% effort, 2.4 calendar months), Mechanism/Announcement: CDMRP W81XWH-16-PRMRP-IIRA. Submitted October 19, 2016. Peer review: February 2017. **(FUNDED)**. September 15, 2017 – September 14, 2021. **\$1,092,713**. Partnering PI, Jay McLaughlin, PR161310P1 W81XWH-17-1-0558 \$949,864. Total awards together: \$2,042,577. **COMPLETED**

NIH UG3 DA048353-01, NIDA “Opioid use disorders: UF Pharmacy medications discovery and development”, Multiple PI (Christopher R. McCurdy and Lance R. McMahon) (25% effort, 3 calendar months), RFA DA19-02 “Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3)”. Submitted June 28, 2018. Priority Score 44. **(FUNDED)**. Project period: December 15, 2018 – December 14, 2020. UG3 phase awarded; Total costs funded: **\$3,574,538**. Total costs year 1: \$2,023,489. Total costs year 2: \$1,551,049. **COMPLETED**

NIH R01 DA0391167-01A1, NIDA “Deterrents for prescription opioid abuse”, Co-Investigator (Freeman, Kevin – PI), PA13-015. Submitted March 5, 2015. Priority Score 20; 8th percentile. **(FUNDED)**. Total costs year 1: \$301,396. **COMPLETED**

NIH R01 DA034777-05, NIDA “Optimization of non-peptide probes for Neuropeptide FF receptors”, Principal Investigator (25% effort, 3 calendar months), PAR-12-060 “Solicitation of validated hits for the discovery of in vivo chemical probes”. Submitted March 5, 2013. **(FUNDED)**. Priority Score 32, 16th Percentile). Total Costs as Submitted \$2,161,110. Review group: NIDA ZRG1-MDCN-C (58), June 21, 2013. Funded Project Period: September 15, 2014 – August 31, 2017. Total costs funded: **\$ 1,473,763**. Total costs year 1: \$498,705. Total costs year 2: \$485,817. Total costs year 3: \$489,241. Currently in No Cost Extension until August 31, 2019. **COMPLETED**

DAA2-15-61222-1, U.S. Civilian Research & Development Foundation (CRDF) and U.S. Department of Agriculture, Agricultural Research Service (USDA ARS) “Isolation and Biological Evaluation of Opioid Receptor Modulators from *Asteraceae* Plants Growing in Egypt”, Principal Investigator. **\$29,762.42 COMPLETED**

NIH P20 GM104932-10, NIGMS, “Center for Research Excellence in Natural Products Neuroscience” Principal Investigator (**FUNDED**) September 24, 2012 – August 31, 2017. Total costs funded: **\$10,086,529**. Total costs year 6; \$1,871,576. Total costs year 7; \$2,099,508. Total costs year 8; \$2,063,370. Total costs year 9; \$2,045,714. Total costs year 10; \$2,006,361. **COMPLETED**

NIH R01 DA023205 NIDA, “Novel Pharmacologic Interventions for Drugs of Abuse”, Principal Investigator (25% time, 3 calendar months), (**FUNDED**) Submitted June 1, 2006. \$1,250,000 direct cost. Review group: NIDA Special Emphasis Panel ZDA1 RXL-E (11), October 4, 2006. Priority Score 157 on 1st submission (23.3rd percentile). April 9, 2007 – March 31, 2012. Total costs funded: **\$1,734,900** Total costs year 1; \$355,949. Total costs year 2; \$349,075. Total costs year 3; \$349,075. Total costs year 4; \$345,584. Total costs year 5; \$311,025 + \$24,192. In no-cost extension from April 1, 2012 – March 31, 2013. **COMPLETED**

NIH R03 DA029738, ECHEM NIDA, “Non-peptide ligands for NPFF receptors”, Co-Investigator (5% time, 0.6 cal mo), PAS-07-327 **\$347,814** total costs funded. Submitted October 16, 2009. (**FUNDED**) (Priority Score 42 on 1st submission). July 1, 2010 – June 30, 2012. Total costs year 1; \$176,555. Total costs year 2; \$171,259. **COMPLETED**

NIH COBRE, 1 P20 RR021929, NCCR, “Center for Research Excellence in Natural Products Neuroscience” Co-Investigator, submitted for review Oct. 20, 2004. **\$11,000,000 total. \$750,000** direct cost to my lab (Rae Matsumoto, PI). **FUNDED** (50% time). Priority score 152 on 1st submission. Total costs year 1; \$188,986. Total costs year 2; \$199,699. **COMPLETED**

NSF/IGERT grant 0333136 from the University of Mississippi and the University of Southern Mississippi. “Entrepreneurship at the Interface of Polymer Science and Medicinal Chemistry” Co-PI (Lon Mathias, PI) 08/03-07/08. **\$3,600,000 total costs. COMPLETED**

NIH R03 DA017360, NIDA Small Grants Program DA017360-01. “Salvinorin A: A novel opioid agonist lead” Principal Investigator, 01/04-01/06. **\$140,673**, total costs (funded 9/30/03, priority score 169 on 1st submission) **COMPLETED**

CDC grant U01 CI000211 “Development and Testing of New Antimalarial Drugs.” Co-Investigator (M. Avery, PI). August 1, 2004 - July 31, 2009. **\$3,000,000/year** total costs. **COMPLETED**

CDC grant U50/CCU423310, “Development and Testing of New Medicines for Treatment of Emerging Infectious Diseases.” Co-Investigator (M. Avery, PI). September 15, 2003 – September 14, 2006. **COMPLETED**

CDC grant U50/CCU418839-02, \$50,000/year. “Development and Testing of New Medications for the Treatment of Emerging Infectious Diseases.” Co-investigator (M. Avery, PI). September 15, 2002- September 14, 2005. **COMPLETED**

CDC grant UR3/CCU418652-02, \$80,000/year. “Development and Testing of New Antimalarial Drugs”. Co-investigator (M. Avery, PI). August 31, 2002- June 30, 2005. **COMPLETED**

American Association of Colleges of Pharmacy New Investigator Award. “Molecular Modeling, Design, Synthesis and Biological Evaluation of Novel Nociceptin/ Orphanin FQ (N/OFQ) Receptor Ligands. Principal Investigator. December 15, 2002-December 15, 2003. **\$10,000. COMPLETED**

University of Mississippi, Faculty small grant award. “Design and Synthesis of ORL-1 Receptor Ligands” Principal Investigator. April 16, 2002-April 16, 2003. **\$5,000. COMPLETED**

Research Training Award, National Institute on Drug Abuse, University of Minnesota, Minneapolis, MN. 07/98-07/01. \$86,000 salary support. \$4,500 materials support.

University of Georgia, College of Pharmacy. Pre-doctoral teaching assistantship award. 08/94-05/98, salary support.

Submitted – Not awarded

NIH UG3 NS127264-01, NINDS “Sigma ligands as non-opioid analgesics” Multiple PI (Christopher R. McCurdy and Jay P. McLaughlin). RFA NS-21-010 “HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain”. Submitted to NINDS program on July 14, 2021. **(PENDING COUNCIL REVIEW)** Project Period: 02/01/2022 – 01/31/2027. Impact Score 43. Total costs submitted: **\$7,000,909.**

NIH P30 DA056409-01, NIDA “UF Center of Excellence in Pharmacokinetics and Chemistry of Substance Use/misuse”, Principal Investigator/Center Director, Mechanism Announcement: PAR-20-267 NIDA Core “Center of Excellence” Grant Program (P30 Clinical Trial Optional). Submitted September 27, 2021. Project Period 07/01/22 – 06/30/27. Total costs submitted: **\$9,669,312.**

NIH R41 NS125655-01, NINDS “STTR: LEA Inhibitors of Lipid Autoinducers for Therapy of Glioblastoma” (Svetlov PI: Immunova, LLC). PA-21-262. Project Period: 11/01/2021 – 10/31/23. Impact Score 33.

NIH R01 DA052567-01A1, NIDA “Reinforcing properties of low- and high-nicotine cigarettes in rats”, Co-Investigator (Bruijnzeel PI). Project period: 09/01/2021 – 08/30/2024. \$43,659 (subproject)

NIH R21 DA053084-01A1, NIDA “Effects of advanced age on cannabis behavioral pharmacology and pharmacokinetics”, Co-Investigator (Setlow PI). Mechanism/Announcement: PA-18-079. Submitted April 29, 2021. Project period: 07/01/2021 – 06/30/2023. Impact Score 40; 29th percentile.

GRANT13327586, US Army Med Res Acquisition “Inhibitors of lipid autoinducers as a novel therapeutic intervention for breast cancer brain metastases”, Co-Investigator (Heldermon PI). Project period: 09/01/2021 – 08/31/2024. \$9,050 subproject.

NIH R01 DA054376-01, NIDA “A Multimodal Molecular Imaging Pipeline to Map Opioid Response”, Multiple PI (Christina Boucher, Paul Gader, Christopher R. McCurdy, Boone Prentice, Richard Yost, Eric Vitriol) (10% effort). Mechanism/Announcement: PAR-20-241. Submitted October 30, 2020. Project period: 06/01/2021 – 05/31/2026. Total direct cost: \$5,000,000. Total costs: \$7,284,577.

NIH R01 DA053071-01, NIDA “Opioid and Cannabinoid interactions in pain and reward”, Co-Investigator (Neubert PI). Submitted May 5, 2020. Project period: 09/01/2020 – 8/31/2025. Impact Score: 47; 39th percentile.

NIH P30 DA048777-01A1, NIDA “University of Florida P30 Center for Research to Investigate Substance Use and Pain (UF-CRISP)”, Principal Investigator (40% effort, 4.8 calendar months), Mechanism/Announcement: PAR-18-225 NIDA Core “Center of Excellence” Grant Program (P30 Clinical Trial Optional). Submitted September 25, 2019. Project period: July 1, 2020 – June 30, 2025. Priority Score 42.

DoD JW190171 “Non-Opioid Analgesic for Safe Battlefield Pain Management”. Pre-proposal submitted January 31, 2019.

NIH R01 DA047857-01, NIDA “Analogues of mitragynine as treatments for opioid withdrawal syndrome”, Principal Investigator (25% effort, 3 calendar months), PAR-16-041 “Drug Discovery for Nervous System Disorders (R01)”. Submitted April 16, 2018 under continuous submission privilege. Review group: DDNS. Peer review June 28, 2018. Project period: September 1, 2018 – August 31, 2023.

NIH R01 DA047855-01, NIDA “Kratom alkaloids: in vitro and in vivo pharmacological mechanisms” Multiple PI (Lance R. McMahon, Bonnie A. Avery, Christopher R. McCurdy) Submitted April 16, 2018 under continuous submission privilege. Review group: MNPS. Peer review June 14, 2018. Project period: September 1, 2018 – August 31, 2023. (Not Discussed)

NIH R01 DA042488-01, NIDA “Novel pharmacotherapy for peripheral pain with significantly reduced liabilities”, Principal Investigator (25% effort, 3 calendar months), PAR-13-048 Drug Discovery for Nervous System Disorders. Submitted under continuous submission privilege November 18, 2015. Priority Score 47; 28th percentile.

NIH R15 DA042406-01A1, NIDA “Rational Design of Opioids Lacking P-glycoprotein Activity”, Co-Investigator (Mercer, PI). Submitted October 25, 2016.

NIH R21 DAXXXXXX-01, NIDA “Developmental Toxicity of Cannabidiol and Δ^9 -Tetrahydrocannabinol”, Co-Investigator (Willett, PI), PA-14-162. Submitted October 12, 2016.

NIH P30 GM122733-01, NIGMS “Phase III Center of Biological Research Excellence”, Principal Investigator (45% effort, 5.4 calendar months), PAR-14-178 Limited Competition:

Centers of Biomedical Research Excellence. Submitted May 25, 2016. Reviewed November 2, 2016. Priority Score: 46.

NIH R21/R33 DA041507-01A1, NIDA “Development of New GABA-B Receptor Agonists for Drug Addiction”, Co-Investigator (Colby, PI). Submitted March 15, 2016.

NSF EPSCoR 1632856, “RII Track-2 FEC: Improving Learning and Memory in Juveniles: Environmental Enrichment Strategies and Cognitive Enhancers.” Co-Investigator (Coolen, PI). Submitted February 4, 2016.

NIH R15 DA042406-01, NIDA “Rational Design of Opioids Lacking P-glycoprotein Activity”, Co-Investigator (Mercer, PI). Submitted October 25, 2015. ZRG1 MDCN-R (86). Priority Score 49 (Not Funded).

NIH R21/R33 DA041507-01, NIDA “Development of New GABA-B Receptor Agonists for Drug Addiction”, Co-Investigator (Colby, PI). Submitted June 16, 2015. (Not Discussed).

NIH R01 DA040669-01, NIDA “Hit-to-Lead Optimization Studies of Cannabinoid Receptor 2 (CB2) Agonists Discovered Through In Silico Virtual Screening”, Co-Investigator (Doerksen, PI), PA-13-302. Submitted February 5, 2015. (Not Discussed).

NIH R01 DA0391167-01, NIDA “Deterrents for prescription opioid abuse”, Co-Investigator (Freeman, PI), PA13-015 BRLE review group. Submitted June 5, 2014. Impact score:40 Percentile 37. (Not Funded)

NIH R21 GRANT11586190, NINDS “A New Sigma-1 Receptor Antagonist to Diagnose Chronic Pain Generators”, Principal Investigator (5% effort, 0.6 calendar months) on Sub-Contract to Stanford University (Biswal, PI), PA-13-303 “NIH Exploratory/Developmental Research Grant Program.” Submitted February 17, 2014. (Not Funded).

NIH R01 DA039392-01 GRANT11669797, NIDA “Non-Peptide Ligands for NPFF Receptors”, Principal Investigator (25% effort, 3 calendar months), PAR-13-048 “Drug Discovery for Nervous System Disorders (R01).” Submitted June 5, 2014. (**WITHDRAWN**).

NIH R21, NINDS, “A New Sigma-1 Receptor Antagonist to Diagnose and Treat Chronic Pain Generators”, Principal Investigator (5% effort, 0.6 calendar months) on Sub-Contract to Stanford University (Biswal, PI), PA-11-261 “NIH Exploratory/Developmental Research Grant Program.” Submitted February 15, 2013. (not funded)

NIH R01, NIDA, “Pharmacology of MDPV and related bath salts. Co-Investigator, Consortium with Temple University, submitted June 5, 2012 in response to PA-10-268 (Liu-Chen & Rawls, PIs) (not funded)

NIH R21, “Novel Diagnostic Agents for Imaging Sigma-1 Receptor Drug Therapy in Alzheimer’s Disease. Co-Investigator, Consortium with Stanford University, submitted February 16, 2012 in response to PAR-11-100 (Chin, PI) (not funded)

NIH R01 DA034777-01, NIDA, "Optimization of non-peptide probes for the Neuropeptide FF receptor system", Principal Investigator, submitted February 7, 2012 in response to PAR-12-060 (not funded)

NIH R01 DA030971-01, NIDA, "Development of Sigma Ligands as Antipsychostimulant Drugs", Principal Investigator (25% time, 3 cal mo), RFA-DA-10-018. **\$4,887,984** total costs. Submitted April 29, 2010 (not funded)

NIH R21/R33 DA029967-01, NIDA, "Selective Sigma-2 Receptor Ligands", Principal Investigator (25% time, 3 cal mo), RFA-DA-10-005 **\$1,800,277** total costs. Submitted December 4, 2009; (Priority Score 39, not funded)

NIH RC1 GM091443, NIGM, "Selective Sigma-2 Receptor Probes", Principal Investigator (25% time, 3 cal mo), Submitted April 24, 2009. **\$986,219** total costs. Broad Challenge Area (06) Enabling Technologies and Specific Challenge Topic. 06-GM-102: Chemist/biologist collaborations facilitating tool development. RFA-OD-09-003 (not funded)

NIH, R01 DA023205-03S1 competitive revision to **DA023205**, NIDA, "Lead Optimization of Anti-psychostimulants", Principal Investigator (25% time, 3 cal mo), Submitted April 21, 2009. **\$1,028,858** total costs. NOT-OD-09-058 (not funded)

NIH R01 DA025775-01, NIDA, "Opioids derived from Kratom, a psychoactive botanical", Principle Investigator (25% time, 3 cal mo), Submitted February 5, 2008. **\$1,250,000** direct costs. PA-07-374 (not funded)

NIH R21, NINDS, "Prolylcarboxypeptidase Dysfunction in Stroke", Co-Investigator (5% time, 0.6 cal mo), submitted for review June, 2007. (not funded)

NIH R01 DA023939-01, NIDA, "Novel Pharmacologic Interventions for Psychostimulant Abuse", Principle Investigator (25% time, 3 cal mo), (**WITHDRAWN**) Submitted January 25, 2007. \$1,250,000 direct cost. RFA-DA-07-006. Review group: NIDA Special Emphasis Panel ZDA1 MXS-M (17).

NIH R03, NIDA, "The pharmacokinetics of Salvia divinorum, an emerging hallucinogen", Co-Investigator (K. Babu, Harvard, PI). Submitted June 1, 2005. 2% time/salary (not funded)

NIH R01, NIDA, "Opioid Ligands Based on Salvinorin A" Principal Investigator, Submitted for review Oct. 1, 2004. \$1,250,000 direct cost. (not funded)

NIH R01, Consortium grant with Reza Mehvar at Texas Tech University Health Sciences Center, Amarillo, TX. Co-Investigator, 01/04-01/09. \$100,000 (not funded)

NIH RFA, NIGMS, 1 P50 GM067025-01, "Chemical Methodologies and Library Development Centers" Co-PI (M. Avery, UM, PI). Submitted February 1, 2002. **\$2,526,094** (not funded)

NIH COBRE, NCCR, Grant with Chemistry Department, Co-PI (D. Graves, UM, PI) Submitted February 2002. (not funded).

PROFESSIONAL DEVELOPMENT

2023-2024	Executive Coaching, Pivot, Inc. Heathere Evans https://pivotincorporated.com
2021-2022	Executive Coaching, Pivot, Inc. Heathere Evans https://pivotincorporated.com
2020-2021	University of Florida's Advanced Leadership for Academics and Professionals, Reprise.
2019-2020	Southeastern Conference Academic Consortium's Academic Leadership Development Program (SECU/ALDP) Fellow.
2019-2020	University of Florida's Advanced Leadership for Academics and Professionals.
07/18	Alan Alda Center for Communicating Science Workshop. University of Florida, Gainesville, FL. July 18-19, 2018.
06/12	University of Utah School on Alcoholism and Other Drug Dependencies. Salt Lake City, UT. June 17-22, 2012
01/12-03/12	ACS Shortcourse on Pharmacokinetics and Pharmacodynamics. On-line (webinar) format, 6 one-hour lectures.
03/09	CITI Collaborative Institutional Training Initiative Course in the Responsible Conduct of Research, Office of Research and Sponsored Programs, The University of Mississippi, on-line
08/05-07/06	Academic Leadership Fellows Program, American Association of Colleges of Pharmacy.
10/04	National Association of Boards of Pharmacy, Foreign Pharmacy Graduate Equivalency Examination Item Writing Workshop. Park Ridge, IL.
09/00-12/00	Pharmacology of Drugs of Abuse, National Institute on Drug Abuse Training Grant Course, University of Minnesota, Department of Neuroscience.
09/00	Responsible conduct of research course. Office of Research, University of Minnesota.

BIBLIOGRAPHY

SCIENTIFIC PUBLICATIONS (PEER REVIEWED):

1. Ching-Ga, T.A.F.; Chear, N.J.-Y.; Ahad, M.A.; Leon, F.; Sharma, A.; Seabra, M.; Tan, W.-N.; Hassan, Z.; Murugaiyah, V.; **McCurdy, C.R.**; Ramanathan, S. *In vivo, in vitro*, and molecular docking assessment of the opioid analgesic activity of *Uncaria attenuata* Korth. (Rubiaceae) and its main indole alkaloids, villocarine A. (SUBMISSION February 2024)
2. Galal, K.; Mottinelli, M.; Mesangeau, C.; **McCurdy, C.R.** Structure-Activity Relationship (SAR) Study of Rigid Guanidine and Guanidino-mimetic Analogues of the Neuropeptide FF Receptor Antagonist MES304. *Medicinal Chemistry Research* (SUBMITTED)
3. Berthold, E.C.; Kamble, S.H.; Kanumuri, S.R.R.; Kuntz, M.A.; Senetra, A.S.; Chiang, Y.-H.; **McCurdy, C.R.**; Sharma, A. Pharmacokinetic interaction of kratom and cannabidiol (CBD) in rats. *Pharmaceutics* (SUBMITTED)
4. Liang, Z.; Guo, Y.; Ellin, N.; King, T.I.; Sharma, A.; **McCurdy, C.R.**; Prentice, B.M. Formation of multiple ion types during MALDI imaging mass spectrometry analysis of *Mitragyna speciosa* alkaloids in dosed rat brain tissue. *Talanta* (SUBMITTED)
5. Zamarripa, A.; Spindle, T.R.; Panlilio, L.V.; Strickland, J.C.; Feldman, J.D.; Novak, M.D.; Epstein, D.H.; Dunn, K.E.; Kuntz, M.A.; Mukhopadhyay, S.; Kanumuri, S.R.R.; Sharma, A.; **McCurdy, C.R.**; Rogers, J.M.; Smith, K.E. Effects of Kratom on Driving: Results from a Cross-Sectional Survey, Ecological Momentary Assessment, and a Pilot Simulated Driving Study. *Drug and Alcohol Dependence* (SUBMITTED)
6. Chiang, Y.-H.; Chear, N.J.-Y.; Berthold, E.C.; Kuntz, M.A.; Kanumuri, S.R.R.; Senetra, A.S.; Ramanathan, S.; **McCurdy, C.R.**; Sharma, A. Development and validation of a bioanalytical UPLC-MS/MS method for the quantification of villocarine A in pharmacokinetic studies. *Journal of Chromatography B* (SUBMITTED)
7. Galal, K.A.; Obeng, S.; Pallares, V.L.C.; Senetra, A.; **McCurdy, C.R.** Guanidine-to-Piperidine Switch Affords High Affinity Small Molecule NPFF Ligands with Preference for NPFF1-R and NPFF2-R Subtypes. *European Journal of Medicinal Chemistry* (REVISION REQUESTED)
8. Smith, K.E.; Panlilio, L.V.; Feldman, J.D.; Grundmann, O.; Dunn, K.E.; **McCurdy, C.R.**; Garcia-Romeu, A.; Epstein, D.H. The first ecological momentary assessment (EMA) of kratom use, in a nationwide US sample. *Neuropsychopharmacology* (SUBMITTED)
9. Obeng, S.; Crowley, M.L.; Mottinelli, M.; Leon, F.; Zuarth-Gonzalez, J.D.; Chen, Y.; Gamez-Jimenez, L.R.; Restrepo, L.F.; Ho, N.P.; Patel, A.; Martin-Rocha, J.; Alvarez, M.A.; Thadisetti, A.M.; Park, C.R.; Pallares, V.L.C.; Milner, M.J.; Canal, C.E.; Hampson, A.J.; **McCurdy, C.R.**; McMahon, L.R.; Wilkerson, J.L.; Hiranita, T.

Mitragynine, the Primary Alkaloid in *Mitragyna speciosa* (Kratom), as an *In Vivo* Adrenergic α_2 Receptor Agonist in Rats. *Journal of Pharmacology and Experimental Therapeutics* (SUBMITTED)

10. Hoefflich, C.C.; Kuntz, M.A.; **McCurdy, C.R.**; Striley, C.W. Kratom use and withdrawal during pregnancy: A qualitative analysis of perceptions and experiences among Reddit communities. *Journal of Substance Use and Misuse* (SUBMITTED)
11. Suriaga, A.; Tappen, R.M.; **McCurdy, C.R.**; Newman, D. Mitragynine-Associated Drug Intoxications Among Florida Counties, 2020-2021. (SUBMITTED)
12. Andriyas, T.; Leksungnoen, N.; Ngernsaengsarua, C.; Uthairatsamee, S.; Tansawat, R.; Sirilertpanich, P.; Kjelgren, R.; Pearson, B.J.; **McCurdy, C.R.**; Sharma, A. Secondary metabolites in the naturally growing *Mitragyna* species of Thailand. *Frontiers in Plant Science* (SUBMITTED)
13. Yoon, L.; Yoon, P.; Park, J.H.; Zhang, B.; **McCurdy, C.R.**; Roh, E.; Curtin, C.; Davidson, G.; Biswal, S. Sigma-1 receptor changes in chronic knee pain: preliminary results of. Ten patients using PET/MRI. *Pain* (SUBMITTED)
14. Haider, G.; Schonfeld, E.; Yoon, D.; Shen, B.; Van Der Heijden, R.A.; Jin, M.; **McCurdy, C.R.**; Davidson, G.; Biswal S.; Verravagu, A. Accurate Localization of Back Pain by Assessment of Sigma-1 Receptor Expression using PET/MRI scan. *Journal of Neurosurgery* (SUBMITTED)
15. Smith, K.E.; Colvin, K.; Rogers, J.M.; Grundmann, O.; **McCurdy, C.R.**; Epstein, D.H. Growing pains with kratom: Reddit posts highlight changing use and quit motivations amidst changing product formulations. *International Journal of Drug Policy* (SUBMITTED)
16. Galal, K.A.; Obeng, S.; Pallares, V.L.C.; Senetra, A.S.; Eans, S.O.; McLaughlin, J.P.; **McCurdy, C.R.** Utilizing the Modified Bargellini Multicomponent Reaction to Access Selective Neuropeptide FF-1 (NPFF1) Receptor Antagonists with Anti-Hyperalgesic Effects in Mice. *ACS Chemical Neuroscience* (REVISION REQUESTED)
17. Mottinelli, M.; Journigan, V.B.; Obeng, S.; Pallares, V.L.C.; Mesangeau, C.; Kapanda, C.N.; Cutler, S.J.; Lambert, J.A.; Eans, S.O.; Ganno, M.L.; Sheng, W.; King, T.I.; Sharma, A.; Mollereau, C.; Avery, B.A.; McLaughlin, J.P.; **McCurdy, C.R.** Dual Opioid-Neuropeptide FF Small Molecule Ligands Demonstrate Analgesia with Reduced Tolerance Liabilities. *Journal of Medicinal Chemistry* (REVISION REQUESTED)
18. **McCurdy C.R.**; Sharma, A.; Smith, K.E.; Veltri, C.A.; Weiss, S.T.; White, C.M.; Grundmann, O. An update on the clinical pharmacology of kratom: uses, abuse potential and future considerations. *Expert Reviews in Clinical Pharmacology*, **2024** Jan13. Web Published January 13, 2024. DOI: 10.1080/17512433.2024.2305798. PMID: 38217374

19. Smith, K.E.; Rogers, J.M.; Sharma, A.; **McCurdy, C.R.**; Dunn, K.E.; Weiss, S.T.; Feldman, J.D.; Kuntz, M.A.; Mukhopadhyay, S.; Kanumuri, S.R.R.; Taylor, R. Epstein, D.H. Responses to a “typical” morning dose of kratom in people who use kratom regularly: A direct-observation study. *Journal of Addiction Medicine*, **2024**, Jan 4. Web Published January 4, 2024. DOI: 10.1097/ADM.0000000000001259 PMID: 38174871
20. Berkowitz, R.L.; Bluhm, A.P.; Know, G.W.; **McCurdy, C.R.**; Ostrov, D.A.; Norris, M.H. Sigma receptor ligands prevent COVID mortality *in vivo*: Implications for future therapeutics. *Journal of Molecular Sciences*, **2023**, 24(21), 15718; Web Published October 29, 2023. DOI: 10.3390/ijms242115718 PMID: 37958703 PMCID: PMC10647780
21. Melchert, P.W.; Zhang, Q.; Mukhopadhyay, S.; **McCurdy, C.R.**; Markowitz, J.S. An *in vitro* evaluation of kratom (*Mitragyna speciosa*) on the catalytic activity of carboxylesterase 1 (CES1). *Chemico-Biological Interactions*, **2023** Sep 14:110715. Web Published September 14, 2023. DOI: 10.1016/j.cbi.2023.110715 PMID: 37716419
22. Penman, S.L.; Roeder, N.; Berthold, E.C.; Senetra, A.S.; Marion, M.; Richardson, B.J.; White, O.; Fearby, N.L.; **McCurdy, C.R.**; Hamilton, J.; Sharma, A.; Thanos, P.K. The role of FABP5 on the pharmacokinetic and behavioral response to Δ^9 -tetrahydrocannabinol inhalation. *Pharmacology, Biochemistry and Behavior*, **2023** Sep 14:173633 Web Published September 14, 2023. DOI: 10.1016/j.pbb.2023.173633 PMID: 37716413
23. Gazarov, E.A.; Zequeira, S.; Senetra, A.S.; Howard, J.; Sharma, A.; **McCurdy, C.R.**; Lewis, J.; Bizon, J.L.; Setlow, B. Pharmacokinetics of delta-9-tetrahydrocannabinol following acute cannabis smoke exposure in mice; effects of sex, age, and strain. *Frontiers in Pharmacology Neuropharmacology*, **2023** Aug 28;14:1227220. Web Published August 28, 2023. DOI: 10.3389/fphar.2023.227220 PMID: 37701025 PMCID: PMC10493391
24. Berthold, E.C.; Kamble, S.H.; Kanumuri, S.R.R.; Kuntz, M.A.; Senetra, A.S.; Chiang, Y-H.; McMahon, L.R.; **McCurdy, C.R.**; Sharma, A. Comparative pharmacokinetics of commercially available cannabidiol isolate, broad spectrum, and full spectrum products. *European Journal of Drug Metabolism and Pharmacokinetics*, **2023** Jul;48(4):427-435. Web Published June 19, 2023. DOI: 10.1007/s13318-023-00839-3 PMID: 37337087
25. Ortiz, Y.T.; Bilbrey, J.A.; Felix, J.S.; Kienegger, E.A.; Mottinelli, M.; Mukhopadhyay, S.; **McCurdy, C.R.**; McMahon, L.R.; Wilkerson, J.L. Cannabidiol and Mitragynine Exhibit Differential Interactive Effects in the Attenuation of Paclitaxel-Induced Mechanical Allodynia, Acute Antinociception, and Schedule-Controlled Responding in Mice. *Pharmacological Reports*, **2023** May 27. Web Published May 27, 2023. DOI: 10.1007/s43440-023-0048-w PMID: 37243887
26. Smith, K.E.; Feldman, J.D.; Dunn, K.E.; **McCurdy, C.R.**; Weiss, S.T.; Grundmann, O.; Garcia-Romeu, A.; Nichols, J.; Epstein, D.H. Examining the paradoxical effects of kratom: A narrative inquiry. *Frontiers in Psychology Addictive Behaviors*, **2023** May

5;14:1174139. DOI: 10.3389/fphar.2023.1174139. PMID: 37214465 PMCID: PMC10196254

27. Smith, K.E.; Feldman, J.D.; Dunn, K.E.; **McCurdy, C.R.**; Grundmann, O.; Garcia-Romeu, A.; Panlilio, L.V.; Rogers, J.M.; Sharma, A.; Pont-Fernandez, S.; Kheifets, M.; Epstein, D.H. Novel Methods for the remote investigation of emerging substances: Application to kratom. *Experimental and Clinical Psychopharmacology*, **2023**, May 22. DOI: 10.1037/pha0000656. PMID: 37213182
28. Burns, M.; **McCurdy C.R.** Advances with the discovery and development of novel Sigma-1 receptor antagonists for the management of pain. *Expert Opinion on Drug Discovery*, **2023**, Web Published May 18, 2023. DOI: 10.1080/17460441.2023.2216015 (**Invited Review**)
29. Penman, S.L.; Berthold, E.C.; Mihalkovic, A.; Hammond, N.; **McCurdy, C.R.**; Blum, K.; Elden, R.D.; Sharma, A.; Thanos, P.K. Vaporized Delta-9-tetrahydrocannabinol inhalation in female Sprague Dawley rats: A pharmacokinetic and behavioral assessment. *Current Pharmaceutical Design*, **2023**, Apr 19. Web Published May 3, 2023. DOI: 10.2174/1381612829666120419093809 PMID: 37114788
30. Kamble, S.H.; Obeng, S.; Leon, F.; Restrepo, L.F.; King, T.I.; Berthold, E.C.; Kanumuri, S.R.R.; Gamez-Jimenez, L.R.; Pallares, V.L.C.; Patel, A.; Ho, N.P.; Hampson, A.; **McCurdy, C.R.**; McMahon, L.R.; Wilkerson, J.L.; Sharma, A.; Hiranita, T. Pharmacokinetic and Pharmacodynamic Consequences of CYP3A Inhibition on Mitragynine Metabolism in Rats. *Journal of Pharmacology and Experimental Therapeutics*, **2023**, Jun;385(3):180-192. Web Published April 5, 2023. DOI: 10.1124/jpet.122.001525 PMID: 37019472
31. Smith, K.E.; Feldman, J.D.; Schrieffer, D.; Weiss, S.T.; Grundmann, O.; Dunn, K.E.; Singh, D.; **McCurdy, C.R.**; Butera, G.; Epstein, D.H. Diagnostic ambiguities and underuse of clinical assessment tools: A systematic review of case reports on kratom addiction and physical dependence. *Current Addiction Reports*, **2023**, Web Published April 5, 2023. DOI: 10.1007/s40429-023-00474-7 (**Invited Review**)
32. Nia, S.S.; Hossain, M.A.; Ji, G.; Jonnalagadda, S.K.; Obeng, S.; Rahman, M.A.; Sifat, A.E.; Nozohouri, S.; Blackwell, C.; Patel, D.; Thompson, J.; Runyon, S.; Hiranita, T.; **McCurdy, C.R.**; McMahon, L.R.; Abbruscato, T.J.; Trippier, P.C.; Neugebauer, V.; German, N.A. Studies on diketopiperazine and dipeptide analogs as opioid receptor ligands. *European Journal of Medicinal Chemistry*, **2023**, Jun 5;254:115309. Web Published March 29, 2023. DOI: 10.1016/j.ejmech.2023.115309 PMID: 37054561
33. Mukhopadhyay, S.; Gupta, S.; Wilkerson, J.L.; Sharma, A.; McMahon, L.R.; **McCurdy, C.R.** Receptor Selectivity and Therapeutic Potential of Kratom in Substance use Disorders. *Current Addiction Reports*, **2023**, Web Published March 29, 2023. DOI: 10.1007/s40429-023-00472-9 (**Invited Review**)
34. Henningfield, J.E.; Chawarski, M.C.; Garcia-Romeau, A.; Grundmann, O.; Harun, N.; Hassan, Z.; **McCurdy, C.R.**; McMahon, L.R.; Sharma, A.; Shoaib, M.; Singh, D.;

- Smith, K.E.; Swogger, M.T.; Vicknasingam, B.; Walsh, Z.; Wang, D.W.; Huestis, M.A. Kratom Withdrawal: Discussions and Conclusions of a Scientific Expert Forum. *Drug and Alcohol Dependence Reports*, **2023**, Mar 15;7:100142. Web Published March 15, 2023. DOI: 10.1016/j.dadr.2023.100142 PMID: 37397437 PMCID: PMC10311168
35. Laforest, L.C.; Kuntz, M.A.; Kanumuri, S.R.R.; Schotte, C.; Sharma, A.; O'Connor, S.E.; **McCurdy, C.R.**; Nadakuduti, S.S. Metabolite and molecular characterization of *Mitragyna speciosa* identifies developmental and genotypic effects on monoterpene indole and oxindole alkaloid composition. *Journal of Natural Products*, **2023**, Apr 28;86(4):1042-1052. Web Published March 13, 2023. DOI: 10.1021/acs.jnatprod.3c00092 PMID: 36913648
36. Chear, N. J-Y.; Ching-Ga, T.A.F.; Khaw, K-Y.; Leon, F.; Tan, W-N.; Yusof, S.R.; **McCurdy, C.R.**; Murugaiyah, V.; Ramanathan, S. Natural corynanthe-type cholinesterase inhibitors from Malaysian *Uncaria attenuata* Korth.: Isolation, characterization, *in vitro* and *in silico* studies. *Metabolites*, **2023**, 13(3), 390; Web Published March 7, 2023. DOI: 10.3390/metabo13030390 PMID: 36984830 PMCID: PMC10059728
37. Feldman, J.D.; Schrieffer, D.; Smith, K.E.; Weiss, S.T.; Butera, G.; Dunn, K.E.; Grundmann, O.; **McCurdy, C.R.**; Singh, D.; Epstein, D.H. Omissions, Ambiguities, and Underuse of Causal Assessment Tools: A Systematic Review of Case Reports on Patients Who Use Kratom. *Current Addiction Reports*, **2023**, Web Published March 2 2023. DOI: 10.1007/s40429-023-00466-7 (**Invited Review**)
38. Schotte, C.; Jiang, Y.; Grzech, D.; Dang, T-T.; Laforest, L.; Leon, F.; Mottinelli, M.; Nadakuduti, S.S.; **McCurdy, C.R.**; O'Connor, S.E. Directed Biosynthesis of Mitragynine Stereoisomers. *Journal of the American Chemical Society*, **2023** Mar 8;145(9):4957-4963. Web Published February 22, 2023. DOI: 10.1021/jacs.2c13644 PMID: 36883326 PMCID: PMC9999412 (pre-print Web published December 22, 2022 on bioRxiv2022.12.22.521574; DOI: 10.1101/2022.12.22.521574)
39. Thakur, N.; Ray, A.P.; Sharp, L.; Jin, B.; Duong, A.; Pour, N.G.; Obeng, S.; Wijesekara, A.; Gao, Z.-G.; **McCurdy, C.R.**; Jacobson, K.A.; Lyman, E.; Eddy, M.T. Anionic Phospholipids Control Mechanisms of GPCR-G Protein Recognition. *Nature Communications*, **2023** Feb 13;14(1):794. DOI: 10.1038/s41467-023-36425-z. PMID: 36781870 (pre-print Web published January 13, 2023 on bioRxiv2023.01.11.523010; DOI: 10.1101/2023.01.11.523010 PMID: 36711594 PMCID: PMC9882065)
40. Stanciu, C.; Gnansegaram, S.A.; Radar, G.L.; Sharma, A.; **McCurdy, C.R.** What is the Kratom Overdose Risk? A Systematic Literature Review. *Current Addiction Reports*, **2023**, Web Published January 18, 2023. DOI: 10.1007/s40429-022-00464-1 (**Invited Review**)
41. Smith, K.E.; Sharma, A.; Grundmann, O.; **McCurdy, C.R.** Kratom Alkaloids: A Blueprint? *ACS Chemical Neuroscience*, **2023**, Web Published January 4, 2023. DOI: 10.1021/acscchemneuro.2c00704. (**Invited Review**)

42. Mavlyutov, T.A.; Liu, X.; Yang, H.; Li, J. **McCurdy, C.R.**; Pattnaik, B.; Guo, L-W. Retinal photoreceptor protection in an AMD-related mouse model by selective modulation of sigma-1 or sigma-2 receptor. *Genes*, **2022**, *13*, 2386. Web Published December 16, 2022. DOI: 10.3390/genes13122386. PMID: 36553653 PMCID: PMC9778362
43. Leksungnoen, N.; Andriyas, T.; Ngernsaengsaruy, C.; Uthairatsamee, S.; Racharak, P.; Sonjaroon, W.; Kjelgren, R.; Pearson, B.; **McCurdy, C.R.**; Sharma, A. Variations in mitragynine concentration in the naturally growing kratom (*Mitragyna speciosa*) population of Thailand. *Frontiers in Plant Science*, **2022**, Oct 27;13:1028547. Web Published October 27, 2022. DOI: 10.3389/fpls.2022.1028547. PMID: 36388525 PMCID: PMC9648690
44. Obeng, S.; Leon, F.; Patel, A.; Gonzalez, J.D.Z.; Da Silva, L.C.; Restrepo, L.F.; Gamez-Jimenez, L.R.; Ho, N.P.; Calvache, M.P.G.; Pallares, V.L.C.; Helmes, J.A.; Shiomitsu, S.K.; Soto, P.L.; **McCurdy, C.R.**; McMahon, L.R.; Wilkerson, J.L.; Hiranita, T. Interactive Effects of μ -Opioid and Adrenergic- α_2 Receptor Agonists in Rats: Pharmacological Investigation of the Primary Kratom Alkaloid Mitragynine and its Metabolite 7-Hydroxymitragynine. *Journal of Pharmacology and Experimental Therapeutics*, **2022**, Sept 24; JPET-AR-2022-001192. Web Published September 24, 2022. DOI: 10.1124/jpet.112.001192 PMID: 36153006
45. Stanciu, C.N.; Ahmed, S.; Gnanasegaram, S.; Gibson, S.; Penders, T.; Grundmann, O.; **McCurdy, C.R.** Kratom as an opioid alternative: harm, or harm reduction? A systematic review of the literature. *The American Journal of Drug and Alcohol Abuse*, **2022**, XXX. Web Published August 24, 2022. DOI: 10.1080/00952990.2022.2111685 PMID: 36001875
46. LeSaint, K.T.; Yin, S.; Sharma, A.; Avery, B.A.; **McCurdy, C.R.**; Waksman, J.C. Acute renal insufficiency associated with consumption of hydrocodone- and morphine-adulterated kratom (*Mitragyna speciosa*). *The Journal of Emergency Medicine*, **2022** Aug 5;S0736-4679(22)00161-5 Web Published August 6, 2022. DOI: 10.1016/j.jemermed.2022.02.004 PMID: 35940982
47. Kamble, S.H.; Berthold, E.C.; Kanumuri, S.R.R.; King, T.I.; Kuntz, M.A.; Leon, F.; Mottinelli, M.; McMahon, L.R.; **McCurdy, C.R.**; Sharma, A. Metabolism of speciociliatine, an overlooked kratom alkaloid for its potential pharmacological effects. *AAPS Journal*, **2022**, Jul 19; 24(5):86. Web Published July 19, 2022. DOI: 10.1208/s12248-022-00736-8 PMID: 35854066
48. Kanumuri, S.R.R.; Mamallapalli, J.; Nelson, R.; **McCurdy, C.R.**; Mathews, C.A.; Xing, C.; Sharma, A. Clinical Pharmacokinetics of Kavalactones after Oral Dosing of Standardized Kava Extract in Healthy Volunteers. *Journal of Ethnopharmacology*, **2022**, Oct 28;297:115514 Web Published June 28, 2022. DOI: 10.1016/j.jep.2022.115514. PMID: 35777607
49. Smith, K.E.; Dunn, K.E.; Rogers, J.M.; Grundmann, O.; **McCurdy, C.R.**; Garcia-Romeu, A.; Schriefer, D.; Swogger, M.T.; Epstein, D.H. Kratom use as more than a

- “self-treatment”. *The American Journal of Drug and Alcohol Abuse*, **2022**, Jun 29:1-11 Web Published June 29, 2022. DOI: 10/1080/00952990.2022.2083967 PMID: 35767669
50. Wilson, L.L.; Alleyne, A.R.; Eans, S.O.; Cirino, T.J.; Stacy, H.M.; Mottinelli, M.; Intagliata, S.; **McCurdy, C.R.**; McLaughlin, J.P. Characterization of CM-398, a Novel Selective Sigma-2 Receptor Ligand, as a Potential Therapeutic for Neuropathic Pain. *Molecules*, **2022**, Jun 4;27(11):3617. Web Published June 4, 2022. DOI: 10.3390/molecules27113617 PMID: 35684553 PMCID: PMC9182558
 51. Smith, K.E.; Dunn, K.E.; Epstein, D.H.; Feldman, J.D.; Garcia-Romeu, A.; Grundmann, O.; Henningfield, J.E.; **McCurdy, C.R.**; Rogers, J.M.; Schriefer, D.; Singh, D.; Weiss, S.T. Letter to the Editor: Need for clarity and context in case reports on kratom use, assessment, and intervention. *Substance Abuse Journal*, **2022**;43(1):1221-1224. Web Published June 3, 2022. DOI: 10.1080/08897077.2022.2074608 PMID: 35657649
 52. Striley, C.W.; Hoeflich, C.C.; Viegas, A.T.; Berkowitz, L.A.; Matthews, E.G.; Akin, L.P.; Iheanyi-Okeahialam, C.; Mansoor, U.; **McCurdy, C.R.** Health effects associated with kratom (*Mitragyna speciosa*) and polysubstance use: A narrative review. *Substance Abuse: Research and Treatment*. **2022**, May 20;16:11782218221095873. DOI: 10.1177/11782218221095873 Web Published May 20, 2022. PMID: 35645563 PMCID: PMC9130800
 53. Zhang, M.; Sharma, A.; Leon, F.; Avery, B.A.; Kjelgren, R.; **McCurdy, C.R.**; Pearson, B.J. Plant growth and phytoactive alkaloid synthesis in *Mitragyna speciosa* (kratom) in response to varying radiance. *PLOS ONE*, **2022**, Apr 26;17(4):e0259326 DOI: 10.1371/journal.pone.0259326 PMID: 35472200 PMCID: PMC9041851(pre-print Web published October 18, 2021 on bioRxiv2021.10.18.464895; DOI: 10.1101/2021.100.18.464895)
 54. Grundmann, O.; **McCurdy, C.R.**; Singh, D.; Smith, K.E.; Swogger, M.T. Editorial: The Pharmacology of Kratom and Its Alkaloids. *Frontiers in Pharmacology, section Ethnopharmacology*, **2022**, 13:878376. Web Published March 10, 2022. DOI: 10.3389/fphar.2022.878376. PMID: 35370662 PMCID: PMC8965621
 55. Popa, R.; Kamble, S.H.; Kanumuri, R.S.; King, T.I.; Berthold, E.C.; Intagliata, S.; Sharma, A.; **McCurdy, C.R.** UPLC-MS/MS method for the quantification of MCI-77, a novel sigma-1 receptor ligand, and its application to pharmacokinetic studies. *Journal of Chromatography B*, **2022** Mar 5;1196:123187. Web Published March 5, 2022. DOI: 10.1016/j.chromb.2022.123187. PMID: 35278810
 56. Smith, K.E.; Rogers, J.M.; Dunn, K.E.; Grundmann, O.; **McCurdy, C.R.**; Schriefer, D.; Epstein, D.H. Searching for a signal: Self-reported kratom dose-effect relationships among a sample of US adults with regular kratom use histories. *Frontiers in Pharmacology, section Ethnopharmacology*, **2022** Web Published March 1, 2022. DOI: 10.3389/fphar.2022.765917 PMID: 35300296 PMCID: PMC8921773

57. Wei, S.; Thakur, N.; Ray, A.P.; Jin, B.; Obeng, S.; **McCurdy, C.R.**; McMahon, L.R.; Gutierrez-de-Teran, H.; Eddy, M.T.; Lamichhane, R. Slow Conformational Dynamics of the Human A_{2A} Adenosine Receptor are Temporally Ordered. *Structure*, **2021**, Dec 6:S0969-2126(21)00417-2. Web Published December 6, 2021. DOI: 10.1016/j.str.2021.11.005 PMID: 34895472
58. Mamallapalli, J.; Kanumuri, S.R.R.; Corral, P.; Johnston, E.; Zhuang, C.; **McCurdy, C.R.**; Mathews, C.A.; Sharma, A.; Xing, C. Characterization of different forms of kava (*Piper methysticum*) products by UPLC-MS/MS. *Planta Medica*, **2021**, Nov 28. Web Published November 28, 2021. DOI: 10.1055/a-1708-1994 PMID: 34839465
59. Ostrov, D.A.; Bluhm, A.P.; Li, D.; Khan, J.Q.; Rohamare, M.; Rajamanickam, K.; Bhanumathy, K.K.; Lew, J.; Falzarano, D.; Vizeacoumar, F.J.; Wilson, J.A.; Mottinelli, M.; Kanumuri, S.R.R.; Sharma, A.; **McCurdy, C.R.**; Norris, M.H. Highly specific sigma receptor ligands exhibit anti-viral properties in SARS-CoV-2 infected cells. *Pathogens*, **2021**, Nov20;10(11):1514. Web Published November 20, 2021. DOI: 10.3390/pathogens10111514 PMID: 34832669 PMCID: PMC8620039 **Featured on the Cover**
60. Berthold, E.C.; Kamble, S.H.; Kanumuri, S.R.R.; Kuntz, M.A.; Senetra, A.S.; Mottinelli, M.; Leon, F.; Restrepo, L.F.; Patel, A.; Ho, N.P.; Hiranita, T.; McMahon, L.R.; Sharma, A.; **McCurdy, C.R.** The Lack of Contribution of 7-Hydroxymitragynine to the Antinociceptive Effects of Mitragynine in Mice: A Pharmacokinetic and Pharmacodynamic Study. *Drug Metabolism and Disposition*, **2021**, Web Published November 10, 2021. DOI: 10.1124/dmd.121.000640 PMID: 34759012
61. Yoon, D.; Fast, A.M.; Cipriano, P. Shen, B.; Castillo, J.B.; **McCurdy, C.R.**; Aparici, C.M.; Lum, D.; Biswal, S. Sigma-1 Receptor Changes Observed in Chronic Pelvic Pain Patients: A Pilot PET/MRI Study. *Frontiers in Pain Research*, **2021**. Web Published October 20, 2021. DOI: 10.3389/fpain.2021.711748 PMID: 35295458 PMCID: PMC8915714
62. Gogineni, V.; Nael, M.; Chaurasiya, N.; Elokely, K.; **McCurdy, C.R.**; Rimoldi, J.M.; Cutler, S.J.; Tekwani, B.; Leon, F. Computationally Assisted Lead Optimization of Novel Potent and Selective MAO-B Inhibitors. *Biomedicines*, **2021**, Sep 24;9(10):1304. Web Published September 24, 2021. DOI: 10.3390/biomedicines9101304 PMID: 34680421 PMCID: PMC8533211
63. Leon, F.; Obeng, S.; Mottinelli, M.; Chen, Y.; King, T.I.; Berthold, E.C.; Kamble, S.H.; Restrepo, L.F.; Patel, A.; Gamez-Jimenez, L.R.; Lopera-Londono, C.; Hiranita, T.; Sharma, A.; Hampson, A.J.; Canal, C.E.; McMahon, L.R.; **McCurdy, C.R.** Activity of *Mitragyna speciosa* ('Kratom') Alkaloids at Serotonin Receptors. *Journal of Medicinal Chemistry*, **2021**, Sep 23;64(18):13510-13523. Web Published September 1, 2021. DOI: 10.1021/acs.jmedchem.1c00726 PMID: 34467758
64. Reyes, S.T.; Deacon, R.M.J.; Guo, S.G.; Altimiras F.J.; Castillo, J.B.; van der Wildt, B.; Morales, A.P.; Park, J.H.; Klammer, D.; Rosenberg, J.; Oberman, L.M.; Rebowe, N.; Sprouse, J.; Missling, C.U.; **McCurdy, C.R.**; Cogram, P.; Kaufmann, W.E.; Chin, F.T.

Effects of the Sigma-1 Receptor Agonist Blarcamesine in a Murine Model of Fragile X Syndrome: Neurobehavioral Phenotypes and Receptor Occupancy. *Scientific Reports*, **2021**, Aug 25;11(1):17150. Web Published August 25, 2021. DOI: 10.1038/s41598-021-94079-7 PMID: 34433831 PMCID: PMC8387417

65. Crowley, M.L.; Restrepo, L.F.; Gamez-Jimenez, L.R.; Patel, A.; Braun, T.; Pallares, V.L.C.; Ho, N.P.; **McCurdy, C.R.**; McMahon, L.R.; Hiranita, T. The use of hypercapnic conditions to assess opioid-induced respiratory depression in rats. *Journal of Pharmacological and Toxicological Methods*, **2021**, Jul 7:107101 Web Published July 7, 2021. DOI: 10.1016/j.vascn.2021.107101. PMID: 34242797
66. Liu, C.Z.; Mottinelli, M.; Nicholson, H.E.; McVeigh, B.M.; Wong, N.K.; **McCurdy, C.R.**; Bowen, W.D. Identification and Characterization of MAM03055A: A Novel Bivalent Sigma-2 Receptor/TMEM97 Ligand with Cytotoxic Activity. *European Journal of Pharmacology*, **2021**, Jun 16;906:174263 Web Published June 16, 2021. DOI: 10.1016/j.ejphar.2021.174263. PMID: 34144027
67. Tadjalli, A.; Seven, Y.B.; Sharma, A.; **McCurdy, C.R.**; Bolser, D.C.; Levitt, E.S.; Mitchell, G.S. Acute morphine blocks spinal respiratory motor plasticity via long-latency mechanisms that require toll-like receptor 4 signaling. *The Journal of Physiology*, **2021**, Aug;599(15):3771-3797. Web Published June 19, 2021. DOI: 10.1113/JP281362. PMID: 34142718
68. Obeng, S.; Hiranita, T.; Leon, F.; McMahon, L.R.; **McCurdy, C.R.** Novel Approaches, Drug Candidates, and Targets in Pain Drug Discovery. *Journal of Medicinal Chemistry*, **2021**. Web Published May 6, 2021. DOI: 10.1021/acs.jmedchem.1c00028. PMID: 33956427 (**Invited Review**)
69. Wilkerson, J.L.; Felix, J.S.; Bilbrey, J.A.; **McCurdy, C.R.**; McMahon, L.R. Characterization of a mouse neuropathic pain model caused by the highly active antiviral therapy (HAART) stavudine. *Pharmacological Reports*, **2021**, Apr 16. Web Published April 16, 2021. DOI: 10.1007/s43440-021-00262-y PMID: 33860918
70. Maxwell, E.A.; King, T.I.; Kamble, S.H.; Kanumuri, S.R.R.; Berthold, E.C.; Leon, F.; Hampson, A.; McMahon, L.R.; **McCurdy, C.R.**; Sharma, A. Oral pharmacokinetics in beagle dogs of the mitragynine metabolite, 7-hydroxymitragynine. *European Journal of Drug Metabolism and Pharmacokinetics*, **2021** May; 46(3):459-463. Web Published April 13, 2021. DOI: 10.1007/s13318-021-00684-2 PMID: 33847897
71. Chear, N.J.-Y.; Leon, F.; Sharma, A.; Raju, K.S.R.; Zwolinski, G.; Abboud, K.A.; Singh, D.; Reeves, M.E.; Restrepo, L.F.; Hiranita, T.; Ramanathan, S.; Hampson, A.J.; McMahon, L.R.; **McCurdy, C.R.** Exploring the chemistry of alkaloids from Malaysian *Mitragyna speciosa* (kratom) and the role of oxindoles on human opioid receptors. *Journal of Natural Products*, **2021**, Apr 23; 84(4):1034-1043. Web Published February 26, 2021. DOI: 10.1021/acs.jnatprod.0c01055. PMID: 33635670
72. Kamble, S.H.; Berthold, E.C.; King, T.I.; Kanumuri, S.R.R.; Popa, R.; Herting, J.R.; Leon, F.; Sharma, A.; McMahon, L.R.; Avery, B.A.; **McCurdy, C.R.** Pharmacokinetics

- of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats. *Journal of Natural Products*, **2021**, Apr 23; 84(4):1104-1112. Web Published February 23, 2021. DOI: 10.1021/acsjnatprod.0c01163 PMID: 33620222
73. Obeng, S.; Wilkerson, J.L.; Leon, F.; Reeves, M.E.; Restrepo, L.F.; Gamez-Jimenez, L.R.; Patel, A.; Pennington, A.E.; Taylor, V.A.; Ho, N.P.; Braun, T.; Fortner, J.D.; Crowley, M.L.; Williamson, M.R.; Pallares, V.L.C.; Mottinelli, M.; Lopera-Londono, C.; **McCurdy, C.R.**; McMahon, L.R.; Hiranita, T. Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: *In Vitro* Affinity and Efficacy for Mu-Opioid Receptor and Opioid-Like Behavioral Effects in Rats. *Journal of Pharmacology and Experimental Therapeutics*, **2020**. Web Published December 31, 2020. DOI: 10/1124/jpet.120.000189 PMID: 33384303
74. Berthold, E.C.; Yang, R.; Sharma, A.; Kamble, S.H.; Kanumuri, S.R.; King, T.I.; Popa, R.; Freeman, J.H.; Brym, Z.T.; Avery, B.A.; **McCurdy, C.R.** Regulatory sampling of industrial hemp plant samples (*Cannabis sativa* L.) using UPLC-MS/MS method for detection and quantification of twelve cannabinoids. *Journal of Cannabis Research*, **2020**, 2, 42. Web published December 10, 2020. DOI: 10.1186/s42238-020-00050-0 PMID: 33526142
75. Zhang, M.; Sharma, A.; Leon, F.; Avery, B.A.; Kjelgren, R.; **McCurdy, C.R.**; Pearson, B.J. Effects of nutrient fertility on growth and alkaloidal content in *Mitragyna speciosa* (kratom). *Frontiers in Plant Science*, **2020**. Dec21;11:597696. Web Published Dec 1, 2020. DOI: 10.3389/fpls.2020.597696 PMID: 33408731 PMCID: PMC7779599
76. Berthold, E.C.; Kamble, S.H.; Raju, K.S.; King, T.I.; Popa, R.; Sharma, A.; Leon, F.; Avery, B.A.; McMahon, L.R.; **McCurdy, C.R.** Preclinical pharmacokinetic study of speciociliatine, a kratom alkaloid, in rats using an UPLC-MS/MS method. *Journal of Pharmaceutical and Biomedical Analysis*, **2020**, Nov 21;113778. Web published November 21, 2020. DOI: 10.1016/j.jpba.2020.113778 PMID: 33277117
77. Singh, D.; Brown, P.N.; Cinosi, E.; Corazza, O.; Henningfield, J.E.; Garcia-Romeu, A.; **McCurdy, C.R.**; McMahon, L.R.; Prozialeck, W.C.; Smith, K.E.; Swogger, M.T.; Veltri, C.; Walsh, Z.; Grundmann, O. Current and Future Potential Impact of COVID-19 on Kratom (*Mitragyna speciosa* Korth.) Supply and Use. *Frontiers in Psychiatry*, **2020**, Nov 26;11:574483. Web published November 26, 2020. DOI: 10.3389/fpsy.2020.574483 PMID: 33324252 PMCID: PMC7726130
78. Sharma, A.; **McCurdy, C.R.** Assessing the therapeutic potential and toxicity of *Mitragyna speciosa* in opioid use disorder. *Expert Opinion on Drug Metabolism and Toxicity*, **2021** Mar;17(3):255-257. Web Published November 19, 2020. DOI: 10.1080/17425255.2021.1853706 PMID: 33213215 (Invited Review)
79. Agha, H.; **McCurdy, C.R.** *In vitro* and *in vivo* Sigma-1 Receptor Imaging Studies in Different Disease States. *RSC Medicinal Chemistry*, **2021**, 12, 154-177. Web Published October 8, 2020. DOI: 10.1039/D0MD00186D Cover Featured Article (Invited Review)

80. Popa, R.; Kamble, S.H.; Kanumuri, S.R.; King, T.I.; Berthold, E.C.; Intagliata, S.; Sharma, A.; **McCurdy, C.R.** Bioanalytical method development and pharmacokinetics of MCI-92, a sigma-1 receptor antagonist. *Journal of Pharmaceutical and Biomedical Analysis*, **2020**, Nov 30, *191*, 113610. Web published September 13, 2020. DOI: 10.1016/j.jpba.2020.113610 PMID: 32971495
81. Wilson, L.L.; Harris, H.; Brice-Tutt, A.; Cirino, T.; Eans, S.; Stacy, H.; Simons, C.; Leon, J.F.; Sharma, A.; Boyer, E.; Avery, B.A.; McLaughlin, J.P.; **McCurdy, C.R.** Lyophilized Kratom Tea as a Therapeutic Option for Opioid Dependence. *Drug and Alcohol Dependence*, **2020**, Nov 1;216:108310. Web published September 22, 2020. DOI: 10.1016/j.drugalcdep.2020.108310 PMID: 33017752
82. Behnood-Rod, A.; Chellian, R.; Wilson, R.; Hiranita, T.; Sharma, A.; Leon, F.; **McCurdy, C.R.**; McMahon, L.R.; Bruijnzeel, A.W. Evaluation of the rewarding effects of mitragynine and 7-hydroxymitragynine in an intracranial self-stimulation procedure in male and female rats. *Drug and Alcohol Dependence*, **2020**, Oct 1;215:108235. Web Published August 18, 2020. DOI: 10.1016/j.drugalcdep.2020.108235 PMID: 32889450
83. Kamble, S.H.; Leon, F.; King, T.I.; Berthold, E.C.; Lopera-Londono, C.; Kanumuri, S.R.; Hampson, A.J.; Sharma, A.; Avery, B.A.; McMahon, L.R.; **McCurdy, C.R.** Metabolism of a kratom alkaloid metabolite in human plasma increases its opioid potency and efficacy. *ACS Pharmacology and Translational Science*, **2020**, Jul 31;3(6):1063-1068. Web Published July 31, 2020. DOI: 10.1021/acsptsci.0c00075 PMID: 33344889 PMCID: PMC7737207 **Featured on the cover of the December 11, 2020 issue**
84. Maxwell, E.A.; King, T.I.; Kamble, S.H.; Raju, K.S.R.; Berthold, E.C.; Leon, F.; Avery, B.A.; McMahon, L.R.; **McCurdy, C.R.**; Sharma, A. Pharmacokinetics and Safety of Mitragynine in Beagle Dogs. *Planta Medica*, **2020**, Nov;86(17):1278-1285. Web Published July 21, 2020. DOI: 10.1055/a-1212-5475 PMID: 32693425 PMCID: PMC7907416
85. Chellian, R.; Behnood-Rod, A.; Wilson, R.; Kamble, S.H.; Sharma, A.; **McCurdy, C.R.**; Bruijnzeel, A.W. Adolescent nicotine and tobacco smoke exposure enhances nicotine self-administration in female rats. *Neuropharmacology*, **2020**, Oct 1;176:108243. Web Published July 20, 2020. DOI: 10.1016/j.neuropharm.2020.108243 PMID: 32702403
86. Intagliata, S.; Sharma, A.; King, T.I.; Mesangeau, C.; Seminerio, M.; Chin, F.T.; Wilson, L.L.; Matsumoto, R.R.; McLaughlin, J.P.; Avery, B.A.; **McCurdy, C.R.** Discovery of a Highly Selective Sigma-2 Receptor Ligand, 1-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1*H*)-yl)butyl)-3-methyl-1*H*-benzo[*d*]imidazol-2(3*H*)-one (CM398), with Drug-like Properties and Antinociceptive Effects in Mice. *AAPS Journal*, **2020**, 22, 94. Web Published July 20, 2020. DOI: 10.1208/s12248-020-00472-x PMID: 32691179
87. Intagliata, S.; Agha, H.; Kopajtic, T.A.; Katz, J.L.; Kamble, S.H.; Sharma, A.; Avery, B.A.; **McCurdy, C.R.** Exploring 1-adamantanamine as an alternative amine moiety for

metabolically labile azepane ring in newly synthesized benzo[*d*]thiazol-2(3*H*)one σ receptor ligands. *Medicinal Chemistry Research*, **2020**, *29*, 1697-1706. Web Published July 8, 2020. DOI: 10.1007/s00044-020-02597-2 PMID: 33584084

88. Lepelletier, F-X.; Vandesquille, M.; Asselin, M-C.; Prenant, C.; Robinson, A.C.; Mann, D.M.A.; Green, M.; Barnett, E.; Banister, S.D.; Mottinelli, M.; Mesangeau, C.; **McCurdy, C.R.**; Fricke, I.B.; Jacobs, A.H.; Kassiou, M.; Boutin, H. Evaluation of ¹⁸F-IAM6067 as a sigma-1 receptor PET tracer for neurodegeneration *in vivo* in rodents and in human tissue. *Theranostics*, **2020**, *10*, 7938-7955. DOI: 10.7150/thno.47585 PMID: 32724451 PMCID: PMC7381740
89. Ramanathan, S.; **McCurdy, C.R.** Kratom (*Mitragyna speciosa*): Worldwide Issues. *Current Opinion in Psychiatry*, **2020**, *30*, 312-318. Web Published May 20, 2020. DOI: 10.1097/YCO.0000000000000621 PMID: 32452943 (**Invited Review**)
90. Yang, R.; Berthold, E.; **McCurdy, C.R.**; da Silva Benevenuto, S.; Brym, Z.; Freeman, J.H. Development of Cannabinoids in Flowers of Industrial Hemp (*Cannabis sativa* L.). *Journal of Agricultural and Food Chemistry*, **2020**, *68*, 6058-6064. Web published May 11, 2020. DOI: 10.1021/acs.jafc.0c01211 PMID: 32392412
91. Pearson, B.J.; Campbell, S.M.; Avery, B.; **McCurdy, C.**; Francisco, J.; Sharma, A.; Kjelgren, R. Preliminary examination of mitragynine and 7-hydroxymitragynine synthesis in response to production environment and postharvest techniques of *Mitragyna speciosa*. *Acta Horticulturae*, **2020**, 1274, 89-96. Web Published March 24, 2020. DOI: 10.17660/ActaHortic.2020.1274.10
92. King, T.I.; Sharma, A.; Kamble, S.H.; Leon, F.; Berthold, E.C.; Popa, R.; Cerlati, O.; Prentice, B.M.; McMahon, L.R.; **McCurdy, C.R.**; Avery, B.A. Bioanalytical Method Development and Validation of Corynantheidine, a Kratom Alkaloid, Using UPLC-MS/MS and its Application to Preclinical Pharmacokinetic Studies. *Journal of Pharmaceutical and Biomedical Analysis*, **2020**, Feb 20; *180*: 113019. Web Published December 5, 2019. DOI: 10.1016/j.jpda.2019.113019 PMID: 31838282
93. Obeng, S.; Kamble, S.H.; Reeves, M.E.; Restrepo, L.F.; Chear, N.J.Y.; Ramanathan, S.; Sharma, A.; Leon, F.; Hiranita, T.; Avery, B.A.; McMahon, L.R.; **McCurdy, C.R.** Investigation of the Adrenergic and Opioid Binding affinities, Metabolic Stability, and Plasma Protein Binding Properties of Selected Indole-based Kratom Alkaloids. *Journal of Medicinal Chemistry*, **2020**, *63*, 433-439. Web published December 27, 2019. DOI: 10.1021/acs.jmedchem.9b01465 PMID: 31834797
94. Singh, D.; Chear, N.J.Y.; Narayanan S.; Leon, F.; Sharma, A.; **McCurdy, C.R.**; Avery, B.A.; Balasingam, V. Patterns and Reasons for Kratom (*Mitragyna speciosa*) Use among Current and former Opioid Poly-Drug Users. *Journal of Ethnopharmacology*, **2020**, *249*; 112462. Web published December 7, 2019. DOI: 10.1016/j.jep.2019.112462 PMID: 31816368
95. Khan, S.; Zhang, X.; Lv, D.; Zhang, Q.; He, Y.; Zhang, P.; Yuan, Y.; Liu, X.; Thummuri, D.; Wiegand, J.S.; Pei, J.; Zhang, W.; Sharma, A.; **McCurdy, C.R.**; Kuruvilla, V.M.;

- Baran, N.; Ferrando, A.A.; Rogojina, A.; Houghton, P.J.; Huang, G.; Hromas, R.; Konopleva, M.; Zheng, G.; Zhou, D. DT2216, A BCL-X_L proteolysis targeting chimera, is a safer and more potent antitumor agent than ABT263. *Nature Medicine*, **2019**, Dec 25(12); 1938-1947. Web published December 2, 2019. DOI: 10.1038/s41591-019-0668-z PMID: 31792461
96. King, T.I.; Roewekamp, A.C.; Sharma, A.; Harrison, S.; Mesangeau, C.; Mottinelli, M.; Kamble, S.H.; **McCurdy, C.R.**; Avery, B.A. Bioanalytical method development and validation of MES207, a Neuropeptide FF Receptor Antagonist, and its application in preclinical pharmacokinetics. *Journal of Chromatography B*, **2019**, Dec 15; 1134-1135:121875. Web Published November 12, 2019. DOI: 10.1016/j.jchromb.2019.121875 PMID: 31790916 PMCID: PMC7027589
97. Kamble, S.H.; Sharma, A.; King, T.I.; Berthold, E.C.; Leon, F.; Meyer, K.L.; Kanumuri, S.R.R.; McMahon, L.R.; **McCurdy, C.R.**; Avery, B.A. Exploration of Cytochrome P450 Inhibition Mediated Drug-Drug Interaction Potential of Kratom Alkaloids. *Toxicology Letters*, **2020**, 319:148-154. Web Published November 7, 2019. DOI: 10.1016/j.toxlet.2019.11.005 PMID: 31707106
98. Cirino, T.J.; Eans, S.O.; Medina, J.M.; Wilson, L.L.; Mottinelli, M.; Intagliata, S.; **McCurdy, C.R.**; McLaughlin, J.P. Characterization of Sigma 1 Receptor (S1R) antagonist CM-304 and its analog, AZ-66: Novel therapeutics against allodynia and induced pain. *Frontiers in Pharmacology*, **2019**, 10:678. Web Published June 14, 2019. DOI: 10.3389/fphar.2019.00678. PMID: 31258480
99. Prozialeck, W.C.; Avery, B.A.; Boyer, E.W.; Grundmann, O.; Henningfield, J.E.; Kruegel, A.C.; McMahon, L.R.; **McCurdy, C.R.**; Swogger, M.T.; Veltri, C.A.; Singh, D. Kratom Policy: The Challenge of Balancing Therapeutic Potential with Public Safety. *International Journal of Drug Policy*, **2019**, 70; 70-77. Web Published May 16, 2019. DOI: 10.1016/j.drugpo.2019.05.003 PMID: 31103778
100. Hiranita, T.; Leon, F.; Felix, J.S.; Restrepo, L.F.; Reeves, M.E.; Pennington, A.E.; Obeng, S.; Avery, B.A.; **McCurdy, C.R.**; McMahon, L.R.; Wilkerson, J.L. The Effects of Mitragynine and Morphine on Schedule-Controlled Responding and Antinociception in Rats. *Psychopharmacology (Berl)*, **2019**, 236; 2725-2734. Web Published May 17, 2019. DOI: 10.1007/s00213-019-05247-7 PMID: 31098655
101. Sharma, A.; Kamble, S.H.; Leon, F.; Chear, N.J.; King, T.I.; Berthold, E.C.; Ramanathan, S.; **McCurdy, C.R.**; Avery, B.A. Simultaneous Quantification of Ten Key Kratom Alkaloids in Mitragyna speciosa Leaf Extracts and Commercial Products by Ultra-Performance Liquid Chromatography – Tandem Mass Spectrometry. *Drug Testing and Analysis*, **2019**, 11; 1162-1171. Web Published April 17, 2019. DOI: 10.1002/dta.2604 PMID: 30997725
102. Intagliata, S.; Alsharif, W.F.; Mesangeau, C.; Fazio, N.; Seminerio, M.; Xu, Y-T.; Matsumoto, R.R.; **McCurdy, C.R.** Benzimidazolinone-based selective sigma-2 receptor ligands: synthesis and pharmacological evaluation. *European Journal of*

- Medicinal Chemistry*, **2019**, 165; 250-257. Web Published Jan 9, 2019. DOI: 10.1016/j.ejmech.2019.01.019 PMID: 30685525 PMCID: PMC6369001
103. Singh, D.; Narayanan, S.; Muller, C.P.; Swogger, M.T.; Chear N.J.Y.; Dzulkapli, E.B.; Yusoff, N.S.M.; Ramachandram, D.S.; Leon, F.; **McCurdy, C.R.**; Vicknasingam, B. Motives for using Kratom (*Mitragyna speciosa* Korth.) among regular users in Malaysia. *Journal of Ethnopharmacology*, **2019**, 233, 34-40. Web Published Dec 28, 2018. DOI: 10.1016/j.jep.2018/12/038 PMID: 30594604
 104. Singh, D.; Chye, Y.; Suo, C.; Yucel, M.; Grundmann, O.; Ahmad, M.Z.; Ho, E.T.W.; Mansor, S.M.; Yusof, S.R.; **McCurdy, C.R.**; Muller C.; Boyer, E.W.; Vicknasingam, B. Brain Magnetic Resonance Imaging of Regular Kratom (*Mitragyna speciosa* Korth.) Users: A Preliminary Study. *Malaysian Journal of Medicine and Health Sciences*, **2018**, 14, 65-70. (eISSN 2636-9346) Open Access Web Published, Dec 2018. medic.upm.edu.my/upload/dokumen/2018121315151511_MJMHS_SUPP_2018.pdf
 105. Kamble, S.H.; Sharma, A.; King, T.I.; Leon, F.; **McCurdy, C.R.**; Avery, B.A. Metabolite profiling and identification of enzymes responsible for the metabolism of mitragynine, the major alkaloid of *Mitragyna speciosa* (kratom). *Xenobiotica*, **2018**, Dec 13, 1-31 Epub ahead of print Web Published Dec 14, 2018. DOI: 10.1080/00498254.2018.1552819 PMID: 30547698
 106. Nicholson, H.E.; Alsharif, W.F.; Comeau, A.B.; Mesangeau, C.; Intagliata, S.; Mottinelli, M.; **McCurdy, C.R.**; Bowen, W.D. Divergent Cytotoxic and Metabolically Stimulative Functions of Sigma-2 Receptors: Structure-activity Relationships of 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79) Derivatives. *Journal of Pharmacology and Experimental Therapeutics*, **2019**, 368, 272-281. Web published Dec 7, 2018. DOI: 10.1124/jpet.118.253484 PMID: 30530624
 107. Avery, B.A.; Boddu, S.P.; Sharma, A.; Furr, E.B.; Leon, F.; Cutler, S.J.; **McCurdy, C.R.** Comparative Pharmacokinetics of Mitragynine after Oral Administration of *Mitragyna speciosa* (Kratom) Leaf Extracts in Rats. *Planta Medica*, **2019**, Epub ahead of print Web Published Nov 16, 2018. DOI: 10.1055/z-0770-3683 PMID: 30452072
 108. Cipriano, P.W.; Lee, S-W.; Yoon, D.; Shen, B.; Tawfik, V.L.; Curtin, C.M.; Dragoo, J.L.; James, M.L.; **McCurdy, C.R.**; Chin, F.T.; Biswal, S. Successful treatment of chronic knee pain following localization by a sigma-1 receptor radioligand and PET/MRI: a case report. *Journal of Pain Research*, **2018**, 11, 2353-2357. Web Published Oct 12, 2018. DOI: 10.2147/JPR.S167839 PMID: 30349360 PMCID: PMC6190812
 109. Pandey, P.; Roy, K.K.; Liu, H.; Ma, G.; Pettaway, S.; Alsharif, W.F.; Gadepalli, R.S.; Rimoldi, J.M.; **McCurdy, C.R.**; Cutler, S.J.; Doerksen, R.J. Structure-Based Identification of Potent Natural Product Chemotypes as Cannabinoid Receptor 1 Inverse Agonists. *Molecules*, **2018**, Oct 13; 23(10). pii:E2630 Web Published October 13, 2018. DOI: 10.3390/molecules23102630 PMID: 30322136 PMCID: PMC6222380

110. Hemby, S.E.; McIntosh, S.; Leon, F.; Cutler, S.J.; **McCurdy, C.R.** Abuse liability and therapeutic potential of the *Mitragyna speciosa* (kratom) alkaloids mitragynine and 7-hydroxymitragynine. *Addiction Biology*, **2019**, *24*, 874-885. Web Published June 27, 2018. DOI: 10.1111/adb.12639 PMID: 29949228 PMCID: Pending.
111. Avery, B.A.; Vinnakota, H.; Narayanan, S.; Sharma, A.; Tumuluri, V.S.; **McCurdy, C.R.** Preclinical Pharmacokinetic Studies of SN-79, a Novel Sigma Receptor Antagonist. *Drug Testing and Analysis*, **2017**, (REVISION REQUESTED, SUBMITTED). (MANUSCRIPT WITHDREW DUE TO VINNAKOTA CONFLICT)
112. Liu, X.; Fu, Y.; Yang, H.; Mavlyutov, T.; Li, J.; **McCurdy, C.R.**; Guo, L-W; Pattnaik, B. Potential independent action of sigma receptor ligands through inhibition of the Kv2.1 channel. *Oncotarget*, **2017**, *8*, 59345-59358. Web Published July 26, 2017. DOI: 10.18632/oncotarget.19581 PMID: 28938641 PMCID: PMC5601737
113. Shen, B.; Behera, D.; James, M.L.; Borgohain, P.; Reyes, S.T.; Cipriano, P.W.; Andrews, L.; Klukinov, M.; Lutz, A.B.; Mavlyutov, T.; Rosenberg, J.; Ruoho, A.E.; **McCurdy, C.R.**; Gambhir, S.S.; Yeomans, D.C.; Biswal, S.; Chin, F.T. Visualizing Nerve Injury in a Neuropathic Pain Model with [¹⁸F]FTC-146 PET/MRI. *Theranostics*, **2017**, *7*, 2794-2805. Web Published July 8, 2017. DOI: 10.7150/thno.19378 PMID: 28824716 PMCID: PMC5562216
114. Hjernevik, T.; Cipriano, P.W.; Shen, B.; Park, J.H.; Gulaka, P.; Holley, D.; Gandhi, H.; Yoon, D.; Mittra, E.S.; Zaharchuk, G.; Gambhir, S.S.; **McCurdy, C.R.**; Chin, F.T.; Biswal, S. Biodistribution and radiation dosimetry of ¹⁸F-FTC-146 in humans. *Journal of Nuclear Medicine*, **2017**, *58*, 2004-2009. Web Published June 1, 2017. DOI: 10.2967/jnumed.117.192641 PMID: 28572487 PMCID: Pending
115. Townsend, E.A.; Naylor, J.E.; Negus, S.S.; Edwards, S.R.; Qureshi, H.N.; McLendon, H.W.; **McCurdy, C.R.**; Kapanda, C.N.; do Carmo, J.M.; da Silva, F.S.; Hall, J.E.; Sufka, K.J.; Freeman, K.B. Effects of nalfurafine on the reinforcing, thermal antinociceptive, and respiratory-depressant effects of oxycodone: modeling an abuse-deterrent opioid analgesic in rats. *Psychopharmacology*, **2017**, *234*, 2597-2605. Web Published, May 31, 2017. DOI: 10.1007/s00213-017-4652-3. PMID: 28567699 PMCID: PMC5709149
116. Hong, W.C.; Yano, H.; Hiranita, T.; Chin, F.T.; **McCurdy, C.R.**; Su, T-P.; Amara, S.G.; Katz, J.L. The sigma-1 receptor modulates dopamine transporter conformation and cocaine binding and may thereby potentiate cocaine self-administration in rats. *Journal of Biological Chemistry*, **2017**, *292*, 11250-11261. Web Published May 11, 2017. DOI: 10.1074/jbc.M116.774075. PMID: 28495886 PMCID: PMC5500793
117. Shen, B.; Park, J.H.; Hjernevik, T.; Cipriano, P.W.; Yoon, D.; Gulaka, P.K.; Holly, D.; Behera, D.; Avery, B.A.; Gambhir, S.S.; **McCurdy, C.R.**; Biswal, S.; Chin, F.T. Radiosynthesis and First-in-Human PET/MRI Evaluation with Clinical-Grade [¹⁸F]FTC-146. *Molecular Imaging and Biology*, **2017**, *19*, 779-786. Web Published March 9, 2017. DOI: 10.1007/s11307-017-1064-z PMID: 28280965 PMCID: Pending

118. Katz, J.L.; Hiranita, T.; Hong, W.C.; Job, M.O.; **McCurdy, C.R.** A Role for Sigma Receptors in Stimulant Self-Administration and Addiction. *Handbook of Experimental Pharmacology*, **2017**, 244, 177-218. Web Published January 22, 2017. DOI: 10.1007/164_2016_94 PMID: 28110353 PMCID: Pending
119. Avery, B.A.; Vuppala, P.K.; Jamalapuram, S.; Sharma, A.; Mesangeau, C.; Chin, F.T.; **McCurdy, C.R.** Quantification of highly selective sigma-1 receptor antagonist CM304 using liquid chromatography tandem mass spectrometry and its application to a pre-clinical pharmacokinetic study. *Drug Testing and Analysis*, **2017**, 9, 1236-1242. Web Published December 30, 2016. DOI: 10.1002/dta.2156 PMID: 28039926 PMCID: pending
120. Lydecker, A.G.; Sharma, A.; **McCurdy, C.R.**; Avery, B.A.; Babu, K.M.; Boyer, E.W. Suspected Adulteration of Commercial Kratom Products with 7-Hydroxymitragynine. *Journal of Medical Toxicology*, **2016**, 12, 341-349. Web Published October 17, 2016. DOI: 10.1007/s13181-016-0588-y PMID: 27752985 PMCID: PMC5135684
121. Katz, J.L.; Hiranita, T.; Kopajtic, T.A.; Rice, K.C.; Mesangeau, C.; Narayanan, S.; Abdelazeem, A.H.; **McCurdy, C.R.** Blockade of Cocaine or Sigma Receptor Agonist Self-Administration by Selective Sigma Receptor Subtype-Selective Antagonists. *Journal of Pharmacology and Experimental Therapeutics*, **2016**, 358, 109-124. Web Published April 21, 2016. DOI: 10.1124/jpet.116.232728 PMID: 27189970 PMCID: PMC4931880
122. Nicholson, H.; Mesangeau, C.; **McCurdy, C.R.**; Bowen, W.D. Sigma-2 receptors play a role in cellular metabolism: Stimulation of glycolytic hallmarks by CM764 in human SK-N-SH neuroblastoma. *Journal of Pharmacology and Experimental Therapeutics*, **2016**, 356, 434-445. Web Published November 16, 2015. DOI: 10.1124/jpet.115.228387 PMID: 26874517 PMCID: PMC4746495
123. Chu, U.B.; Mavlyutov, T.A.; Chu, M-L; Yang, H.; Schulman, A.; Mesangeau, C.; **McCurdy, C.R.**; Guo, L-W.; Ruoho, A.E. The Sigma-2 Receptor and PGRMC1 are Different Binding Sites Derived from Independent Genes. *EBioMedicine*, **2015**, 2, 1806-1813. Web Published October 21, 2015. DOI: 10.1016/j.ebiom.2015.10.017 PMID: 26870805 PMCID: PMC4740303
124. Shen, B.; James, M.L.; Andrews, L.; Lau, C.; Chen, S.; Palner, M.; Miao, Z.; Arksey, N.C.; Shuhendler, A.; Scatliffe, S.; Kaneshige, K.; Parsons, S.M.; **McCurdy, C.R.**; Salehi, A.; Gambhir, S.S.; Chin, F.T. Further Validation to support clinical translation of [¹⁸F]FTC-146 for imaging sigma-1 receptors. *European Journal of Nuclear Medicine and Molecular Imaging*, **2015**, 5, 49. Web Published September 17, 2015. DOI: 10.1186/s13550-015-0122-2 PMID: 26384292 PMCID: PMC4573970
125. Kumarihamy, M.; Leon, F.; Pettaway, S.; Wilson, L.; Lambert, J.A.; Wang, M.; Hill, C.; **McCurdy, C.R.**; ElSohly, M.A.; Cutler, S.J.; Muhammad, I. In vitro Opioid Receptor Displacement Affinity and in vivo Behavioral Studies by Tetrad Assay of *Nelumbo nucifera* Flower. *Journal of Ethnopharmacology*, **2015**, 174, 57-65. Web

Published August 7, 2015. DOI: 10.1016/j.jep.2015.08.006 PMID: 26260436 PMCID: PMC4636954

126. Gbaguidi, F.A.; Kassehin, U.C.; Prevost, J.R.C.; Frederick, R.; **McCurdy, C.R.**; Poupaert, J.H. Insight into the Diels-Alder reaction: A green chemistry revisitation of the synthesis of a cantharidine-like trypanocidal pilot-molecule. *Journal of Chemical and Pharmaceutical Research*, **2015**, 7, 1109-1113. Open Access Web Published: July 2015. ISSN: 0975-7384 CODEN(USA): JCPRC5
127. Kassehin, U.C.; Gbaguidi, F.A.; **McCurdy, C.R.**; Poupaert, J.H. Trypanocidal activity of a thioacyl-thiosemicarbazide derivative associating both immunostimulating thalidomide and anti-parasitic thiosemicarbazide pharmacophores. *Journal of Chemical and Pharmaceutical Research*, **2015**, 7, 48-55. Open Access Web Published: July 2015. ISSN: 0975-7384 CODEN(USA): JCPRC5
128. Nicholson, H.; Comeau, A.; Mesangeau, C.; **McCurdy, C.R.**; Bowen, W.D. Characterization of CM572, a selective irreversible partial agonist of the sigma-2 receptor with Antitumor Activity. *Journal of Pharmacology and Experimental Therapeutics*, **2015**, 354, 203-212. Web Published June 1, 2015. DOI: 10.1124/jpet.115.224105 PMID: 26034081 PMCID: PMC4518069
129. Abdelazeem, A.H.; Khan, S.I.; White, S.W.; Sufka, K.J.; **McCurdy, C.R.** Design, Synthesis and Biological Evaluation of Bivalent Benzoxazolone and Benzothiazolone Ligands, as Potential Anti-inflammatory/Analgesic Agents. *Bioorganic & Medicinal Chemistry*, **2015**, 23, 3248-3259. Web Published April 25, 2015. DOI: 10.1016/j.bmc.2015.04.057 PMID: 25975638 PMCID: PMC4467529
130. Kassehin, U.C.; Gbaguidi, F.A.; Kapanda, C.N.; **McCurdy, C.R.**; Poupaert, J.H. Insight into the Willgerodt-Kindler reaction of ω -haloacetophenone derivatives – Mechanistic Implication. *Organic Chemistry International*, **2014**, 2014, 5 pages. Web Published December 10, 2014. DOI: 10.1155/2014/486540
131. Kassehin, U.C.; Gbaguidi, F.A.; Carato, P.; **McCurdy, C.R.**; Poupaert, J.H. Synthesis and Antiepileptic Activity Assessment of 5-Benzoyloxindole, a Novel Phenytoinergic Template. *Organic Chemistry Current Research*, **2014**, 4, 4 pages, Open Access Web Published: November 8, 2014. DOI: 10.4172/2161-0401.1000133
132. Kassehin, U.C.; Gbaguidi, F.A.; **McCurdy, C.R.**; Poupaert, J.H. Synthesis of antitrypanosomal thiosemicarbazones using anthranilic acid as an innovative *Green* nucleophilic catalyst. *Journal of Chemical and Pharmaceutical Research*, **2014**, 6, 10, 607-612. Open Access Web Published: October, 2014. ISSN: 0975-7384 CODEN(USA): JCPRC5
133. Journigan, V.B.; Mesangeau, C.; Vyas, N.; Eans, S.O.; Cutler, S.J.; McLaughlin, J.P.; Mollereau, C.; **McCurdy, C.R.** Nonpeptide Small Molecule Agonist and Antagonist Original Leads for Neuropeptide FF1 and FF2 Receptors. *Journal of Medicinal Chemistry*, **2014**, 57, 8903-8927. Web Published September 28, 2014. DOI: 10.1021/jm500989n PMID: 25268943 PMCID: PMC4234442

134. Kassehin, U.C.; Gbaguidi, F.A.; Kapanda, C.N.; **McCurdy, C.R.**; Poupaert, J.H. Solvent effect and catalysis in the synthesis of thiosemicarbazone derivatives from ketones and 4'-phenylthiosemicarbazide. *African Journal of Pure and Applied Chemistry*, **2014**, 8, 110-115. DOI: 10.5891/AJPAC2014.0575
135. Abdelazeem, A.H.; Abdelatef, S.A.; El-Saadi, M.T.; Omar, H.A.; Khan, S.I.; **McCurdy, C.R.**; El-Moghazy, S.M. Novel Pyrazolopyrimidine Derivatives Targeting COXs and iNOS enzymes; Design, Synthesis and Biological Evaluation as Potential Anti-inflammatory Agents. *European Journal of Pharmaceutical Sciences*, **2014**, 62, 197-211. Web Published June 4, 2014. DOI: 10.1016/j.ejps.2014.05.025 PMID: 24907682 PMCID: Pending
136. Husni, A.S.; **McCurdy, C.R.**; Radwan, M.M.; Ahmed, S.A.; Slade, D.; Ross, S.A.; ElSohly, M.A.; Cutler, S.J. Evaluation of Phytocannabinoids from High Potency *Cannabis sativa* using *In Vitro* Bioassays to Determine Structure-Activity Relationships for Cannabinoid Receptor 1 and Cannabinoid Receptor 2. *Medicinal Chemistry Research*, **2014**, 23, 4295-4300. Web Published April 26, 2014. DOI: 10.1007/s00044-014-0972-6 PMID: 25419092 PMCID: PMC4235762
137. Robson, M.J.; Turner, R.C.; Naser, Z.J.; **McCurdy, C.R.**; O'Callaghan, J.P.; Huber, J.D.; Matsumoto, R.R. SN79, a sigma receptor antagonist, attenuates methamphetamine-induced astrogliosis through a blockade of OSMR/gp130 signaling and STAT3 phosphorylation. *Experimental Neurology*, **2014**, 254, 180-189. Web Published February 6, 2014. DOI: 10.1016/j.expneurol.2014.01.020 PMID: 24508558 PMCID: PMC4241368
138. Kaushal, N.; Robson, M.J.; Rosen, A. **McCurdy, C.R.**; Matsumoto, R.R. Neuroprotective targets through which 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a sigma receptor ligand, mitigates the effects of methamphetamine in vitro. *European Journal of Pharmacology*, **2014**, 724, 193-203. Web Published December 28, 2013. DOI: 10.1016/j.ejphar.2013.12.039 PMID: 24380829 PMCID: PMC3993961
139. James, M.L.; Shen, B.; Nielsen, C.H.; Behera, D.; Buckmaster, C.L.; Mesangeau, C.; Zavaleta, C.; Vuppala, P.K.; Jamalapuram, S.; Avery, B.A.; Lyons, D.M.; **McCurdy, C.R.**; Biswal, S.; Gambhir, S.S.; Chin, F.T. Evaluation of Sigma-1 Receptor Radioligand [¹⁸F]FTC-146 in Rats and Squirrel Monkeys using Positron Emission Tomography. *Journal of Nuclear Medicine*, **2014**, 55, 147-153. Web Published December 12, 2013. DOI: 10.2967/jnumed.113.120261 PMID: 24337599 PMCID: PMC4170105
140. Tarawneh, A.H.; Leon, F.; Ibrahim, M.A.; Pettaway, S.; **McCurdy, C.R.**; Cutler, S.J. Flavones from *Miconia prasina*. *Phytochemistry Letters*, **2014**, 7, 130-132. Web Published December 4, 2013. DOI: 10.1016/j.phytol.2013.11.001 PMID: 24976876 PMCID: PMC4070512
141. Kassehin, U.C.; Gbaguidi, F.A.; Kapanda, C.N.; **McCurdy, C.**; Bigot, A.K.; Poupaert, J.H. Electronic and steric effects in the control of the Anilinium chloride catalyzed

- condensation reaction between Aldones and 4-Phenylthiosemicarbazide. *African Journal of Pure and Applied Chemistry*, **2013**, 7, 325-392. DOI: 10.5897/AJPAC2013.0514
142. Gregg, R.A.; Tallarida, C.S.; Reitz, A.; **McCurdy, C.**; Rawls, S.M. Mephedrone (4-methylmethcathinone), a principal constituent of psychoactive bath salts, produces behavioral sensitization in rats. *Drug and Alcohol Dependence*, **2013**, 133, 746-750. Web Published July 23, 2013. DOI: 10.1016/j.drugalcdep.2013.06.014 PMID: 23890492 PMCID: PMC3989200
 143. Vuppala, P.K.; Jamalapuram, S.; Furr, E.B.; **McCurdy, C.R.**; Avery, B.A. Development and validation of a UPLC-MS/MS method for the determination of 7-hydroxymitragynine, a μ -opioid agonist, in rat plasma and its application to a pharmacokinetic study. *Biomedical Chromatography*, **2013**, 12, 1726-1732. Web Published July 24, 2013. DOI: 10.1002/bmc.2986 PMID: 23893615 PMCID: PMC4029328
 144. Bhat, R.; Fishback, J.A.; Matsumoto, R.R.; Poupaert, J.H.; **McCurdy, C.R.** Structure Activity Relationship of benzo[d]thiazol-2(3H)one Based Sigma Receptor Ligands. *Bioorganic Medicinal Chemistry Letters*, **2013**, 23, 5011-5013. Web Published June 29, 2013. DOI: 10.1016/j.bmcl.2013.06.032 PMID: 23867168 PMCID: PMC3762478
 145. Robson, M.J.; Seminerio, M.J.; **McCurdy, C.R.**; Coop, A.; Matsumoto, R.R. Sigma receptor antagonist attenuation of methamphetamine-induced neurotoxicity is correlated to body temperature modulation. *Pharmacological Reports*, **2013**, 65, 343-349. DOI: 10.1016/S1734-1140(13)71009-0 PMID: 23744418
 146. Jamalapuram, S.; Vuppala, P.K.; Abdelazeem, A.H.; **McCurdy, C.R.**; Avery, B.A. Ultra performance liquid chromatography tandem mass spectrometry method for the determination of AZ66, a sigma receptor ligand, in rat plasma and its application to in vivo pharmacokinetic study. *Biomedical Chromatography*, **2013**, 27, 1034-1040. Web Published 4-5-2013. DOI: 10.1002/bmc.2901 PMID: 23558564 PMCID: PMC4122523
 147. Robson, M.J.; Turner, R.C.; Naser, Z.J.; **McCurdy, C.R.**; Huber, J.D.; Matsumoto, R.R. SN79, a sigma receptor ligand, blocks methamphetamine-induced microglial activation and cytokine upregulation. *Experimental Neurology*, **2013**, 247C, 134-142. Web Published 4-27-2013. DOI: S0014-4886(13)00137-4. 10.1016/j.expneurol.2013.04.009 PMID: 23631864 PMCID: PMC3742718
 148. Giacometti, R.D.; Duchek, J.; Werner, L.; Husni, A.S.; **McCurdy, C.R.**; Cutler, S.J.; Cox, D.P.; Hudlicky, T. Heteroatom Analogues of Hydrocodone: Synthesis and Biological Activity. *Journal of Organic Chemistry*, **2013**, 78, 2914-2925. Web Published 2-11-2013. DOI: 10.1021/jo3026753 PMID: 23397939 PMCID: PMC3618612
 149. Poupaert, J.H.; Gbaguidi, F.A.; Kapanda, C.N.; Aichaoui, H.; **McCurdy, C.R.** Is Cocaine a Social Drug? Exploration of the Stereo-structure of Cocaine's

- Pharmacophore. *Medicinal Chemistry Research*, **2013**, 22, 247-252. Web Published 3-25-2012. DOI: 10.1007/s00044-012-0005-2
150. Kaushal, N.; Seminerio, M.J.; Robson, M.J.; **McCurdy, C.R.**; Matsumoto, R.R. Pharmacological evaluation of SN79, a sigma (σ) receptor putative antagonist, against methamphetamine-induced neurotoxicity in vivo. *European Neuropsychopharmacology*, **2013**, 23, 960-971. Web Published 8-24-2012. DOI: 10.1016/j.euroneuro.2012.08.005 PMID: 22921523. PMCID: PMC3748261
151. Harden, M.T.; Smith, S.E.; Niehoff, J.A.; **McCurdy, C.R.**; Taylor, G.T. Antidepressive effects of the κ -opioid receptor agonist salvinorin A in a rat model of anhedonia. *Behavioural Pharmacology*, **2012**, 23, 710-715. Web Published 8-23-2012. DOI: 10/1097/FBP.0b013e3283586189 PMID: 22926298
152. Seminerio, M.J.; Hansen, R.; Kaushal, N.; Zhang, H.T.; **McCurdy, C.R.**; Matsumoto, R.R. The evaluation of AZ66, an optimized sigma receptor antagonist, against methamphetamine-induced dopaminergic neurotoxicity and memory impairment in mice. *International Journal of Neuropsychopharmacology*, **2012**, 16, 1033-1044. Web Published 8-29-2012. DOI: 10.1017/S1461145712000831 PMID: 22932447
153. Seminerio, M.J.; Robson, M.J.; **McCurdy, C.R.**; Matsumoto, R.R. Sigma receptor antagonists attenuate acute methamphetamine-induced hyperthermia by a mechanism independent of IL-1 β mRNA expression in the hypothalamus. *European Journal of Pharmacology*, **2012**, 691(1-3), 103-109. Web Published 7-20-2012. DOI: 10.1016/j.ejphar.2012.07.029 PMID: 22820108 PMCID: PMC3726051
154. Fishback, J.A.; Rosen, A.; Bhat, R.; **McCurdy, C.R.**; Matsumoto, R.R. A 96-well method for the analysis of sigma receptor radioligand binding. *Journal of Pharmaceutical and Biomedical Analysis*, **2012**, 71, 157-161. Web Published 8-9-2012. DOI: 10.1016/j.jpba.2012.07.023 PMID: 22910107 PMCID: PMC3726061
155. James, M.L.; Shen, B.; Zavaleta, C.L.; Nielsen, C.H.; Mesangeau, C.; Vupalla, P.K.; Chan C.; Avery, B.A.; Fishback, J.A.; Matsumoto, R.R.; Gambhir, S.S.; **McCurdy, C.R.**; Chin, F.T. A New Positron Emission Tomography (PET) Radioligand for Imaging Sigma-1 Receptors in Living Subjects. *Journal of Medicinal Chemistry*, **2012**, 55, 8272-8282. Web Published 8-1-2012. DOI: 10.1021/jm300371c PMID: 22853801 PMCID: PMC4106900
156. Mankus, J.V.; **McCurdy, C.R.** Non-Peptide Ligands of Neuropeptide FF: Current Status and Structural Insights. *Future Medicinal Chemistry*, **2012**, 4, 1085-1092. DOI: 10.4155/fmc.12.67 PMID: 22709252 PMCID: PMC3606921(**Invited Review**)
157. Nieto, M.J.; Pierini, A.B.; Singh, N.; **McCurdy, C.R.**; Manzo, R.H.; Mazzieri, M.R. SAR Analysis of New Dual Targeting Fluoroquinolones. Implications of the Benzenesulfonyl Group. *Medicinal Chemistry*, **2012**, 8, 349-360. Web Published 4-24-2012. PMID: 22530906

158. Xu, Y.T.; Robson, M.J.; Szeszel-Fedorowicz, W.; Patel, D.; Rooney, R.; **McCurdy, C.R.**; Matsumoto, R.R. CM156, a Sigma Receptor Ligand, Reverses Cocaine-Induced Place Conditioning and Transcriptional Responses in the Brain. *Pharmacology, Biochemistry and Behavior*, **2012**, *101*, 174-180. Web Published 12-30-2011. DOI: 10.1016/j.pbb.2011.12.016 PMID: 22234290 PMCID: PMC3726055
159. Seminerio, M.J.; Robson, M.J.; Abdelazeem, A.H.; Mesangeau, C.; Avery, B.A.; **McCurdy, C.R.**; Matsumoto, R.R. Synthesis and Pharmacological Characterization of a Novel Sigma Receptor Ligand with Improved Metabolic Stability and Antagonistic Effects Against Methamphetamine. *AAPS Journal*, **2012**, *14*, 43-51. Web Published 12-20-2011. DOI: 10.1208/s12248-011-9311-8 PMID: 22183188 PMCID: PMC3291180
160. Jamalapuram, S.; Vuppala, P.K.; Mesangeau, C.; **McCurdy, C.R.**; Avery, B.A. Determination of a highly selective mixed-affinity sigma receptor ligand, in rat plasma by ultra performance liquid chromatography mass spectrometry and its application to a pharmacokinetic study. *Journal of Chromatography B*, **2012**, *891-892*, 1-6. Web Published 12-20-2011. DOI: 10.1016/j.jchromb.2011.12.013 PMID: 22406103 PMCID: PMC3992999
161. Ward, J.; Rosenbau, C.; Hernon, C.; **McCurdy, C.R.**; Boyer, E.W. Herbal Medicine for the Management of Opioid Addiction: Safe and Effective Alternatives to Conventional Pharmacotherapy? *CNS Drugs*, **2011**, *25*, 999-1007. Web Published 12-1-2011. DOI: 10.2165/11596830-000000000-00000. PMID: 22133323 (**Invited Review**)
162. Mesangeau, C.; Amata, E.; Alsharif, W.; Seminerio, M.J.; Robson, M.J.; Matsumoto, R.R.; **McCurdy, C.R.** Synthesis and pharmacological evaluation of indole-based sigma receptor ligands. *European Journal of Medicinal Chemistry*, **2011**, *46*, 5154-5161. Web Published 8-29-2011. DOI: 10.1016/j.ejmech.2011.08.031 PMID: 21899931 PMCID: PMC3272488
163. Vuppala, P.K.; Boddu, S.P.; Furr, E.B.; **McCurdy, C.R.**; Avery, B.A. Development and Validation of a Simple, Sensitive, High-Throughput Method for the Quantification of Mitragynine in Rat Plasma using Ultra Performance Liquid Chromatography-Mass Spectrometry and its Application to an Intravenous Pharmacokinetic Study. *Chromatographia*, **2011**, *74*, 703-710. Web Published 7-31-2011. DOI: 10.1007/s10337-011-2128-x
164. Kaushal, N.; Seminerio, M.J.; Shaikh, J.; Medina, M.A.; Mesangeau, C.; Wilson, L.L.; **McCurdy, C.R.**; Matsumoto, R.R. CM156, a high affinity sigma ligand, attenuates the stimulant and neurotoxic effects of methamphetamine in mice. *Neuropharmacology*, **2011**, *61*, 992-1000. Web Published 7-7-2011. DOI: 10.1016/j.neuropharm.2011.06.028. PMID: 21762711 PMCID: PMC3615888
165. Adkins, J.E.; Boyer, E.W.; **McCurdy, C.R.** *Mitragyna Speciosa*, a Psychoactive Tree From Southeast Asia. *Current Topics in Medicinal Chemistry*, **2011**, *11*, 1165-1175. Web Published 5-1-2011. DOI: 10.2174/156802611795371305 PMID: 21050173 (**Invited Review**)

166. Narayanan, S.; Mesangeau, C.; Poupaert, J.H.; **McCurdy, C.R.** Sigma Receptors and Cocaine Abuse. *Current Topics in Medicinal Chemistry*, **2011**, *11*, 1128-1150. Web Published 5-1-2011. DOI: 10.2174/156802611795371323 PMID: 21050176 (**Invited Review**)
167. Narayanan, S.; Bhat, R.; Mesangeau, C.; Poupaert, J.H.; **McCurdy, C.R.** Early Development of Sigma Receptor Ligands. *Future Medicinal Chemistry*, **2011**, *3*, 79-94. DOI: 10.4155/FMC.10.279 PMID: 21428827 (**Invited Review**)
168. Kaushal, N.; Robson, M.J.; Vinnakota, H.; Narayanan, S.; Avery, B.A.; **McCurdy, C.R.**, Matsumoto, R.R. Synthesis and Pharmacological Evaluation of 6-Acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a Cocaine Antagonist, in Rodents. *The AAPS Journal*, **2011**, *13*, 336-346. Web Published 4-15-2011. DOI: 10.1208/s12248-011-9274-9. PMID: 21494909 PMCID: PMC3160158
169. Yekkirala, A.S.; Lunzer, M.M.; **McCurdy, C.R.**, Powers, M.D.; Kalyuzhny, A.E.; Roerig, S.C.; Portoghese, P.S. *N*-Naphthoyl- β -naltrexamine (NNTA), a highly selective and potent activator of heteromeric mu/kappa opioid receptors. *Proceedings of the National Academy of Science USA*, **2011**, *108*, 5098-5103. Web Published 3-8-2011. DOI: 10.1073/pnas.1016277108 PMID: 21385944 PMCID: PMC3064379
170. Chajkowski, S.M.; Mallela, J.; Watson, D.E.; Wang, J.; **McCurdy, C.R.**; Rimoldi, J.M.; Shariat-Madar, Z. Highly selective hydrolysis of kinins by recombinant prolylcarboxypeptidase. *Biochemical and Biophysical Research Communications*, **2011**, *405*, 338-343. Web Published 12-16-2010. DOI: 10.1016/j.bbrc.2010.12.036 PMID: 21167814 PMCID: PMC3052280
171. Guenadil, F.; Aichaoui, H.; Kapanda, C.N.; Lambert, D.M.; **McCurdy, C.R.**; Poupaert, J.H. Design and synthesis of 3-acyl-2(3H)-benzoxazolone and 3-acyl-2(3H)-benzothiazolone derivatives. *Monatshefte fur Chemie (Chemical Monthly)*. **2011**, *142*, 67-80. Web Published 12-2-2010. DOI: 10.1007/s00706-010-0419-9
172. Fishback, J.A.; Mesangeau, C.; Poupaert, J.H.; **McCurdy, C.R.**; Matsumoto, R.R. Synthesis and characterization of [³H]SN56, a novel radioligand for the sigma-1 receptor. *European Journal of Pharmacology*, **2011**, *653*, 1-7. Web Published 12-6-2010. DOI: 10.1016/j.ejphar.2010.10.099 PMID: 21130085 PMCID: PMC3726058
173. Garces-Ramirez, L.; Green, J.L.; Hiranita, T.; Kopajtic, T.A.; Mereu, M.; Thomas, A.; Mesangeau, C.; Narayanan, S.; **McCurdy, C.R.**; Katz, J.L.; Tanda, G. Sigma receptor agonists: Receptor binding and effects on mesolimbic dopamine neurotransmission assessed by microdialysis in rats. *Biological Psychiatry*, **2011**, *69*, 208-217. Web Published 10-14-2010. DOI: 10.1016/j.biopsych.2010.07.026 PMID: 20950794 PMCID: PMC3015019
174. Liu, H.; **McCurdy, C.R.**; Doerksen, R.J. Computational Study on the Conformations of Mitragynine and Mitragynaline. *Journal of Molecular Structure: THEOCHEM*. **2010**, *945*, 57-63. Web Published 1-18-2010. DOI: 10.1016/j.theochem.2010.01.011 PMID: 21293786 PMCID: PMC3031075

175. Xu, Y.T.; Kaushal, N.; Shaikh, J.; Wilson, L.L.; Mesangeau, C.; **McCurdy, C.R.**; Matsumoto, R.R. A novel substituted piperazine, 3-(4-(4-cyclohexylpiperazine-1-yl)butyl)benzo[d]thiazole-2(3*H*)-thione (CM156), attenuates the stimulant and toxic effects of psychostimulants in mice: Effects on cocaine. *Journal of Pharmacology and Experimental Therapeutics*. **2010**, 333, 491-500. Web Published 1-25-2010. DOI: 10.1124/jpet.109.161398 PMID: 20100904 PMCID: PMC2872963
176. Leon, F.; Habib, E.; Adkins, J.E.; Furr, E.B.; **McCurdy, C.R.**; Cutler, S.J. Phytochemical characterization of the leaves of *Mitragyna speciosa* grown in USA. *Natural Product Communications*. **2009**, 4, 907-910. PMID: 19731590
177. de Moraes, N.V.; Moretti, R.A.C.; Furr, E.B.; **McCurdy, C.R.**; Lanchote, V.L. Determination of mitragynine in rat plasma by LC-MS-MS: Application to pharmacokinetics. *Journal of Chromatography B*. **2009**, 877, 2593-2597. Web Published 6-21-2009. DOI: 10.1016/j.jchromb.2009.06.023 PMID: 19589735
178. Carvalho, P.; Furr, E.B. III; **McCurdy, C.R.** (E)-methyl 2-((2*S*,3*S*,12*b**R*)-3-ethyl-8-methoxy-1,2,3,4,6,7,12,12*b*-octahydroindolo [2,3-*a*]quinolizin-2-yl)-3-methoxyacrylate. *Acta Cryst.* **2009**, E65, o1441-o1442. Web Published 5-29-2009. DOI: 10.1107/S1600536809017309
179. Dayan, F.; Singh, N.; **McCurdy, C.R.**; Godfrey, C.; Larsen, L.; Weavers, R.; Van Klink, J.; Perry, N. β -Triketone Inhibitors of Plant *p*-Hydroxyphenylpyruvate Dioxygenase: Modeling and Comparative Molecular Field Analysis of their Interactions. *J. Agric. Food Chem.*, **2009**, 57, 5194-5200. Web Published 5-12-2009. DOI: 10.1021/jf9005593 PMID: 19435355
180. Aichaoui, H.; Guenadil, F.; **McCurdy, C.R.**; Coco, N.; Lambert, D.M.; Poupaert, J.H. Synthesis and pharmacological evaluation of antioxidant chalcone derivatives of 2(3*H*)-benzoxazolones. *Med. Chem. Res.*, **2009**, 18, 665-668. Web Published 12-4-2008. DOI: 10.1007/s00044-008-9143-y
181. Guenadil, F.; Aichaoui, H.; Lambert, D.M.; **McCurdy, C.R.**, Poupaert, J.H. Highly selective catalytic Friedel-Crafts acylation of activated aromatic compounds using I₂-DMF complex as catalyst. *Lett. Org. Chem.*, **2008**, 5, 665-668. DOI: 10.2174/157017808786857624
182. Singh, N.; Nolan, T.L.; **McCurdy, C.R.** Chemical Function Based Pharmacophore Development for Novel, Selective Kappa Opioid Receptor Agonists. *J. Mol. Graph. Model.*, **2008**, 27, 131-139. Web Published 3-29-2008. DOI: 10.1016/j.jmgm.2008.03.007 PMID: 18456526
183. Boyer, E.W.; Babu, K.M.; Adkins, J.E.; **McCurdy, C.R.**, Halpern, J.H. Self-Treatment of Chronic Pain and Opioid Withdrawal with Kratom. *Addiction*, **2008**, 103, 1048-1050. DOI: 10.1111/j.1360-0443.2008.02209.x PMID: 18482427 PMCID: PMC3670991

184. Kane, B.; **McCurdy, C.R.**, Ferguson, D.M. Towards a Structure-Based Model of Salvinorin A Recognition of the Kappa Opioid Receptor. *J. Med. Chem.* **2008**, *51*, 1824-1830. Web Published 2-23-2008. DOI: 10.1021/jm701040v PMID: 18293909
185. Mesangeau, C.; Narayanan, S.; Shaikh, J.; Kaushal, N.; Viard, E.; Xu, Y.; Matsumoto, R.R.; Poupaert, J.H.; **McCurdy, C.R.** Conversion of a highly selective sigma-1 receptor ligand to sigma-2 receptor preferring ligands with anti-cocaine activity. *J. Med. Chem.*, **2008**, *51*, 1482-1486. Web Published 2-16-2008. DOI: 10.1021/jm701357m PMID: 18278854
186. Babu, K.M.; **McCurdy, C.R.**; Boyer, E.W. Opioid Receptors and Legal Highs: *Salvia divinorum* and kratom. *Clin. Toxicol.* **2008**, *46*, 146-152. Web Published 1-10-2008. DOI: 10.1080/15563650701241795 PMID: 18259963
187. Willmore-Fordham C.B.; Krall, D.M., **McCurdy, C.R.**; Kinder, D.H. The hallucinogen derived from *Salvia divinorum*, salvinorin A, has kappa opioid agonist discriminative stimulus effects in rats. *Neuropharmacol.* **2007**, *53*, 481-486. Web Published 6-27-2007. DOI: 10.1016/j.neuropharm.2007.06.008 PMID: 17681558
188. Haris, S.P.; Zhang, Y.; Le Bourdonnec, B.; **McCurdy, C.R.**; Portoghese, P.S. *o*-Naphthalenedicarboxaldehyde Derivative of 7'-Aminonaltrindole as a Selective δ -Opioid Receptor Affinity Label. *J. Med. Chem.* **2007**, *50*, 3392-3396. Web Published 6-8-2007. DOI: 10.1021/jm061194h PMID: 17555306
189. Singh, N.; Avery, M.A.; **McCurdy, C.R.** Toward *Mycobacterium tuberculosis* DXR Inhibitor Design: Homology Modeling, Docking Studies, and Molecular Dynamics Simulations. *J. Comput. Aided Mol. Des.* **2007**, *21*, 511-522. Web Published 9-14-2007. DOI: 10.1007/s10822-007-9132-0 PMID: 17430177
190. Singh, N.; Cheve, G.; Avery, M.A.; **McCurdy, C.R.** Targeting the Methyl Erythritol Phosphate (MEP) Pathway for Novel Antimalarial, Antibacterial and Herbicidal Drug Discovery: Inhibition of 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase (DXR) Enzyme. *Curr. Pharm. Des.* **2007**, *13*, 1161-1177. PMID: 17430177
191. Philip, A.E.; Poupaert, J.H.; Cheve, G.; Muccioli, G.; Lambert, D.; **McCurdy, C.R.** Structure-Activity Relationships of Phenytoinergic Antiepileptic Drugs Related to Ameltolide. *Med. Chem. Res.* **2007**, *15*, 130-135. Web Published 7-26-2007. DOI: 10.1007/s00044-007-9016-9
192. Dayan, F.E.; Duke, S.O.; Sauldubois, A.; Singh, N.; **McCurdy, C.**; Cantrell, C. *p*-Hydroxyphenylpyruvate Dioxygenase is a Target Site for β -Triketone Phytochemicals. *Phytochemistry* **2007**, *68*, 2004-2014. Web Published 3-17-2007. DOI: 10.1016/j.phytochem.2007.01.026
193. Singh, N.; Cheve, G.; Ferguson, D.M.; **McCurdy, C.R.** A Combined Ligand-Based and Target-Based Drug Design Approach for G-Protein Coupled Receptors: Application to Salvinorin A, A Selective Kappa Opioid Receptor Agonist. *J. Comput.*

Aided Mol. Des. **2006**, 20, 471-493. Web Published 9-29-2006. DOI: 10.1007/s10822-006-9067-x PMID: 17009091

194. Kane, B.E.; **McCurdy, C.R.**; Nieto, M.J.; Ferguson, D.M. A Unique Binding Epitope for Salvinorin A, a Non-Nitrogenous Kappa Opioid Receptor Agonist. *FEBS J.* **2006**, 273, 1966-1974. Web Published 4-5-2006. DOI: 10.1111/j.1742-4658.2006.05212.x PMID: 16640560
195. Singh, N.; Cheve, G.; Avery, M.A.; **McCurdy, C.R.** Comparative Protein Modeling of 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase Enzyme from *Plasmodium falciparum*: A Potential Target for Antimalarial Drug Discovery. *J. Chem. Inf. Model.* **2006**, 46, 1360-1370. Web Published 4-4-2006. DOI: 10.1021/ci050523w PMID: 16711755
196. Vyas, N.; Mollereau, C.; Cheve, G.; **McCurdy, C.R.** Structure Activity Relationships of Neuropeptide FF and Related Peptidic and Non-Peptidic Derivatives. *Peptides*, **2006**, 27, 990-996. Web Published 2-21-2006. DOI: 10.1016/j.peptides.2005.07.024 PMID: 16490282 (Invited Review)
197. **McCurdy, C.R.**; Sufka, K.J.; Smith, G.H.; Warnick, J.E.; Nieto, M.J. Analgesic Profile of Salvinorin A, a Structurally Unique Kappa Opioid Receptor Agonist. *Pharmacol. Biochem. Behav.*, **2006**, 83, 109-113. Web Published 1-23-2006. DOI: 10.1016/j.pbb.2005.12.011 PMID: 16434091
198. **McCurdy, C.R.**, Scully, S.S. Analgesic Substances Derived from Natural Products (Naturceuticals). *Life Sciences*, **2005**, 78, 476-484. Web Published 10-10-2005. DOI: 10.1016/j.lfs.2005.09.006 PMID: 16216276 (Invited Review)
199. Yous, S.; Wallez, V.; Belloir, M.; Caignard, D.H.; **McCurdy, C.R.**; Poupaert, J.H. Novel 2(3*H*)-Benzothiazolones as Highly Potent and Selective Sigma-1 Receptor Ligands. *Med. Chem. Res.*, **2005**, 14, 158-168. DOI: 10.1007/s00044-005-0131-1
200. Geldenhuys, W.J.; Lockman, P.R.; Philip, A.E.; Miller, B.L.; **McCurdy, C.R.**; Allen, D.D. Inhibition of choline uptake by *N*-cyclohexylcholine, a high affinity ligand for the choline transporter at the Blood-Brain Barrier. *J. Drug Target.*, **2005**, 13, 259-266. DOI: 10.1080/10611860500139222 PMID: 16051538
201. Poupaert, J.H.; Carato, P.; **McCurdy, C.R.** A Simple and Effective Method for the Thionation of Amides to Thioamides using Al₂O₃-supported P₄S₁₀. *Lett. Org. Chem.*, **2005**, 2, 330-333. DOI: 10.2174/1570178054038957
202. Warnick, J.E.; **McCurdy, C.R.**; Sufka, K.J. Opiate Modulation of Social Attachment. *Behav. Brain Res.*, **2005**, 160, 277-285. Web Published 1-16-2005. DOI: 10.1016/j.bbr.2004.12.009 PMID: 15863224
203. Philip, A.E.; Poupaert, J.H.; **McCurdy, C.R.** Opioid Receptor Like-1 (ORL1) molecular "road map" to understanding ligand interaction and selectivity. *Current*

Topics in Medicinal Chemistry, **2005**, 5, 325-340. DOI: 10.2174/1568026053544489
PMID: 15857315 (**Invited Review**)

204. Nieto, M.; Philip, A.E.; Poupaert, J.H.; **McCurdy, C.R.** Solution Phase Parallel Synthesis of Spirohydantoins. *J. Combi. Chem.*, **2005**, 7, 258-263. Web Published 12-24-2004. DOI: 10.1021/cc049870t PMID: 15762754
205. Zhang, Y.; **McCurdy, C.R.**; Metzger, T.G.; Portoghese, P.S. Specific cross-linking of LYS233 and CYS235 in the mu opioid receptor by a reporter affinity label. *Biochemistry*, **2005**, 44, 2271-2275. Web Published 1-25-2005. DOI: 10.1021/bi048049v PMID: 15709739
206. Poupaert, J.H.; Duarte, S.; Depreux, P.; **McCurdy, C.R.**; Lambert, D.L. Willgerodt-Kindler's Microwave-enhanced Synthesis of Thioamide Derivatives. *Phosphorus, Sulfur, and Silicon and the related elements*. **2004**, 179, 1959-1973. DOI: 10.1080/10426500490466977
207. Poupaert, J.H.; Depreux, P.; **McCurdy, C.R.** Unsymmetrical diarylketones from electron-rich heterocyclic arenes. *Monatshefte für Chemie (Chemical Monthly)*. **2003**, 134, 823-830. Web Published 3-6-2003. DOI: 10.1007/s00706-002-0573-9
208. **McCurdy, C.R.**; Le Bourdonnec, B.; Metzger, T.G.; El Kouhen, R.; Zhang, Y.; Law, P.Y.; Portoghese, P.S. Naphthalene dicarboxaldehyde as an electrophilic fluorogenic moiety for affinity labeling: Application to opioid receptor affinity labels with greatly improved fluorogenic properties. *J. Med. Chem.* **2002**, 45, 2887-2890. Web Published 6-12-2002. DOI: 10.1021/jm015586u PMID: 12086475
209. **McCurdy, C.R.**; Jones, R.M.; Portoghese, P.S. Investigation of phenolic bioisosterism in opioids: Synthesis and biological evaluation of 3-methylsulfonamide analogues of naltrexone and oxymorphone. *Org. Lett.* **2000**, 2, 819-821. DOI: 10.1021/ol005561+ PMID: 10754685
210. **McCurdy, C.R.**; Venkateshwaran, T.G.; Beach, J.W.; Stewart, J.T. Capillary electrophoretic separation of lobeline analogues using derivatized cyclodextrins: Effects of pH, additive and organic modifier concentration. *Electrophoresis*, **1999**, 20, 212-218. DOI: 10.1002/(SICI) 1522-2683(19990101)20:1<212:AID-ELPS212>3.0.CO;2-I PMID: 10065979
211. Metting T.L.; Burgio D.E.; Terry A.V.; Beach J.W.; **McCurdy C.R.**; Allen D.D. Inhibition of choline uptake by isoarecolone and lobeline derivatives: Implications for potential vector mediated brain drug delivery. *Neurosci. Lett.* **1998**, 258, 25-28. DOI: 10.1016/S0304-3940(98)00871-4 PMID: 9876043
212. Terry Jr., A.V.; Williamson, R.; Gattu, M.; Beach, J.W.; **McCurdy, C.R.**; Sparks, J.A.; Pauly, J.R. Lobeline and structurally simplified analogs exhibit differential agonist activity and sensitivity to antagonist blockade when compared to nicotine. *Neuropharmacol.* **1998**, 37, 93-102. DOI: 10.1016/S0028-3908(97)00142-1 PMID: 9680262

213. Beach, J.W.; **McCurdy, C.R.**; Gattu, M.; Boss, K.L.; Templeton, R.E.; Terry Jr., A.V. Synthesis and receptor binding of N-substituted-2-styryl-1,2,3,6-tetrahydropyridines as potential nicotinic agonists. *Med. Chem. Res.* **1997**, *7*, 271-281.

PROFESSIONAL PUBLICATIONS MANUSCRIPTS:

1. Grundmann, O.; Garcia-Romeu, A.; **McCurdy, C.R.**; Sharma, A.; Smith, K.E.; Swogger, M.T.; Weiss, S.T. Not all kratom is equal: The important distinction between native leaf and extract products. *Addiction*, **2024** Jan;119(1):202-203. Web Published October 9, 2023. DOI: 10.1111/add.16366 PMID: 37814405
2. Smith, K.; Sharma, A.; Grundmann, O.; **McCurdy, C.R.** Kratom Alkaloids: A Blueprint? *ACS Chemical Neuroscience*, **2023** Jan 18;14(2):195-197. Web Published Jan 3, 2023. DOI: 10.1021/acschemneuro.2c00704 PMID: 96594896 PMCID: PMC9910625
3. Polli, J.W.; **McCurdy C.R.**; Wurster, D.E.; DeSilva, B.S.; Bak, A.; Bendayan, R.; Beibohm, B.; Templeton, A.C.; Weiser, W. The Journey to AAPS 2020: A Reflection from Strategic Planning to PharmSci 360. *AAPS Journal*, **2018**, *21*, 2. Web Published Nov 3, 2018. DOI: 10.1208/s12248-018-0273-y PMID: 30392015
4. Polli, J.W.; **McCurdy C.R.**; Wurster, D.E.; DeSilva, B.S.; Bak, A.; Bendayan, R.; Beibohm, B.; Templeton, A.C.; Weiser, W. The Journey to AAPS 2020: A Reflection from Strategic Planning to PharmSci 360. *AAPS PharmSciTech*, **2018**, *19*, 3325-3327. Web Published Nov 3, 2018. DOI: 10.1208/s12249-018-1200-3 PMID: 30390237
5. **McCurdy, C.R.** Strategies to treat substance abuse and addiction. *Current Topics in Medicinal Chemistry*, **2011**, *11*, 1102. Editorial PMID: 21506917
6. **McCurdy, C.R.** Drug Design and Discovery: D3I Current Trends and Implications for Academia. *AAPS Newsmagazine*, **2009**, *12*, 16-23. **Featured Cover Story**, July Issue.
7. Martinez, M.N.; Bonate, P.; Chapman, R.L.; De Groot, A.; D'Souza, S.; Ghilazi, N.; Gray, V.; Gupta, V.K.; Huynh-Ba, K.; Iyer, S.; Jayatilaka, A.; Joshi, A.; Karnes, H.T.; Kahn, M.; Liu, P.; Lunte, C.; **McCurdy, C.R.**; Morris, M.E.; Norris, K.J.; Ramsey, P.; Sehgal, S.; Zahn, M. 2007 Highlights of Advances in Pharmaceutical Sciences: An American Association of Pharmaceutical Scientists (AAPS) Perspective. *AAPS Journal*, **2007**, *9*, Article 24. DOI: 10.1208/aapsj0902024
8. **McCurdy, C.R.** Pharmacy Education: From Prescott to Pharmacogenomics. *Journal of the American Pharmaceutical Association* **2002**, *42*, 688-691. PMID: 12269703

PUBLISHED ABSTRACTS:

1. Hoefflich, C.C.; Kuntz, M.A.; **McCurdy, C.R.**; Striley, C.W. 419 A CTS team approach to identifying thematic constructs related to kratom use during pregnancy and breastfeeding: A qualitative analysis of social media posts. *Journal of Clinical and*

Translational Sciences, **2023**, Jul 26;7(1):e156. DOI: 10.1017/cts.2023.592 PMID: 37535328 PMCID: PMC10388429

2. McMahon, L.R.; Hiranita, T.; Wilkerson, J.L.; Francisco, J.; **McCurdy, C.R.** Pharmacological characterization of mitragynine, the primary constituent in kratom, as a potential medication for opioid use disorder. *Journal of Pharmacological and Toxicological Methods*, **2019**, 99, 106595. Web Published October 17, 2019. DOI: 10.1016/j.vascn.2019.05.012 PMID: 31963089
3. **McCurdy, C.R.**, Nieto, M.J.; Kane, B.E.; Ferguson, D.M. Non-nitrogenous kappa opioid receptor ligands based on salvinorin A, a unique and naturally occurring opiate lead. *Fundamental and Clinical Pharmacology*, **2004**, 18, 597. DOI: 10.1111/j.1472-8206.2004.00288.x
4. **McCurdy, C.R.**; Sufka, K.J.; Warnick, J.E.; Nieto, M.J. Salvinorin A, a Kappa Opioid Receptor Agonist is a Fast Acting, Potent Analgesic. Abstract for presentation at the American Association of Pharmaceutical Scientists/National Institute of Drug Abuse Symposium Frontiers in Science, Drug Addiction – From Basic Research to Therapies. *The AAPS Journal*, **2004**, 6. http://www.aapsj.org/theme_issues/theme_issue7.asp
5. Metting T.L.; Burgio D.E.; Terry A.V.; Beach J.W.; **McCurdy C.R.**; Allen D.D. Evaluation of lobeline and arecoline derivative inhibition of blood-brain barrier (BBB) choline transport by the in situ brain perfusion technique. Abstract for presentation at the American Association of Pharmaceutical Scientists annual meeting, San Francisco, California. *PharmSci.*, **1998**, (Suppl) 1(1): S395.
6. Smith, J.B.; **McCurdy, C.R.**; Beach, J.W.; Cutler, S.J. Behavioral and discriminative-stimulus effects of nicotinic agonists. Abstract for presentation at the Experimental Biology annual meeting. *FASEB Journal*, **1998**, 12, pA137.

INVITED BOOK REVIEWS:

1. **McCurdy, C.R.** Modern Alkaloids. Structure, Isolation, Synthesis and Biology edited by Ernesto Fattorusso and Orazio Tagliatella-Scafati. *J. Med. Chem.*, **2008**, 51, 4356.

BOOK CHAPTERS:

1. McMahon, L.R.; Obeng, S.; **McCurdy, C.R.**; Barrett, J.E.; Kim, F.J. Drug Discovery, Development, and Regulation. In: Brody's Human Pharmacology. 7th Ed. Chapter 5. (ACCEPTED)
2. Hiranita, T.; Obeng, S.; Sharma, A.; Wilkerson, J.L.; **McCurdy, C.R.**; McMahon, L.R. *In Vitro* and *In Vivo* Pharmacology of Kratom. *Advances in Pharmacology*, Elsevier, **2022**. Volume 93, Chapter 2. pp 35-76. ISBN: 1054-3589 DOI: 10.1016/bs.apha.2021.10.001 Web Published December 13, 2021.
3. Ramanathan, S.; Leon, F.; Chear, N.J.Y.; Yusof, S.R.; Murugaiyah, V.; McMahon, L.R.; **McCurdy, C.R.** Kratom (*Mitragyna speciosa* Korth.): A description on the ethnobotany, alkaloid chemistry, and neuropharmacology. In: Studies on Natural Products Chemistry. Ed. Atta-ur-Rahman. Elsevier, **2021**. Chapter 5. pp 195-225. Web Published April 16, 2021. Hardcover ISBN: 9780128194874. eBook ISBN: 9780323898157 DOI: 10.1016/B978-0-12-819487-4.00003-3
4. **McCurdy, C.R.**; Prisinzano, T.E. Opioid Receptor Ligands. In: Burger's Medicinal Chemistry, Drug Discovery and Development. Volume 8. Eds. Abraham, D.J.; Myers, M. 8th Ed. Wiley, **2021**. ISBN: 978-1-119-53030-5
5. Leon, F.; Gogineni, V.; Avery, B.A.; **McCurdy, C.R.**; Cutler, S.J. Phytochemistry of *Mitragyna speciosa*. In: Kratom and Other Mitragynines: The Chemistry and Pharmacology of Opioids from a Non-Opium Source. Ed. Raffa, R.B. CRC Press, USA, **2014**. pp 77-94. ISBN: 978-1-4822-2518-1
6. **McCurdy, C.R.**; Prisinzano, T.E. Opioid Receptor Ligands. In: Burger's Medicinal Chemistry, Drug Discovery and Development. Volume 8. Eds. Abraham, D.J.; Rotella, D.P. 7th Ed. Wiley, **2010**. ISBN: 978-0-470-27815-4
7. Nolan, T.L.; Singh, N.; **McCurdy, C.R.** Ligand Macromolecule Interactions: Theoretical Principles of Molecular Recognition. In: Methods in Molecular Biology: 572 Ligand-Macromolecule Interactions in Drug Discovery. Ed. Roque, A.C.A. Humana Press, USA, **2010**. pp 13-29. ISBN: 978-1-60761-243-8
8. **McCurdy, C.R.** Development of Opioid Receptor Ligands. In: Analog-Based Drug Discovery. Eds. Fischer, J.; Ganellin, C.R. IUPAC. Wiley-VCH, **2005**. pp 259-276. ISBN: 3-527-31257-9
9. **McCurdy, C.R.**, Miller, R.L., and Beach, J.W. Lobeline: A Natural Product With High Affinity for Neuronal Nicotinic Receptors and a Vast Potential for use in Neurological Disorders. Biologically Active Natural Products: Pharmaceuticals. Eds. Cutler, S.J., and Cutler, H.G. CRC Press LLC, **2000**.

PATENTS ISSUED:

1. **McCurdy, Christopher R.**; Mesangeau, Christophe; Chin, Frederick T.; James, Michelle L.; Shen, Bin; Gambhir, Sanjiv; Biswal, Sandip; Behera, Deepak. Highly Selective Sigma Receptor Ligands and Radioligands as Probes in Nociceptive Processing and the Pathphysiological Study of Memory Deficits and Cognitive Disorders. **Canadian Patent CA2941634**. Issue Date: Notice of Allowance issued
2. **McCurdy, Christopher R.**; Mesangeau, Christophe; Chin, Frederick T.; James, Michelle L.; Shen, Bin; Gambhir, Sanjiv; Biswal, Sandip; Behera, Deepak. Highly Selective Sigma Receptor Ligands and Radioligands as Probes in Nociceptive Processing and the Pathphysiological Study of Memory Deficits and Cognitive Disorders. **European Patent EP3102204B1 (Germany, France, Great Britain)**. Issue Date: May 5, 2021.
3. **McCurdy, Christopher R.**; Mesangeau, Christophe; Chin, Frederick T.; James, Michelle L.; Shen, Bin; Gambhir, Sanjiv; Biswal, Sandip; Behera, Deepak. Highly Selective Sigma Receptor Ligands and Radioligands as Probes in Nociceptive Processing and the Pathphysiological Study of Memory Deficits and Cognitive Disorders. **Australia Patent AU2015227342B2**. Issue Date: June 25, 2020.
4. **McCurdy, Christopher R.**; Mesangeau, Christophe; Chin, Frederick T.; James, Michelle L.; Shen, Bin; Gambhir, Sanjiv; Biswal, Sandip; Behera, Deepak. Highly Selective Sigma Receptor Ligands and Radioligands as Probes in Nociceptive Processing and the Pathphysiological Study of Memory Deficits and Cognitive Disorders. **Japan Patent JP6591431B2**. Issue Date: October 16, 2019.
5. **McCurdy, Christopher R.**; Mesangeau, Christophe; Chin, Frederick T.; James, Michelle L.; Shen, Bin; Gambhir, Sanjiv; Biswal, Sandip; Behera, Deepak. Highly Selective Sigma Receptor Ligands and Radioligands as Probes in Nociceptive Processing and the Pathphysiological Study of Memory Deficits and Cognitive Disorders. **United States Patent US 9,724,435 B2**. Issue Date: August 8, 2017. Filed: March 4, 2014.
6. **McCurdy, Christopher R.**; Mesangeau, Christophe; Chin, Frederick T.; James, Michelle, L.; Chen, Bin; Gambhir, Sanjiv. Highly Selective Sigma Receptor Radioligands. **United States Patent US 9,604,926**. Issue Date: March 28, 2017. Filed: June 1, 2011.
7. **McCurdy, Christopher R.**; Mesangeau, Christophe; Narayanan, Sanju; Matsumoto, Rae Reiko; Poupaert, Jacques Henri. Highly Selective Sigma Receptor Ligands. **United States Patent US 8,809,381**. Issue Date: August 19, 2014.
8. **McCurdy, Christopher R.**; Mesangeau, Christophe; Matsumoto, Rae R.; Poupaert, Jacques H.; Avery, Bonnie A.; Abdelazeem, Ahmed H. Highly Selective Sigma Receptor Ligands. **United States Patent US 8,686,008 B2**. Issue Date: April 1, 2014.

PATENTS PENDING/EXPIRED:

1. **McCurdy, C.R.;** Crowley, M.L. Compounds for treating opioid misuse. U.S. Provisional Patent Application No. 63/444010, Filed February 8, 2023. ***Pending.***
2. **McCurdy, C.R.;** Burns, S.M. Sigma Receptor Ligand Compounds. U.S. Provisional Patent Application No. 63/443116, Filed February 3, 2023. ***Pending.***
3. **McCurdy, C.R.;** Agha, H.M.; Intagliata, S. Metabolically Stable Sigma Receptor Ligands. U.S. Provisional Patent Application No. 63/434848, Filed December 22, 2022. ***Pending.***
4. Berthold, E.C.; **McCurdy, C.R.;** Sharma, A.; Maxwell, E. Oral Bioavailability Formulation for *Mitragyna speciosa* (Kratom). U.S. Provisional Patent Application No. 63/420216, Filed October 28, 2022. ***Pending.***
5. **McCurdy, C.R.;** Norris, M.H.; Ostrov, D.A. Sigma Receptor Ligands for Treating SARS-CoV-2 Infection. International Application Published Under the Patent Cooperation Treaty (PCT). World Intellectual Property Organization. International Publication Number WO 2022/169961 A1, International Filing Date: February 3, 2022, International Publication Date: August 11, 2022. ***Pending.***
6. **McCurdy, C.R.** Compounds for treating psychostimulant misuse. U.S. Provisional Patent Application No. 63/325513, Filed March 30, 2022. ***Pending.***
7. **McCurdy, C.R.;** Norris, M.H.; Ostrov, D.A. Sigma Receptor Ligands for Treating SARS-CoV-2 Infection. U.S. Provisional Patent Application No. 63/145807, Filed 2/4/2021. Converted to full PCT application February 4, 2022. ***Pending.***
8. **McCurdy, C.R.** Synthesis and Evaluation of Dual-Activity Opioid-NPFF Ligands for Receptor Affinity, Antinociception and Tolerance Liabilities. U.S. Provisional Patent Application No. 62/026378, Filed 7/18/2014. ***Expired.***
9. **McCurdy, C.R.;** Mesangeau, C.; Narayanan, S.; Matsumoto, R.R.; Poupaert, J.H. Highly Selective Sigma Receptor Ligands. WO2009/026227 A2. Priority Date 08/16/2007. International Filing Date: 08/18/2008. International Application Number: PCT/US2008/073478. ***Nationalized.***
10. **Boyer, E.W.** Method for Treating Withdrawal From Addictive Compounds. U.S. Provisional Patent Application No. 61/116912. Filed 11/21/2008. Priority Application US 2008-116912P. Date: 11/21/2008. ***Expired.***
11. Boyer, E.W.; **McCurdy, C.R.;** Adkins, J.E. Methods for treating withdrawal from addictive compounds using Kratom. U.S. Application Number 20100209542 A1. Date: 08/19/2010. ***Expired.***

INVESTIGATIONAL NEW DRUG (IND) APPLICATIONS:

1. On May 28, 2015 our collaborative team (filed under Sanjiv Sam Gambhir, M.D., Ph.D.) had an eIND (126459) approved on May 28, 2015 to proceed with study by the US FDA (submitted April 24, 2015). This eIND will utilize our original sigma-1 receptor antagonist (CM304/FTC146) as a PET/MR imaging diagnostic agent. This has been accomplished with funds in part from the National Institutes of Health (NIDA & NIGMS), the University of Mississippi, and Stanford University. Clinical studies will be carried out at Stanford University School of Medicine.
2. On June 9, 2023 our collaborative team (filed under Altasciences) had an IND (167413) approved on July 6, 2023 to proceed with study by the US FDA. This is Altasciences project US FDA 75F40121C00199 (FDU-P4-117). The first cohort was dosed in September 2023 with anticipated completion in January 2024.

PHASE 1 CLINICAL TRIALS WITH [18F]FTC-146 (aka CM304):

1. Biodistribution and Pharmacokinetic Determination of the PET Radiopharmaceutical [18F]FTC-146 Using PET/MRI in Healthy (Asymptomatic) Volunteers and in Patients With CRPS and Sciatica. Early Phase I. First Posted: April 27, 2016. ClinicalTrials.gov Identifier: **NCT02753101**. Sponsor: Stanford University. Collaborator: University of Mississippi Medical Center. Responsible Party: Sandip Biswal, Stanford University. Actual enrollment: 24 participants. **COMPLETED**
2. Use of [18F]FTC-146 PET/MRI in the Diagnosis of Chronic Pain. First Posted: June 14, 2018. ClinicalTrials.gov Identifier: **NCT03556137**. Sponsor: Stanford University. Collaborator: GE Healthcare. Responsible Party: Sandip Biswal, Stanford University. Estimated enrollment: 144 participants. **Recruiting**
3. Reliability of [18F]FTC-146 Brain Uptake in Healthy Controls. First Posted: August 28, 2018. ClinicalTrials.gov Identifier: **NCT03649555**. Sponsor: Stanford University. Responsible Party: Carolyn Rodriguez, Stanford University. Estimated Enrollment: 6 participants. **Active, not recruiting**
4. Sigma-1 Receptors: A Novel Clinical Target in Fragile X Syndrome. First posted: March 19, 2020. ClinicalTrials.gov Identifier: **NCT04314856**. Sponsor: Stanford University. Responsible Party: Frederick Chin, Stanford University. Estimated enrollment: 20 participants. **Withdrawn**
5. Use of [18F]FTC-146 PET/MRI for Pediatric Chronic Pain. Phase 1 Clinical Trial First Posted: June 17, 2020. ClinicalTrials.gov Identifier: **NCT04435821**. Sponsor: Stanford University. Collaborator: GE Healthcare. Responsible Party: Sandip Biswal, Stanford University. Estimated enrollment: 100 participants. **Enrolling by invitation**

PHASE 2 CLINICAL TRIALS WITH [18F]FTC-146 (aka CM304):

1. A Phase 2 Study of [18F]FTC-146 PET/CT in Patients With Newly Diagnosed Osteosarcoma. First Posted: April 28, 2020. ClinicalTrials.gov Identifier:

NCT04365660. Sponsor: Stanford University. Responsible Party: Kristen Ganjoo, Stanford University. Estimated enrollment: 5 participants. ***Recruiting***